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ABSTRACT
Increased left ventricular (LV) size and deformation of LV geometry are 
associated with LV dysfunction. Regional shape distortion (RSD), detected on 
two-dimensional echocardiography (2D-Echo) after acute myocardial infarction 
(Ml), is associated with poor outcome.
Two hypotheses were tested: i) early RSD of the asynergic infarct zone 
after Ml is followed by progressive global LV dilatation, remodelling towards a 
spheroidal shape, and more LV dysfunction; and ii) the progressive remodelling of 
LV geometry spans the phases of early infarction and healing and may be 
modified by early and prolonged therapies applied over the phases of infarction 
and healing.
A bench to bedside approach was used, with concurrent studies in a dog 
model of healing over 6 weeks after Ml and patients with first Ml's. Computer- 
assisted analysis of the 2D~Echo images with 3D reconstruction was used to 
quantify LV asynergy (akinesis + dyskinesis), LV volumes, LV ejection fraction, 
RSD bulge and global LV shape.
The animal studies showed that collagen deposition during healing after Ml 
increases progressively, reaching a plateau around 2 weeks, and deposition of 
collagen in already dilated infarct zones is followed by late thinning and further 
RSD associated with LV aneurysms. Importantly, serial 2D-Echo tracked the in- 
vivo changes in LV geometry and function and showed greater RSD and LV 
dysfunction with anterior than inferior Ml, and with transmural Ml than non­
transmural Ml. Other studies showed: i) lower LV resistance to distension and 
rupture in infarcted hearts; ii) marked extracellular matrix (ECM) disruption and 
RSD in transmural Ml; iii) delayed effects on LV remodelling after infarct-limiting 
therapies given during acute Ml; iv) loss of beneficial effects of the vasodilator 
nitroglycerin (NTG) with hypotension induced by high doses during acute Ml; v) 
decreased wall stress by prolonged LV unloading after Ml, with nitrates (eccentric 
dosing) and angiotensin-converting enzyme (ACE) inhibitors, limited early RSD
and progressive LV remodelling and dysfunction; this effect was greater with 
therapy over 6-weeks than just over the first 2 weeks; vi) late reperfusion limited 
early RSD and adverse LV remodelling, and preserved ECM in the epicardial rim; 
vii) the resistance of the healed left ventricle to distension and rupture was further 
reduced by prolonged anti-inflammatory therapy (ibuprofen); viii) prolonged ACE 
inhibitor therapy decreases infarct collagen, which may be harmful under certain 
conditions.
The clinical studies with serial 2D-Echo showed that systematic 
tomographic imaging could provide quantitative data on regional and global LV 
geometry and function including the degree of RSD (depth, area, and volume). 
An early 2D-Echo not only provided diagnostic data on LV thrombi and 
complications of Ml, but the extent of LV asynergy on the initial 2D-Echo predicted 
outcome at 3 months and 1 year. Importantly, the degree of RSD on the initial 
2D“Echo predicted patients at high risk of adverse remodelling with infarct 
expansion, greater LV dysfunction, progressive LV dilatation, and poor outcome at 
1 year. Survivors of Ml with > 18% LV asynergy and significant RSD on a 
baseline 2D-Echo were at increased risk of topographic deterioration on exercise 
programs. Anti-inflammatory therapy after Ml resulted in more RSD and adverse 
remodelling. Short-term LV unloading with low-dose intravenous NTG therapy 
during the acute Ml, as well as prolonged nitrate (eccentric dosing) and captopril 
therapy during healing over 6 weeks after Ml, improved 2D-Echo indexes of LV 
geometry and function, decreased complications and improved outcome. Acute 
thrombolytic therapy also limited LV remodelling after Ml. In all these studies, the 
degree of RSD and severity of LV dysfunction were greater with anterior than 
inferior Ml, and with 0-wave than non-Q wave Ml.
In Conclusion, the overall results indicate that early RSD in the infarct zone leads 
to progressive global LV dilatation, LV dysfunction and poor outcome and the 
changes in LV geometry and function can be quantified by serial quantitative 2D- 
Echo imaging. Marked RSD is associated with early ECM disruption and 
aneurysm formation after transmural Ml. During healing, infarct zones may be 
thinned and dilated before the collagen plateau, and collagen deposition into 
these zones result in further RSD and chronic aneurysms. Prolonged anti- 
remodelling therapy during healing, with agents that decrease wall stress without 
damaging the ECM, or decreasing infarct collagen, or causing infarct thinning, or 
impairing healing, might be more effective for reducing RSD, LV aneurysm, global
III
dilatation and poor outcome. The 2D-Echo measurement of RSD early after Ml 
might be potentially important for stratifying patients according to their topographic 
status and for the objective assessment of the effects of anti-remodelling 
strategies during healing after Ml.
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SUMMARY
Background. This dissertation summarizes studies carried out between 1980 
and 1988 on the modification of left ventricular (LV) geometry and function during 
healing after acute myocardial infarction (Ml). A review of pertinent knowledge 
before, during, and after 1980 places the work in perspective and covers the 
following topics: LV geometry and function after Ml; healing and remodelling; the 
application of two-dimensional echocardiography (2D-Echo) to quantify LV 
geometry and function and assess temporal changes; detection of early infarct 
expansion and regional shape distortion (RSD) of asynergic zones by 2D-Echo; 
the anti-remodelling effects of infarct-limiting therapies; the protective role of the 
extracellular matrix (ECM); the potential adverse effects of anti-remodelling 
therapies on the ECM in infarct zones; and the value of non-invasive quantitative 
2D-Echo imaging in assessing the effects of anti-remodelling therapies on 
regional and global LV geometry and function.
Hypotheses. Two main hypotheses were addressed: i) Ml results in early RSD 
followed by progressive global LV dilatation and a more spheroidal shape, and 
more LV dysfunction during and after healing; and ii) the remodelling of LV 
geometry and structure after Ml is a dynamic process that spans the early 
infarction and healing phases, and is largely driven by increased wall stress. 
Mechanical forces acting on the infarct and non-infarct zones, as well as other 
factors, play significant roles in the remodelling of these regions. Progressive 
remodelling occurring during and after healing impacts negatively on outcome and 
may be modified by early and prolonged therapies.
Methods and Results. A multidisciplinary bench to bedside approach was used, 
with concurrent studies in a chronic dog model of healing over 6 weeks after Ml 
and patients with a first Ml. Computer-assisted analysis of the 2D-Echo images 
with 3D reconstruction was used to quantify LV asynergy (akinesis + dyskinesis), 
LV volumes, LV ejection fraction, RSD in short-axis images using novel indices 
[such as the peak (Pk) and depth (ra) of the bulge], RSD in diastolic images, and 
global LV shape.
Animal studies. These showed that collagen deposition increases progressively 
during healing, reaching a plateau around 2 weeks, and is associated with
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significant remodelling such that collagen deposition in already expanded infarct 
zones and late thinning lead to permanent RSD associated with LV aneurysms. 
Importantly, serial 2D-Echo tracked the topographic and functional changes and 
showed greater RSD and dysfunction with anterior than inferior Ml, and with 
transmural than non-transmural Ml. Transmurai Ml showed marked ECM 
disruption and RSD. Infarct-limiting therapies, such as nitroglycerin (NTG) and 
the anti-inflammatory drug ibuprofen, produced delayed effects on LV remodelling. 
Vasodilator-induced hypotension during acute Ml paradoxically negated the 
beneficial effects on collateral blood flow, infarct size and LV geometry seen with 
low-dose NTG. Decreased wall stress by prolonged LV unloading with nitrates 
(eccentric dosing) and angiotensin-converting enzyme (ACE) inhibitors during 
healing after Ml limited RSD, progressive LV remodelling and dysfunction. 
Importantly, this effect was greater when given over 6 weeks than just over the 
first 2 weeks. Late reperfusion, made 2 hours post-occlusion, limited RSD, 
adverse LV remodelling and dysfunction during healing and this effect was 
enhanced by nitrates. The resistance of the healed left ventricle to distension and 
rupture, which was lower for infarcted than normal hearts, was further reduced by 
prolonged therapy with ibuprofen over 6 weeks but was preserved by prolonged 
nitrate. Prolonged ACE inhibitor therapy decreased infarct collagen. Combined 
captopril and nitrate therapy showed similar beneficial effects on LV remodelling 
as compared to monotherapy.
Clinical studies. Serial 2D-Echo studies showed that systematic tomographic 
imaging was feasible and provided reproducible diagnostic and quantitative data 
on regional and global LV geometry and function. Strong correlations were shown 
between 2D-Echo LV volumes and those by biplane LV angiography, LV asynergy 
as percent LV circumference or endocardial surface area and CK infarct size, and 
the degree of RSD and infarct expansion or ventricular septal rupture. An early 
2D-Echo detected thrombi and other complications. In follow-up studies after first 
anterior Ml’s, the extent of LV asynergy on the initial 2D-Echo predicted outcome 
at 3 months and 1 year. In a larger study, the degree of RSD on the initial 2D- 
Echo predicted patients likely to develop adverse remodelling with infarct 
expansion and greater LV dysfunction, in-hospital complications and deaths, 
progressive LV dilatation, and poor outcome at 1 year. In a study of Ml survivors 
started on exercise programs, those with > 18% LV asynergy and significant RSD
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were at increased risk of topographic deterioration. Indomethacin therapy for 
post-MI pericarditis resulted in more RSD and infarct expansion. 2D-Echo 
indexes of LV geometry and function correlated with decreased complications and 
improved outcome after short-term low-dose intravenous NTG therapy during the 
acute Ml, and prolonged nitrate (eccentric dosing) and captopril therapy during 
healing over 6 weeks after Ml. Acute thrombolytic therapy also limited 
remodelling. In all studies, the degree of RSD and severity of LV dysfunction 
were greater with anterior than inferior Ml, and with 0-wave than non-Q wave Ml. 
The degree of early RSD (area, depth or volume) correlated with the severity of 
subsequent LV dilatation and the degree of overestimation of regional LV 
dysfunction.
Conclusion. The overall results indicated that progressive topographical and 
functional changes occur during healing after Ml and can be quantified by serial 
2D-quantitative Echo. Early RSD that develops in the infarct zone leads to 
progressive global LV dilatation involving both the infarct and non-infarct zones 
and is associated with LV dysfunction and poor outcome. Importantly, RSD, LV 
dilatation and LV function can be measured by 2D-Echo. Marked RSD is 
associated with early ECM disruption and aneurysm formation after transmural Ml. 
Collagen deposition into thinned and dilated infarct zones during healing seems to 
result in permanent RSD found with chronic aneurysms. Prolonged therapy, with 
anti-remodelling agents that decrease wall stress but do not damage the ECM, or 
decrease infarct collagen, or cause infarct thinning, or impair healing, might be 
more effective for reducing RSD, LV aneurysm, global dilatation and poor 
outcome. The 2D-Echo measurement of RSD might be potentially important for 
assessing the effects of anti-remodelling strategies during healing after Ml.
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1. INTRODUCTION
This dissertation for the degree of MD is submitted in the form of an essay entitled 
‘Modification of left ventricular geometry and function during healing after 
acute myocardial infarction (Ml)’. The work was conducted at the University of 
Alberta Hospital between 1980 and 1988, following the completion of post­
doctoral training and clinical fellowships In cardiovascular research at the 
University of Alberta Hospital (1974-1976) and the Johns Hopkins Hospital (1976- 
1979). In this essay, I have endeavoured to ‘show the relationship between the 
various published papers’ and abstracts relating to the topic, and ‘place the whole 
work critically into perspective with the general state of knowledge’ in this area of 
investigation.
2. REVIEW OF BACKGROUND LITERATURE
In order to place the work in perspective, the background knowledge section 
summarizes the pertinent findings from studies that I conducted on the subject 
during the period between 1980 and 1988 in my laboratory, and those in reports 
from other laboratories before 1980 and after 1988. I have highlighted the 
progress made in my field during the study period and the major advances made 
in subsequent years. For reference, I have included, in the bibliography, 
published papers and some pertinent abstracts of papers that have not yet been 
published.
2.1. Left ventricular geometry and function
The left ventricle, the main pumping chamber of the beating heart, occupies a key 
position in the cardiovascular system as it generates the stroke output critical for 
survival. Since the 1960’s, left ventricular (LV) geometry, which refers to the 
shape, size and structure of the left ventricle, was becoming recognized as an 
important determinant of LV function (1). The normal LV geometry is considered 
to be a prolate ellipsoid, that is elliptical in the long-axis and circular in the short- 
axis (2). Deformation of LV geometry, with a departure from an ellipsoidal to a 
spheroidal configuration, was subsequently shown to be associated with LV 
dysfunction (3-5). Several authors suggested that changes in global LV shape 
and size might influence clinical outcome (1,4,6-12).
Studies since the mid 1970’s suggested that dramatic regional deformation 
of LV geometry may occur after acute myocardial infarction (Ml) (13-
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18,19[Appendix 1],20-22) and have a profound negative impact on LV function 
and outcome (20[Appendix 2],21 [Appendix 3]). Studies in the mid 1980’s 
indicated that these negative effects were evident on both the short-term and 
long-term (21,22;Appendix 4), and depended largely on the initial myocardial 
infarct size (21) as well as the subsequent processes of infarct healing and LV 
remodelling (22).
In general, the term remodelling refers to changes in structure and shape. 
The Oxford and Webster’s English dictionary definitions of “remodel” emphasize 
three-dimensional (3D) reconstruction and shape, while definitions of repair 
emphasize restoration of shape and function (Table 1).
T A B L E  1. D e fin it io n s
R em ode l
W ebste r’s dictionary: to a lte r the structure of; rem ake
The Oxford dictionary: to m ode l again or differently; to  reconstruct or reorganize  
(m odel n: representation in 3 d im ensions o f proposed structure; vb; fash ion , shape} 
R e p a ir
W ebster's d ictionary: vb: to restore, fix, renew, m ake good, mend, rem edy; 
n: rep lacem ent o f destroyed ce ils o r tissues by new  fo rm ations 
The Oxford dictionary; vb: to  restore to good condition a fter dam age or w ear, to  set 
right, to fix, renovate, refix
After Ml, LV remodelling refers to the changes in the geometry, shape, 
structure, architecture and topography of the infarcted left ventricle. Collective 
evidence, mostly over the last two decades, has strengthened the hypothesis that 
these LV remodelling changes after Ml have profound negative effects on LV 
function and survival (22-26,27[Appendix 5],28[Appendix 6],29,30). This has led 
to efforts to develop therapeutic strategies for limiting, preventing and even 
reversing adverse remodelling after Ml (22-30).
An important aspect of the assessment of therapeutic interventions to limit 
adverse remodelling is the ability to reliably quantify LV shape, size, structure and 
function in repeated studies before, during and after therapy (21,28-30). Since the 
early 1980’s, two-dimensional echocardiography (2D-Echo) has emerged as a 
practical tool for the non-invasive quantification of in-vivo LV remodelling and 
function after Ml in research studies at the bedside and in the laboratory (16,19- 
21,28-32,33[Appendix 7],34[Appendix 8],35[Appendix 9],36[Appendix 10],37). 
However, only a few of these studies have applied 2D-Echo with 3D 
reconstruction for quantifying LV size and regional dysfunction (21,28,30-34) or
2D-Echo for quantifying early regional shape distortion (RSD) of the infarct zone 
(13-16,31-36).
2.2. Healing after acute myocardial infarction
The healing process after acute Ml attempts to repair the damaged LV wall, 
preserve its integrity and restore function. Clearly, the healing process is not ideal 
since LV dysfunction usually persists. This topic has been previously reviewed 
(22,37[Appendix 11],38-40).
The collective evidence indicates that healing after Ml is a dynamic and 
time-dependent process (22,23). Pathophysiologically, it involves acute and 
chronic inflammation followed by collagen deposition and scar formation. 
Histopathological studies have shown an early inflammatory component after both 
animal and human Ml. Thus, early pathophysiological events in the occluded 
region during acute Ml closely resemble events during acute inflammation (40,41: 
Appendix 12). These include trapping of leucocyte and inflammatory cells, 
lysosomal membrane breakdown and release of lysosomal enzymes, cellular 
membrane breakdown, release of prostaglandins (PGs), red blood cell sludging, 
blood platelet trapping and aggregation leading to release of granular products, 
hemorrhage, oedema, myocardial tissue necrosis, and necrosis of intramyocardial 
blood vessels (38). The granular products, released by platelet aggregation into 
the ischaemic tissue, appear to lead to a vicious cycle of platelet plugging, 
vasoconstriction, thrombosis, increased vascular permeability, more tissue 
oedema and injury, and more necrosis, especially in the marginal zones of the 
infarcts.
In both animals and humans, acute inflammation is followed by chronic 
inflammation, connective tissue proliferation and collagen deposition until healing 
is completed by formation of a firm, contracted and inelastic scar (40,41). In 
humans, acute inflammation predominates in the first week, chronic inflammation 
in the second week, and collagen deposition from the third week onwards (40). 
The timing of these sequential events during healing might be highly pertinent 
when using agents that impair acute or chronic inflammation and collagen 
deposition during healing after Ml (Table 2) (22).
Evidence indicates that the duration of healing of the infarct zone after Ml 
differs among species (Figure 1), being longer in humans than dogs and rodents
(42). Thus, the interval from the onset of an Ml to the formation of the final scar
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ranges between two and three weeks in rats (43), four and six weeks in dogs (41), 
and between six weeks and six months in humans depending on infarct size 
(40,44). The slower rate of healing in humans compared to dogs and rats is 
therefore pertinent when determining the optimal timing and duration of 
therapeutic interventions on the basis of animal data, so as to avoid confounding 
effects on healing.
TABLE 2. Tem poral staging o f left ventricular remodelling after myocardial 
infarction: A guide fo r the timing of therapy
Timing Pathophysiological process
early ; F irs t 2 4  hours A cu te  evo lu tion  and co m p le tio n  o f 
m yoca rd ia l in fa rc tion
Early: D a y  2 to  2  w e e ks H ea ling  be fo re  in fa rc t co llagen  p la teau
Late ; 3 to  6 w e e k s  
(up to  6 m o n th s )
H ea ling  a fte r in fa rc t co llagen  p la teau
V e ry  la te : A fte r  1 .5  m onths 
(up to  12 m o n th s )
Late  po s tin fa rc t hea ling
From Jugdutt (22[Appendix 2])
As noted above, several pathophysiological studies have documented that 
the rate of healing depends on infarct size, such that the larger the infarct, the 
slower the rate (40,41,43). The rate of healing also depends on cellular, 
metabolic and biochemical factors and the adequacy of nutrient blood flow 
(22,37,39). It follows that therapies that are likely to impair healing may need to 
be delayed for longer in patients with large Ml compared to those with small Ml.
The possibility that certain interventions may accelerate or delay healing 
also needs to be considered when applying therapy. Thus, reperfusion after Ml 
has been shown to be associated with decreased infarct size (45), more rapid 
healing (46) and less adverse remodelling in animals (47,48[Appendix 
13],49[Appendix 14]) and humans (50;Appendix 15).
Collective evidence indicates that LV remodelling and healing after Ml are 
highly dynamic processes that run in parallel (22,23) and significant regional 
remodelling of the infarct zone occurs during the healing phase (22). It follows 
that therapies that modify healing may significantly influence LV remodelling after 
Ml (22,23).
Several experimental studies in the early 1980’s addressed the hypothesis 
that administration of drugs that decrease the inflammatory response, collagen
deposition and collateral blood flow during healing after Ml may promote adverse 
LV remodelling. Thus, anti-inflammatory agents, such as glucocorticoids and non­
steroidal anti-inflammatory drugs (NSAlDs) given during healing after Ml 
consistently induced more thinning of the infarct zone in the dog model (51-54). 
However, these agents did not significantly reduce the collagen content in the 
infarct scar (51-54). Importantly, the NSAIDs caused infarct zone thinning and 
expansion even in small infarcts in dogs (55:Appendix 16). Furthermore, these 
agents exerted different effects on infarct size and remodelling. Thus in the 
infarction phase, indomethacin was shown to increase (56) and ibuprofen to 
decrease (57) infarct size, while both agents increased remodelling of the infarct 
zone (52,54). Interestingly, aspirin did not cause infarct thinning or expansion 
(54), suggesting that it might be safe during healing after Ml. In contrast to 
studies with ibuprofen in the dog (54,55), one study of ibuprofen during healing 
after Ml in rats suggested it may increase infarct collagen by delaying proteolysis 
and, in that setting, did not cause significant infarct thinning (58). Moreover, in the 
clinical setting, therapy with ibuprofen or indomethacin for post-infarction 
pericarditis in patients resulted in enhanced infarct thinning and expansion, and 
increased prevalence of LV aneurysm (35).
2.3. Two-dimensional echocardiography after myocardial infarction and 
the recognition of infarct expansion
Following the introduction of 2D-Echo in the mid 1970’s, several investigators 
recognized the importance of RSDs following Ml and the importance of 
tomographic imaging in multiple planes (5). Others systematically applied 2D- 
Echo to study LV aneurysm (13), LV asynergy (14-17) and regional dilatation in 
acute Ml (18). The latter study led to the first description of clinically significant 
and often fatal myocardial infarct expansion after acute Ml (18).
However, Hutchins and Bulkley (now Healy) first described the pathological 
correlates of clinically significant and fatal infarct expansion after Ml in 1978 (59). 
They defined infarct expansion pathologically, as an increase in the proportion of 
the surface area of the left ventricle occupied by necrotic myocardium with 
concomitant thinning of the infarcted wall, dilatation of the LV cavity and distortion 
of LV topography that was not explained by new necrosis. They found that the 
majority of patients dying within 30 days of an acute Ml had infarct expansion. 
Thus, within six days of transmural (Q-wave) Ml, about 17% developed infarct
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extension with further new necrosis while about 59% developed infarct expansion 
but no new necrosis. This marked and fatal expansion was associated with 
abrupt or insidious disruption of necrotic myocytes where acute inflammatory cells 
were disintegrating. It was compared to an ‘intramural tearing of necrotic muscle’. 
Removal of necrotic cells or mural collapse did not appear to play a significant role 
during the early stages of healing.
In that study (59), Hutchins and Bulkley also graded the severity of infarct 
expansion pathologically. They compared the relative position of internal 
ventricular landmarks such as the papillary muscles and junctions of the right and 
LV free walls with the septum. They found that marked expansion tended to 
develop 5 days or more after acute Ml, and was more frequent with first infarctions 
that were large and transmural. They also found that wall thinning was greater 
with marked expansion in these large transmural infarcts but was less with small 
and subendocardial infarcts.
Clinically, infarct extension in that study was defined as the syndrome 
consisting of new ischaemic chest pain, ST-segment elevation on 
electrocardiography (EGG), rise in serum creatine kinase (CK) levels, and 
increasing congestive heart failure within 10 days of the indexed Ml. 
Pathologically, extension was defined as new necrosis around the area of 
previous acute infarction. However, of the 14 patients who were clinically 
diagnosed as having extension, only two (14%) had isolated extension while as 
many as nine patients (65%) had extension plus expansion, and 3 patients (21%) 
had isolated expansion.
More importantly in that study, the next clinical event associated with the 
syndrome of recurrent chest pain, worsening congestive heart failure, hypotension 
and ST-T wave changes after an acute Ml, was more likely to be due to infarct 
expansion than infarct extension. This fatal syndrome occurred in 70% of patients 
with marked morphologically defined expansion, in 38% with moderate expansion, 
but in none of the patients with mild expansion.
Several mechanisms for components of the clinical syndrome were 
postulated (59). The chest pain was explained by the acute dilatation of the LV 
wall and stretching of the overlying pericardium, which is often involved in the 
inflammatory process associated with transmural infarcts. Reflection of the 
expanded infarct surface area over a greater number of praecordial leads was 
suggested to explain new changes on ECG. A tearing of necrotic myocardium
and new necrosis secondary to adverse haemodynamic consequences of 
expansion (increased wall stress; increased myocardial oxygen demands and 
hypotension; decreased diastolic perfusion, ischaemia and infarction) was 
postulated to result in secondary elevation of serum CK levels or accelerate 
enzyme release.
Thus, this carefully conducted and small clinico-pathological study drew 
attention to the critical role of early infarct expansion in early remodelling after 
acute Ml and underscored the need to recognize significant infarct expansion 
clinically. Subsequent clinical studies using 2D-Echo confirmed that infarct 
expansion with marked acute LV dilatation was associated with moderate to large 
areas of myocardial necrosis and dyskinesis and resulted in acute congestive 
heart failure and hypotension (18,21,28,31,32). Several of these longitudinal 
clinical studies applied 2D-Echo to establish the central role of early infarct 
expansion in early and late stages of remodelling after acute Ml (21,28,31,32). 
Thus, these studies indicated that early infarct expansion in humans plays a role 
in acute LV enlargement (32), accelerated aneurysm formation (21), cardiac 
rupture (20,60), and progressive LV enlargement (31).
The early detection of infarct expansion therefore became important. 
Although several clinical features may lead one to suspect infarct expansion, 
definitive diagnosis has been difficult. Although praecordial ST-segment mapping 
on ECG permits the non-invasive diagnosis of infarct extension (61), it is not 
helpful in the diagnosis of infarct expansion. Several studies suggested that an 
early non-invasive diagnosis of infarct expansion can be made by means of 2D- 
Echo at the bedside (21).
Eaton et al. (18) first reported the recognition of regional LV dilatation or 
infarct expansion by serial 2D-Echo imaging over the first two weeks after anterior 
Q-wave Ml in 8 of 28 patients. They assessed infarct expansion on end-diastolic 
outlines of short-axis 2D-Echo images by means of a computer-aided semi­
automated contouring system. They measured: i) the length of the infarct- 
containing segment between anterior and posterior papillary muscle markings; ii) 
the average thickness of the segments; and iii) the total LV circumference. They 
were able to make a retrospective diagnosis of expansion in 8 patients (29%) who 
showed evidence, between initial and final echocardiograms, of an increase in the 
infarct-containing segment length by 48% (range, 26% to 108%), marked infarct 
thinning by 26% (range 17% to 44%) and an increase in LV circumference by
8
25%. These expanders represented a high-risk group and showed greater 
functional deterioration and higher eight-week mortality compared to non- 
expanders (50% versus 0%).
Subsequent studies with serial 2D-Echo after Ml (20,21,28,31,32,34,35) 
used two more variables to quantify infarct expansion on 2D-Echo: i) expansion 
index or ratio of the length of the infarct-containing endocardia! segment to the 
length of the non-infarct containing endocardial segment; ii) thinning ratio or ratio 
of the average thickness of the infarct zone to the average thickness of the non­
infarct zone. In all these studies, the infarcted zone was defined as the zone 
containing asynergy, usually defined as akinesis plus dyskinesis. The relationship 
between asynergy and myocardial necrosis was established in an earlier study 
(62). Erlebacher et al. (31) found that at 10 to 21 days after Ml, an anterior infarct- 
containing segment length of more than 11.0 cm indicated anterior infarct 
expansion.
It is important to note that these five measurements allowed the diagnosis 
of expansion to be made after the event, or retrospectively, after repeated studies. 
There was still a need in the mid 1980’s to identify expanders on the initial 2D- 
Echo. My laboratory therefore attempted to quantify the regional diastolic bulge, 
or RSD, of asynergic zones on short-axis 2D-Echo images (19,20,21,34). In a 
large prospective study of 244 consecutive patients with a first Q-wave Ml, the 
degree of RSD on an early 2D-Echo within 2 days of the Ml was found to identify 
potential expanders (21). Specifically, 50 of 51 expanders, compared to 3 of 193 
non-expanders, had a peak regional shape distortion index (Pk) or depth of 
outward bulging (rj) of more than 10 mm on the initial 2D-Echo.
The ability to predict which patients are likely to develop infarct expansion 
on an initial 2D-Echo is of considerable clinical importance if timely therapy is to 
be applied to attenuate remodelling. The prospective evaluation of several 
predictive indexes has been a prime objective in my laboratory. In two recent 
large prospective clinical studies (28,35), prospective diagnosis of the infarct 
expansion syndrome was made possible, at 40 hours or more, when the acute 
event was associated with the following two sets of criteria:
i) clinical: acute hypotension (systolic blood pressure <90 mm Hg and 
peripheral hypoperfusion), LV failure with pulmonary congestion, evidence of 
LV dilatation with or without further chest pain, no new ECG changes of injury,
no significant new plasma CK elevation (<100 lU/L) suggesting new necrosis; 
and
ii) 2D-Echo: evidence of marked regional diastolic stretching (>25% increase in 
asynergy-containing endocardia! segment length), marked thinning (>25% 
decrease in thickness of asynergic wall), and dilatation (>25% increase In 
diameter, area and volume) compared to the initial recording.
In summary, acute infarct expansion is now recognized as the cornerstone 
of remodelling after Ml. The topic has been previously reviewed (63[Appendix 
17],64). The determinants of infarct expansion and early remodelling are 
summarized in Table 3. The overall findings suggest that, within the first few 
hours to days after an acute Ml, early remodelling with.expansion of the infarcted 
segment involves acute outward bulging of the infarct zone, with stretching, 
thinning and dilatation of that zone, resulting in RSD that can be detected on end- 
diastolic 2D-Echo images.
TABLE 3- Determ inants o f m yocardial in fa rc t expansion and early 
rem odelling
Physical characteristics o f the Infarct 
® Size of the infarction
* Transmuraiity of infarction 
« Location of Infarction
» Type of infarction
•  Age of infarction 
E fficacy o f the  healing processes
» Infiammatory response 
«> Collagen deposition 
® Collatéral circulation 
« Reperfusion
Mechanical forces {strength, duration and frequency o f application) 
e Intracavitary distending forces {Push)
Preload
Afterload
Wait stress (dimension dependent, Laplace effect)
® Intramural forces (Stretch and Pull)
Contractility 
Heart rate:
Treppe effect (increased contractility)
Increased frequency of contraction 
® External restraining forces 
Pericardium and fluid 
Pericardial pressure 
Extracardiac structures
"I
From Jugdutt (67[Appendix 18])
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2.4. Changes in left ventricular geometry and function during healing after 
myocardial infarction
It is well known that most acute infarcts bulge out during systole. In 1935, 
Tennant and Wiggers first reported systolic expansion of the cyanotic zone after
acute coronary artery ligation in the dog (65). However, with infarct expansion, 
outward bulging is also present in diastole, implying more profound shape 
deformation and architectural change in the left ventricle (41). Initially, the 
increase in cavity area, and therefore the diameter, is confined to the zone with 
regional bulging. Subsequently, further progressive remodelling takes place and 
the end-result is global LV cavity dilatation, with generalized increase in LV cavity 
area and diameter (21,28), and a more spherical LV shape (7-12).
Experimental studies suggested that the early thinning in the infarct zone is 
due to a slippage between muscle bundles so that the number of myocytes across 
the thickness of the infarct zone is reduced (66). It was reasonable to suggest 
that the necrotic myocardium during the early stage of healing after Ml, when 
inflammation is active, might be more susceptible to shape deformation due to 
distending intracavitary forces, such as high preload and afterload, and intramural 
traction, or pull, of the adjacent non-infarcted myocardium (63,67:Appendix 18).
It appears that RSD results in increased regional wall stress and the 
associated gradient in wall stress may drive the remodelling of LV shape in an
I
%
attempt to normalize wall stress, thereby resulting in the spherical LV shape. 
Several forces at work in every individual case, and at different stages of healing, 
appear to influence the final outcome.
Before 1980, it was known that infarcted hearts often underwent marked 
dilatation associated with dilated cardiomyopathies (7), lengthening of the non­
infarct segment played a role in the late LV dilatation (7,68), and healed scars 
were less distensible and more resistant to deformation (69). However, the 
mechanisms were not known and it was not clear whether significant late 
remodelling of the infarct scar occurred consistently after the healing phase.
In the 1980’s, my laboratory proposed a sequence of changes during early 
and late stages of remodelling during healing after Ml (Figure 2). Theoretically, 
the early infarct expansion and RSD that develop after acute Ml initiate a vicious 
cycle of ineffective cardiac contraction, decreased systolic ejection, decreased 
cardiac output, increased systolic and diastolic volumes, which in turn lead to 
more LV enlargement, LV dysfunction, physical disability and death.
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Within the first few hours to days after acute Ml, the infarcted wall 
undergoes regional expansion, with stretching, thinning and dilatation; this results 
in early RSD, with outward bulging in diastole and ballooning in systole. The 
acute remodelling of LV shape and structure after acute Ml undergoes further 
alterations during subsequent healing and may, under certain conditions, trigger 
the vicious cycle of progressive global LV dilatation, LV failure, LV rupture, and 
death.
Major forces in the development of early infarct expansion and RSD 
include: i) physical characteristics of the infarct such as infarct size and location; ii) 
other factors relating to the efficacy of early healing such as cellular infiltration, 
fibroblast activity and collagen deposition, metabolism and nutrient collateral blood 
flow; and iii) haemodynamic factors, such as the magnitude, duration and 
frequency of mechanical forces acting on the infarct zone, such as afterload, 
preload, wall stress, heart rate and contractile pull of the adjacent normal 
myocardium (22,37,39,63) (Table 3).
During healing, collagen deposition into the already thinned and stretched 
infarct segment fixes or cements’ the early RSD, resulting in the permanent RSD 
associated with aneurysm formation (41). The permanent scars that develop in 
thinned infarct tend to be thin and weak, ballooning out during contraction, thereby 
leading to incomplete emptying of the pumping chamber and permanent disability.
Further late remodelling, with compaction of the infarct scar and 
lengthening and hypertrophy of the non-infarcted segment, may initially provide 
some some compensation but is eventually followed by LV dilatation and 
dysfunction.
Several studies have documented the importance of infarct size and 
location on the severity of infarct expansion and the degree of RSD. All 
pathologic studies have suggested that first, large and transmural infarcts are 
prone to expansion (18,59,60,70-72,73[Appendix 19],74[Appendix 20]). Clinical 
studies have confirmed that first, large, 'transmural’ or ‘Q-wave’ infarcts are prone 
to expand (21,28). The reason why nontransmural or subendocardial infarcts do 
not expand might be because the subepicardial rim of normal myocardium 
provides a buttress or scaffold that protects against the distending forces. Small 
infarcts, that tend to be subendocardial, are less likely to expand (21). The critical 
infarct size for expansion to occur was found to be 11% of the LV weight in the 
dog heart (70) and 17% in the rat heart (71). However, there was no strong
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correlation between infarct size and the degree of infarct expansion in these 
studies, suggesting that other factors are involved. In the rat model, infarct size 
was found to influence LV function (75), dilatation (76) and survival (77).
Although the frequency and severity of infarct expansion did not differ 
between anterior and posterior infarcts in the dog (70), all clinical studies indicate 
that topographic deterioration is greater with anterior infarcts (18, 20,21,28,78). In 
a clinico-pathologic study, Pirolo et al. (79) also found that patients with 
transmural infarction of the LV antero-apical area are more likely to develop 
expansion. This might be due to the fact that this region of the left ventricle is the 
thinnest, has the greatest curvature and is under more stress (1,80). The greater 
restraining effect of the posterior pericardium and adjacent extracardiac structures 
might explain why topographic deterioration is less with infarction at the inferior 
than the antero-apical location. Pirolo et al (79) also found in their study that 
hearts with prior LV hypertrophy are less prone to develop infarct expansion.
Other factors, such as prior collagen content, infarct age, the patient’s age, 
presence of multivessel disease, collateral reserve and concomitant drugs also 
appear to be important (63). The importance of nutrient flow during healing after 
acute Ml is becoming recognized. In antero-apical infarcts of fixed size and 
produced by left anterior descending (LAD) coronary artery ligation and collateral 
obliteration, expansion was more severe than with coronary ligation alone (73,74).
Factors that increased wall stress, such as hypertension (32) and exercise 
(34,81-83), were shown to increase expansion in animals and humans. An acute : .increase in afterload and wall stress with methoxamine was found to increase 
expansion in dogs (84). Conversely, an acute decrease in afterload and wall 
stress with intravenous nitroglycerin (NTG) and intra-aortic counterpulsation was 
shown to reduce LV dilatation in humans (85). Venodilatation, decreased blood 
volume and preload with long-term treatment with captopril, an angiotensin- 
converting enzyme (ACE) inhibitor, was shown to be an important mechanism for 
attenuation of LV dilatation in rats (86).
2.5. Effect of potential infarct-limiting therapies on healing and left
ventricular geometry and function after myocardial infarction
In the mid 1970’s, a major goal of therapy after Ml was to reduce infarct size
(87,88). Around the early 1980’s, several experimental studies using the rat
model of Ml showed a negative relation between myocardial infarct size and LV
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function (75), LV dilatation (76), and survival (77). However, those studies did not 
address infarct expansion or RSD or topographic changes during infarct healing. 
Early scepticism about infarct-limiting therapies and the potential for limiting 
remodelling was rooted mainly in the lack of robust in-vivo quantitative 
methodology.
Subsequent experimental and clinical studies over the 1980’s provided 
further evidence in support of the idea that infarct size is a major determinant of 
the degree of LV remodelling and dysfunction after Ml (18,21,26,34-36,60,70-75). 
Several of these studies assessed infarct expansion (21,34-36,60,70-75) or both 
infarct expansion and RSD (21,34-36,73,74), and many used 2D-Echo clinically 
(18,21,34-36,89) or in the dog model (70,73,74).
Three other clinical studies in the early 1980’s supported the idea that 
infarct size was a major determinant of outcome. First, one study confirmed that 
acute extension of infarct size is associated with a high mortality (90). Second, 
another study showed the 21 day mortality after acute Ml was higher with 
transmural than non-transmural Ml (23 % versus 10 %, P<0.01) and early infarct 
recurrence had an additional adverse effect on survival (91). Third, a study using 
equilibrium radio-nuclide angiocardiograms, confirmed that early functional 
aneurysms in patients after anterior Ml carries a high-risk of death within one year 
that is independent of LV ejection fraction and its absence identified a group with 
low mortality despite impaired ejection fraction (92).
Other studies documented early and late topographic changes after Ml in 
the rat model ex-vivo (93,94). One study addressed healing and repair after Ml in 
the rabbit model and suggested that LV rupture was more common 1-4 days after 
Ml and collagen content was a determinant of infarct stiffness and the resistance 
of the left ventricle to rupture (95). In a comparative study of healing after Ml in 
the dog and rat models, healing was shown to be more rapid and LV remodelling 
more severe in the rat than the dog (96).
In the mid 1980’s, a novel concept was that limitation of infarct size and 
preserving ventricular muscle might be the most effective means of limiting LV 
remodelling, dilatation and dysfunction, and thereby improving survival. I 
therefore embarked, as others did, on studies of the limitation of LV remodelling 
via limitation of infarct size. I pursued the hypothesis that therapy given during 
healing after Ml, using agents that decrease afterload, preload, chamber size, 
heart rate, contractility and wall stress without impairing healing, decreasing
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infarct collagen, or causing infarct thinning, might reduce the extent of RSD and 
thereby improve myocardial performance and have a positive impact on overall 
outcome. Furthermore, the potential beneficial effects of such agents on scar 
topography and collagen deposition might be expected to enhance the 
mechanical strength of the scar and thereby limit LV distension and aneurysm 
formation, and prevent LV rupture. However, on the basis of my findings in on­
going studies of healing after Ml (55) and those from other laboratories (51-54), I 
considered it was pertinent to address the issue of potential effects of infarct- 
limiting therapies on the healing phase during which significant LV remodelling 
occurred.
By the mid 1980’s, three categories of infarct-limiting therapy were 
becoming available for testing: i) non-thrombolytic pharmacological therapy; ii) 
pharmacologically-mediated thrombolysis with or without coronary angioplasty; 
and iii) the combination of thrombolytic and non-thrombolytic therapies.
2.5.1. Anti-inflammatory agents
The effects of methyl prednisolone on infarct size have been controversial (51). 
However, methyl prednisolone delayed inflammation and disintegration of necrotic 
myocytes, decreased infarct collagen, and impaired healing after Ml in the rat
(43). It also caused infarct thinning, infarct expansion and LV dilatation despite a 
decreased infarct size in the rat model (97). Furthermore, short-term methyl 
prednisolone given after Ml in the dog induced marked infarct thinning and 
regional dilatation although collagen did not change (51).
As mentioned previously, the NSAID ibuprofen decreases infarct size (55) 
but also aggravates thinning and expansion during early healing of the infarct 
without altering the collagen content of the infarct scar (54). However, one study 
in the rat model, where ibuprofen was given at 1, 6 and 18 hours after Ml did not 
detect infarct thinning but found increased Infarct collagen (58). Since a 
randomized clinical study of the effect of Ibuprofen after Ml could not be ethically 
justified, the effects of ibuprofen and indomethacin (another NSAID) therapy on 
LV remodelling and function was studied In patients given these drugs for 
pericarditis associated with acute transmural Ml and both agents were shown to 
enhance LV aneurysm formation (35).
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2.5.2. Nitroglycerin, prostaglandins, and ibubrofen
Several therapies that are potentially infarct-limiting when given during the 
infarction phase over the first few hours after acute Ml, such as NTG (98) and 
prostacyclin or prostaglandin (PG) b (99), were shown to result in delayed 
beneficial effects on infarct collagen and LV geometry at 7 days post Ml in the dog 
model (55). In that study, ibuprofen given after acute Ml decreased infarct size 
and the infarct expansion index, did not decrease Infarct collagen, but induced 
infarct wall thinning (55). Interestingly, NTG therapy was associated with 
increased infarct collagen and no infarct expansion or thinning (55).
The effects of long-term NTG therapy (100[Appendlx 21], 101) during 
healing after Ml were subsequently tested in the dog. model (48,102[Appendix 
22],103[Appendix 23],) and in patients (104,105[Appendix 24], 106,107,108 
[Appendix 25],109[Appendix 26]). Briefly, these studies demonstrated beneficial 
effects of NTG on LV geometry and function as well as clinical outcome (104- 
109). The potential mechanisms of benefit with nitrates after Ml are summarized 
in Table 4.
TAB LE  4. P o te n tia l m e ch a n ism s  fo r  b e n e fit w ith  low -dose  in tra v e n o u s  
n itro g ly c e r in  th e ra p y  in acute  m yo ca rd ia l in fa rc tio n
1. improved haem odynam ics
Decreased preload; increased venous capacitance 
Decreased afterload and Impedance
2. improved flow  and perfusion
increased collateral blood flow
Decreased coronary artery spasm
Increased d iam eter o f epicardial arteries and stenoses
Increased endothelial relaxation factor activity
Increased prostacyclin activity
Decreased platelet adhesiveness and plateau plugs
Increased coronary vein and lym phatic flow
Increased removal o f noxious m etabolites of ischaemia
3. Decreased ischaem ic Injury and infarct size
4. Improved cardiac geom etry
Decreased cham ber size and wall stress 
Decreased deform ation forces 
Decreased regional dilatation and expansion 
Decreased global dilatation 
Decreased aneuysm  formation
5. improved regional and global ventricular performance
6. Decreased infarct related complications
7. Improved survival
::
Modified from Jugdutt (22[Appendix 4])
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2.5.3. The RAAS and ACE-inhibition
During the early 1980’s, interest in the role of the renin-angiotensin-aldosterone 
system (RAAS) in heart failure after Ml was increasing. Collective evidence 
indicated that cardiac failure from myocardial loss, or other causes, is associated 
with excessive rise in preload, systemic vascular resistance and afterload, heart 
rate, catecholamines and activation of the RAAS (110). This leads to angiotensin- 
mediated vasoconstriction and aldosterone-mediated sodium retention result 
(111). The end-result of significant myocardial loss is congestive heart failure 
(Table 5). Various factors in congestive heart failure lead to the release of renin, 
the rate-limiting enzyme for the generation of angiotensin II and aldosterone. 
Several compensatory mechanisms become activated in the very early stages of 
heart failure (Table 5).
TABLE 5. Pathophysiology of congestive heart failure after myocardial 
infarction
Special features
Loss of ventricu la r m ass 
Ischaem ia in ad jacen t regions 
A neurysm  (regional shape distortion)
- paradoxical systo lic  expansion
- d iasto lic expansion
- increased w all s tress 
increased wait stress in norm al muscle 
Decreased ven tricu la r com pliance 
G lobal ventricu la r d ila ta tion  
V entricu lar vo lum e overload hypertrophy
G enera l fe a tu re s  
Pressure overload 
Volum e overload 
Further loss of ven tricu la r muscle 
D ecreased systo lic  contractile  function 
Restricted d iasto lic filling
P o te n tia lly  d e le te r io u s  c o m p e n s a to ry  m e c h a n is m s  
Increase in ren in-angio tensin-a ldosterone 
Increase in c ircu lating catecholam ines 
increase in preload
Increase in system ic vascu lar resistance 
Increase in heart rate
It has been shown that neurohumoral activation is present after acute Ml 
(112,113), even in haemodynamically compensated patients (114). 
Neurohumoral activation results in increased vasoconstrictor activity and retention 
of sodium and water, due mainly to the effect of angiotensin II, norepinephrine and
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vasopressin (110,111). This is only partially counter-balanced by the vasodilator 
and natriuretic actions of atrial natriuretic peptide. Activation of the RAAS is the 
dominant feature of congestive heart failure. Angiotensin II contributes to the 
excessive rise in systemic vascular resistance, increased sympathetic outflow and 
increased levels of circulating catecholamines, and increased release of 
aldosterone which promotes more salt and water retention. Although 
compensatory mechanisms initially serve to maintain cardiac performance, they 
can potentially overshoot and produce deleterious effects, with excessive rise in 
preload, systemic vascular resistance and heart rate (115).
Although pharmacological inhibition of the RAAS may be produced at 
several points along the hormonal pathway (111), a practical and effective means 
of blocking the renin-angiotensin axis is by angiotensin-converting enzyme (ACE)- 
inhibition. ACE-inhibition was suggested for preventing the haemodynamic and 
metabolic changes, and thereby decreasing preload, afterload, and leading to 
improved cardiac output (111,116). I therefore pursued the hypothesis that ACE- 
inhibition might potentially limit infarct expansion, RSD, LV dilatation and 
aneurysm formation after Ml. Long-term treatment with ACE inhibitors might be 
more effective than NTG alone because of their combined metabolic and 
haemodynamic effects and the fact that continuous NTG administration might be 
complicated by nitrate tolerance (117,118:Appendix 27).
In the early 1980’s, ACE inhibitors, like captopril and enalapril, had been 
shown to effectively decrease preload and afterload, reduce cardiac size, and 
improve cardiac output in patients with severe and refractory heart failure 
(111,116). The ACE inhibitor captopril was also shown to reduce infarct size in 
rats (119). In 1985, Pfeffer et al. first reported the beneficial effects of 3 to 4 
months of captopril therapy, begun 2 and 21 days after Ml, on LV dilatation, 
cardiac output, and chamber stiffness after Ml in the rat (120). The groups with 
initiation of treatment at 2 and 21 days after Ml did not differ in that study (120). In 
a later study, Pfeffer et al. showed that captopril therapy prolonged survival in the 
rat model when begun 14 days after Ml, after the early healing phase was mostly 
over (76). However, infarct expansion, RSD and infarct collagen were not 
evaluated in those studies.
By 1988, two randomized, double-blind clinical trials reported the beneficial 
effects of prolonged captopril therapy after acute Ml, on LV size and function 
(29,30). First, Sharpe et al. (29) showed that captopril therapy (25 mg t.i.d.), in 60
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patients with one-week old Q-wave Ml but no heart failure prevented the increase 
in LV diastolic volume, reduced the LV systolic volume, increased stroke volume 
index, and improved LV ejection fraction after one month and up to one year by 
quantitative 2D-Echo. Second, Pfeffer et al. (30) showed that captopril therapy 
decreased LV diastolic volume, decreased filling pressure and increased exercise 
capacity during one year of follow-up in 59 patients with 11-day to 31-day old 
anterior Ml and radio-nuclide ejection fractions of 45% or less but no heart failure.
The subsequent ‘Survival and Ventricular Enlargement’ (SAVE) trial 
showed beneficial effects of prolonged captopril therapy, started between 3 and 
14 days (mean 11) after acute Ml, on mortality and morbidity after Ml (121). The 
effect on prolongation of survival in the patients with objective evidence of LV 
dysfunction on 2D-Echo was sustained for 3.5 years.
Because of fear that clinically significant vasodilator-induced hypotension 
during acute Ml might increase infarct size and potentially result in more infarct 
expansion, as reported with NTG from my laboratory (122:Appendix 28), ACE 
inhibitors were avoided in the very early stage of Ml. The relatively long half-lives 
of ACE inhibitors suggested the need for caution when used in that setting since 
timely withdrawal of the drug effect following a hypotensive event might not be 
possible. This possibility was expressed in the ‘Cooperative New Scandinavian 
Enalapril Survival Study II’ (CONSENSUS II) trial, where the ACE inhibitor was 
initiated intravenously on day 1 after Ml and followed by oral therapy for 6 months 
(123).
The subsequent Healing and Early Afterload Reducing Therapy’ (HEART) 
trial evaluated the effect of early (day 1 onwards) or delayed (day 14 onwards) 
ACE-inhibition with ramipril on LV enlargement by 2D-Echo in patients after acute 
anterior Q-wave Ml (124,125). In this study, LV enlargement on quantitative 2D- 
Echo was used as a surrogate marker for the risk of clinical events (125). The 
results showed that early ACE-inhibition attenuated LV remodelling, assessed by 
the LV area, and resulted in earlier recovery of LV ejection fraction (124). The 
HEART trial was terminated early, because the results of the concurrent trials 
evaluating early ACE inhibitor therapy begun within 24 hours after Ml indicated 
that substantial lives were saved by early therapy (124).
Meanwhile, studies from my laboratory in the canine model of relatively 
small Ml suggested that long-term ACE inhibitor therapy during healing after Ml 
limited LV remodelling and dysfunction (126[Appendix 29],127[Appendix 30],
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128:Appendix 31) but also decreased infarct collagen (127-129), which was 
harmful in some cases (129:Appendix 32). The beneficial effects of ACE- 
inhibition of LV geometry and function were also confirmed in patients during 
healing after Q-wave Ml (130). The combination of captopril and isosorbide 
dinitrate (ISDN) therapy during healing did not prevent the decrease in infarct 
collagen seen with captopril alone in the dog model (131:Appendix 33). In a 
parallel randomized double-blind clinical study that compared prolonged therapy 
with buccal nitrate (eccentric dosing, allowing a daily nitrate-free interval), oral 
captopril, or both given between 48 hours and 6 weeks after Q-wave Ml, all three 
active treatments preserved LV function and equally attenuated LV remodelling 
and LV aneurysm (108).
In all these studies from my laboratory, the evaluation of LV geometry 
included 3D-reconstruction and assessment of RSD and infarct expansion on 2D- 
Echo. In contrast, the evaluation of LV geometry by 2D-Echo in the large clinical 
trials were somewhat limited and did not include 3D reconstruction and 
assessment of RSD or infarct expansion (132). Nevertheless, the finding of 
decreased infarct collagen is difficult to reconcile (27,133) with the overwhelming 
evidence in favour of the use of ACE inhibitors after Ml (134). It is possible that 
pleiotropic effects of ACE inhibitors are involved in the overall benefits. The 
potential mechanisms of benefit from ACE inhibitors after Ml are summarized in 
Table 6. TABLE 6. Potential mechanisms for benefit from ACE-inhibition therapy after 
acute myocardial infarction
1. improved haemodynamics
Decreased preload: increased venous capacitance 
Decreased afterload and impedance
2. ACE-inhibition
Decreased renin-angiotensin-aldosterone system 
Decreased catecholamine secretion 
Decreased inotropic stimulation 
Decreased systemic vascular resistance 
Decreased vasoconstrictor tone 
Improved collateral blood flow 
Decreased heart rate 
Decreased salt retention
3. Kininase inhibition
4. Improved cardiac geometry
Decreased chamber size and wall stress 
Decreased deformation forces 
Decreased regional dilatation and expansion 
Decreased global ventricular dilatation
5. improved regional and global ventricular performance 
S. (improved survival)
Moditied Irom Jugdutt (22] Appendix 4J)
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The short-term trials of early ACE inhibitor therapy, initiated within 24 hours 
of Ml, included the ‘Fourth International Study of Infarct Survival’ (ISIS 4) study 
(135), the ‘Gruppo Italiano per lo Studio della Sopravivvenza nell’ Infarcto 
Miocardico’ (GISSI-3) study (136), the ‘Chinese Captopril Study’ (CCS-1) (137), 
and the ‘Survival of Myocardial Infarction Long-term Evaluation’ (SMILE) study
(138). In addition, the ‘Acute Infarction Ramipril Efficacy’ (AIRE) study initiated 
ACE inhibitor therapy 3 to 10 days after Ml in patients with congestive symptoms
(139) and the ‘Trandolapril Cardiac Evaluation’ (TRACE) study began ACE 
inhibitor therapy 2 to 7 days after Ml (140). The ‘Captopril and Thrombolysis 
Study’ (CATS) began the ACE inhibitor within 6 hours of Ml (141). Of note, 
although these trials were conducted in the thrombolytic era, the SMILE study 
patients did not receive thrombolytic therapy (138).
Previous trials of ACE inhibitors in heart failure, including the ‘Cooperative 
New Scandinavian Enalapril Survival Study’ (CONSENSUS-1) (142), the ‘Studies 
of Left Ventricular Dysfunction’ (SOLVD treatment) with enalapril (143), the 
Veterans Administration Cooperative Vasodilator-Heart Failure Trial’ (V-HeFT) 
(144) and SOLVD prevention trial with enalapril (145), were all beneficial but did 
not include detailed evaluation of regional infarct expansion, RSD or global LV 
shape on 2D-Echo.
2.5.4. Reperfusion
By the 1980’s, several key studies in the dog model had demonstrated that acute 
coronary artery occlusion renders myocardium in the distal coronary bed at risk of 
infarction (146-148), and a gradient of nutrient flow from the central to border 
regions and from the endocardium to the epicardium is a major determinant of 
infarct size (149). Biochemical abnormalities that ensue in the ischaemic zone, 
such as increased lactate, acidosis, ionic pump failure and adenosine 
triphosphate (ATP) depletion, were postulated to set in motion a chain of events 
that lead to rapid loss of cellular homeostasis and progression to cell death (150). 
The biochemical studies suggested that the march to cell death is modulated by 
the severity of ischaemia and the levels of calcium ions, reactive oxygen species 
and ATP (150).
In the dog model of reperfused Ml, Reimer et al. showed that necrosis 
marches from the endocardium to the epicardium as a wavefront between 40 
minutes and 3-6 hours post-occlusion, and the march can be interrupted by
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reperfusion (151). Furthermore, the transmural extent of necrosis in that study 
was 38% after 40 minutes, 57% after 3 hours, 71% after 6 hours and 85% after 24 
hours, suggesting that the therapeutic time window for myocardial salvage was 3- 
6 hours in the dog (151). These findings continue to provide the rationale for early 
reperfusion to reduce infarct size (152).
The timing of therapy has been shown to be a critical factor for salvage of 
muscle, geometry and function after Ml following permanent occlusion or post 
ischaemic reperfusion. It was recognized that the interval between the onset and 
completion of myocardial necrosis provides time for applying protective therapy to 
limit infarct size. Collective evidence suggests that this interval might be longer in 
humans than dogs or rodents (Figure 3). Thus, interventions applied 9 hours after 
coronary artery occlusion did not decrease infarct size in the dog model (153) 
while several studies in humans demonstrated salvage beyond 6 hours from the 
onset of Ml (28,154). For example, Flaherty et al. (154) demonstrated that NTG 
therapy, given within 10 hours (range 6 to 13.5) after Ml, improved thallium-201 
scintigrams in patients and suggested that the ‘cut-off for reversibility was about 
14 hours. In a subsequent study from my laboratory, NTG therapy given within 12 
hours of onset of Ml was associated with beneficial effects on clinical and 
laboratory parameters of myocardial necrosis and remodelling (28).
Several factors may explain the slower march to necrosis in humans 
compared to smaller animals (Figure 3). These include: i) the larger heart size 
and the slower heart rate in humans; ii) a more gradual occlusion process, 
involving thrombus formation on long-standing atheromatous plaques and/or 
spasm, and often subtotal in humans compared to the sudden and complete total 
occlusion induced in animal experiments. Evidence in the early 1980’s suggested 
that the syndrome of severe chest pain associated with ECG changes signals the 
onset of the infarction process, and both occlusion and necrosis are not 
completed for several hours. This concept was supported by findings of the 
prolonged release of CK enzyme over 16 to 60 hours (155) and myoglobin over 2 
to 3 days (156), or prolonged ST-segment elevation for several days (157), or 
improvement in multiple clinical and laboratory indicators of infarction in patients 
given therapy later than 6 hours after onset of chest pain (154). Other possibilities 
were also considered: i) that slow enzyme or protein release might merely reflect 
poor perfusion of the central core of necrosis rather than continued cell death; and
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ii) that early therapy might prolong the interval to completion of necrosis by 
delaying its evolution, and this prolongation may be longer in man than dogs.
Although a slower march to necrosis might apply to permanent occlusion, 
subsequent data indicated that reperfusion, with thrombolytic therapy and/or 
percutaneous transluminal coronary angioplasty (PTCA), is most beneficial if 
performed very early (152). This led to the concept that other factors might be 
associated with the sudden restoration of flow to ischaemic myocardium by 
reperfusion. Thus, reperfusion may be associated with ‘myocardial stunning’ and 
reperfusion injury (158-162), resulting in mismatches between restoration of flow 
and salvage of muscle, LV geometry or LV function.
The mechanisms of reperfusion injury have been reviewed (158,163). 
Even successful reperfusion, that does not result in coagulative necrosis, may 
cause persistent mechanical dysfunction for 1 week or more. This delayed 
recovery of function, termed ‘myocardial stunning’, is associated with delayed 
recovery of adenosine triphosphate (ATP) (80% within 3 days). Other prolonged 
biochemical abnormalities include: increased oxygen-free radicals, calcium 
overload, interrupted creatine phosphate shuttle, cardiac sympathetic nerve 
dysfunction, and vascular ‘no reflow’. Reperfusion itself can cause paradoxical 
injury and ‘necrosis’ that is predominantly of the contraction band type and may be 
potentially reversible. Reperfusion also causes extracellular collagen matrix 
(ECM) disruption, which may lead to disruption of mechanical coupling and 
contribute to dysfunction (164-166).
Evidence in the early 1980’s suggested that late reperfusion, beyond 2 
hours and up to a maximum of 6 hours in the dog (151,162), and probably 14 
hours in humans (154), might result in significant reperfusion injury. Although late 
reperfusion results in persistent and prolonged mechanical dysfunction and ECM 
disruption (164-166), it still seemed to preserve LV geometry and limit acute 
expansion (47,167). Whether this beneficial effect might persist throughout the 
healing phase was controversial.
Three experimental studies in the rat model confirmed the benefits of very 
early reperfusion. First, late reperfusion made 2 hours post-occlusion did not limit 
infarct size or transmurality but reduced infarct expansion (47). Second, early 
reperfusion made 1 hour post-occlusion reduced infarct size and expansion while 
late reperfusion at 6 hours did not limit infarct size or expansion but accelerated 
healing (168). Third, late reperfusion made 6-8 hours post-occlusion did not limit
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infarct size as seen with early reperfusion after 1-2 hours but limited infarct 
expansion and accelerated healing, with more rapid removal of dead myofibrils 
and increased myocytolysis (46).
Eight studies in the dog model supported the idea of greater overall 
benefits with very early rather than late reperfusion. These studies were:
First, reperfusion made 2 hours after left circumflex (LCX) coronary artery 
occlusion was associated with decreased tissue loss but delayed improvement of 
regional LV function over 4 weeks (169).
Second, reperfusion made 3 hours after LAD or LCX coronary artery 
occlusion showed little evidence of myocardial salvage (170).
Third, LV function at 4 weeks improved with reperfusion made 2 hours 
after LAD occlusion but not with reperfusion made 4 hours after LAD occlusion 
despite similar infarct sizes in the two groups (171).
Fourth, reperfusion made 90-120 minutes after LCX occlusion resulted in 
late recovery of function and hypertrophy of salvaged cardiomyocytes in the 
border regions at 3 weeks (172).
Fifth, reperfusion made at 2 hours after LAD occlusion resulted in delayed 
recovery of global LV function without change in regional LV asynergy, attenuation 
of global and regional dilatation, less infarct expansion and thinning during healing 
over 6 weeks despite decreased infarct collagen (49).
Sixth, reperfusion made 6 hours after LCX occlusion did not decrease 
infarct or scar size but still increased the rate of healing over 6 weeks (173).
Seventh, reperfusion after 4 hours. In a mid-LAD and LCX branch 
occlusion model, was associated with significant intra-myocardial haemorrhage in 
necrotic areas, decreased early granulocyte response, suggesting impaired early 
healing, and no decrease in infarct size (174).
Eighth, very late reperfusion, made at 1 day or 7 days after completion of 
necrosis from an LAD occlusion, had no effect on infarct size, transmurality, 
collagen, haemorrhage, calcification or inflammation, suggesting that there was no 
effect on healing in that setting (175).
A study of the mechanical properties of the infarcted left ventricle following 
reperfusion, made 1-3 hours after coronary occlusion in the rabbit model, 
demonstrated that the reperfused scars had lower collagen content and lower 
tensile strength and ruptured more easily at high stresses (176). The late group in
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that study also showed lower collagen cross-linking density in the 3-week-old 
scars.
A clinical study assessed the effect of time to reperfusion on infarct size by 
imaging with thallium-201 (TI-201) single-photon emission computed tomography 
(SPECT) and LV function by LV angiography in patients with anterior Ml (177). 
Compared to non-reperfused patients, reperfusion decreased infarct size and 
improved global LV ejection fraction in early (within 3 hours of the onset of pain) 
and intermediate (3-6 hours) groups but not the late (>6 hours) group. 
Importantly, reperfusion limited LV dilatation in all three groups (177).
Several studies addressed the effect of adjunctive therapies after 
reperfusion. In the dog model of reperfusion made 4 hours after LAD occlusion 
for 2 hours, methyl prednisolone decreased infarct size but did not improve 
function on 2D-Echo (178).
In the dog model of reperfusion for 2 days after 90 minutes of LAD 
occlusion, the diffusible anti-oxidant and hydrogen peroxide scavenger N-(2- 
mercaptopropionyl)-glycine, given between 30 minutes and 4 hours after 
reperfusion, decreased infarct size (179). Data in a clinical study from my 
laboratory indicated that early and prolonged intravenous low-dose NTG therapy 
(>24 hours) during and after late reperfusion (at 4 hours) was associated with 
prompt improvement of LV function and a decrease in infarct expansion that 
persisted up to 6 months on serial 2D-Echo (50,180).
In the dog model, the oxygen free radical scavenger, superoxide 
dismutase, given for 1 hour from the time of reperfusion made at 90 minutes post­
occlusion, reduced infarct size (159). In the same model, superoxide dismutase 
given for 2 hours from the time of reperfusion made 2 hours post-occlusion, 
reduced infarct size and infarct expansion and improved LV function beyond that 
achieved with reperfusion alone (181). The overall findings suggest that 
myocardial stunning and reperfusion injury can be prevented by early reperfusion 
and adjunctive therapy (182).
There is now general agreement that greatest success is achieved when 
reperfusion is established within 2 hours after Ml in humans (152). Although this 
is not always clinically possible, aggressive approaches to abbreviate the interval 
between the onset of pain and therapy have been beneficial (183). Reperfusion 
therapy alone, with coronary angioplasty and thrombolysis (184) or in combination 
with other pharmacological agents such as NTG (50), has been shown to limit
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infarct expansion. Thrombolytic therapy has already been shown to improve 
survival in both the GISSI trial (185) and the international ISIS-2 trial (186,187).
Recent studies in the rat model have suggested that early cell death after 
coronary occlusion involves apoptosis, a form of genetically programmed cell 
death, followed by necrosis (188). After reperfusion in the rat, early cell death has 
been suggested to also involve oncosis (cell swelling) together with nuclear 
changes seen with apoptosis (189). The topics of apoptotic and oncotic cell death 
in acute coronary syndromes have been reviewed (190). Imaging of apoptotic cell 
death after reperfused Ml has confirmed that very early cell death occurs within 
the 2-hour time window in mice (191) and within the 6-hour time window in 
patients (192,193). In one clinical study, 99m-technetium (99m-Tc)-labeled 
annexin-V uptake reflecting cardiomyocyte apoptosis increased between early 
(3.4 hours) and late (20.5 hours) on SPECT images, and 99m-Tc -sestamibi 
imaging at 6-8 weeks confirmed defects seen at the earlier annexin-V uptake sites
(192). In the other clinical study, 99m-Tc-sestamibi imaging showed perfusion 
defects that decreased in size between baseline and 5-19 day studies and all 
patients showed 99m-Tc-annexin-V-positive cardiomyocytes in the infarct zone
(193). The overall findings support the concept of reversible myocardial damage 
being present beyond 6 hours after the onset of Ml in humans.
After 1985, several laboratories applied imaging techniques to study LV 
remodelling after Ml in patients with or without reperfusion. Of eight reported 
studies, none addressed RSD and LV remodelling in a systematic fashion. These 
studies were:
First, a study of 30 patients receiving thrombolysis after a first Q-wave Ml 
(15 anterior, 15 inferior) showed, by serial M-mode echocardiography and LV 
angiography over 2 weeks, that early infarct expansion and global LV dilatation 
correlated with the extent of wall motion abnormality on the baseline study (194).
Second, a study of 54 patients with a first Ml (29 anterior, 25 inferior) and 
no thrombolysis, showed evidence of early LV dilatation which was more marked 
in anterior Ml, and LV diastolic dysfunction even in patients with preserved LV 
systolic function using serial blood pool radio-nuclide (99m-Tc) angiography over 
10 days (195).
Third, in a randomized study of 99 patients with acute Ml (50 placebo, 49 
captopril; 12 previous Ml; 76 with new Q waves; 59 anterior; 40 infero-posterior; 
no thrombolysis), serial 2D-Echo over 2 months documented evidence of early
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2.5.5. Importance of collateral blood flow in remodelling and healing after Ml
In the 1980’s, there was continuing controversy about the existence of intramural 
coronary collaterals in the normal human heart and their functional significance in 
patients with coronary artery disease (For review see Gregg, 202). Post-mortem 
studies (203,204) had demonstrated inter-coronary arterial collateral channels, 
measuring 20 to 350 pm and more prevalent in the endocardium, in both normal 
and diseased human hearts. Blumgart had pointed out that the majority of 
intramural collaterals were too small to be visualized on routine coronary 
angiography (205). It was postulated that chronic ischaemia stimulates the
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infarct expansion which was attenuated by captopril (196). However, that study 
did not show improvement of exercise capacity or attenuation of LV dilatation with 
captopril (196).
f
Fourth, a study of 56 patients with acute Ml using 2D-Echo over 6 months, 
confirmed that successful reperfusion preserves LV systolic volumes and regional 
function (197).
Fifth, a study of 14 patients with a first acute Ml (12 anterior, 2 inferior) and 
receiving reperfusion therapy with PTCA and rt-PA (recombinant tissue-type 
plasminogen activator) used 99m-Tc-sestamibi for measuring infarct size and 
electron beam computed tomographic imaging for LV volumes and function (198). 
This study showed significant LV dilatation over 1 year and correlation between 
infarct size and LV volume and function at 1 year (198).
Sixth, in a study of 233 patients with a first anterior Ml treated with 
thrombolysis, the baseline wall motion score index was shown to predict LV 
dilatation and mortality (199). The enzymatic infarct size, which is not available 
until 3 days after Ml, also predicted LV dilatation in that study (199).
Seventh, in a study of 53 patients after a first anterior Ml treated with 
PTCA, angiographic dye intensity in the myocardial risk area correlated with the 
reduction in LV volume (200).
Eighth, in a randomized study of 352 patients with anterior Q-wave Ml 
treated with reperfusion and the ACE inhibitor ramipril for 90 days, serial 2D-Echo 
confirmed myocardial stunning and delayed recovery and the predictive value of 
CK for functional recovery (201). This study noted that the baseline LV function 
was not a predictor of LV functional recovery after reperfusion (201).
development of collateral channels, thereby resulting in greater increase in their 
size in the subendocardium than subepicardium.
The pattern of collateral anastomoses in dogs is somewhat similar to that in 
human hearts with chronic coronary artery disease (203,205), but there are 
important differences. Dog hearts have a more abundant collateral supply and the 
network is predominantly sub-epicardial (204). Furthermore, the time required for 
inter-coronary collaterals to develop in man in response to ischaemia is not 
known. After abrupt coronary occlusion in dogs, there is a small collateral inflow 
which often doubles in the first 24 hours (206) and increases considerably during 
the first 4 days. In contrast, gradual coronary occlusion in the dog results in a 
large increase in collateral function within days (202,207). Thus, it was postulated 
that chronic ischaemia in man may stimulate enlargement of collaterals and 
development of muscle bundles in their walls within days to weeks (204), and 
blood flow via collaterals into ischaemic areas was possible (208).
In patients with Ml, the degree of collateral development and the amount of 
collateral reserve might differ depending on such factors as duration and severity 
of coronary artery disease, presence of multi-vessel involvement, type of 
occlusion and a history of previous angina pectoris and/or infarction. 
Characterization of coronary anatomy and collateral circulation before and after 
infarct-limiting therapy such as NTG have not been done for practical, ethical and 
technical reasons.
In the pig heart, collaterals are sparse (and concentrated toward the 
endocardium) so that infarcts are predominantly transmural (204). In a dog model 
of collateral obliteration and more LV aneurysms (Figure 4), the infarcts are 
consistently transmural and show greater LV remodelling (73,74).
Attenuation of remodelling might be greater in patients with developed 
collaterals and a patent infarct-related artery (209,210) during healing after Ml. 
Collaterals also appear to influence recovery of function after reperfusion (23). 
Thus, collaterals contribute flow not only for salvage of ischaemic myocardium, 
resulting in small subendocardial infarcts that are less prone to adverse LV 
remodelling, but also provide nutrient flow which likely promotes normal healing, 
thereby limiting remodelling. In the recent Total Occlusion Study of Canada 
(TOSCA), the restoration of flow in the non-acute occluded arteries resulted in a 
small improvement in LV regional and global function (211). However, the effects 
on LV remodelling or RSD were not assessed in that study.
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Figure 4. Transmural infarction and aneurysm in the dog 
induced by collateral obliteration.
A, B. Radiographs showing an LV apical aneurysm and patent coronary 
vessels by post-mortem arteriography. Note the avascular LV apex.
C, D. Transmural infarction produced by mid-LAD ligation (arrow), barium- 
gelatin-polymer injection into distal LAD, and running suture around 
the occluded bed. All myocardium within the ligated bed shows 
infarction, with no sparing.
Jugdutt (74[Appendix 20])
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2.5.6. Beta-adrenergic blockade and calcium channel blockade
Experimental (212) and clinical (213) studies in the mid 1970’s showed that beta- 
adrenergic blockade with propranolol after Ml decreased infarct size (212) and 
improved LV function (213). Beta-adrenergic blockade with metoprolol, given over 
the first 15 days after acute Ml in the large Metoprolol In Acute Myocardial 
Infarction (MIAMI) trial, showed positive effects on CK infarct size in patients 
treated within 7 hours but no survival benefit (214-216). Acute improvement in LV 
function with intravenous metoprolol after Ml was seen in patients with pre-formed 
collaterals to the infarct zone (217). In the dog model of Ml, intravenous 
metoprolol initiated before thrombolytic therapy, increased infarct limitation partly 
by increasing collateral flow (218). In the rat model, propranolol, given over 5 
weeks after Ml, decreased myocyte dimensions, and wall thicknesses, and 
increased LV dimensions (219).
In theory, decreased inotropism and heart rate with beta-adrenergic 
blockade would be expected to decrease the strength and frequency of the 
contractile pull of the non-infarct zone on the infarct zone and thereby reduce 
infarct expansion. However, this beneficial effect may be offset by any increase in 
LV volume secondary to decreased contractility.
The effect of beta-adrenergic blockade on LV function and topography by 
2D-Echo was studied in 63 Ml patients randomized to metoprolol (15 mg 
intravenously initially, given as 5 mg intravenously every 2 minutes for a total of 3 
injections, followed by 100 mg orally twice day trial for 15 days and maintenance 
for 90 days ) or placebo (220). Metoprolol decreased early rate-pressure product 
and CK infarct size, and persistently decreased LV asynergy and increased LV 
ejection fraction on serial 2D-Echo over 24 weeks (220). However, serial 2D- 
Echo revealed similar mean expansion index and thinning ratio in the two 
treatment groups (220). Thus, it is very likely that the beneficial effect of 
metoprolol on infarct size, rate-pressure product and contractile pull was offset by 
the effect on chamber size, which was similar to that in the placebo group.
The effect of the calcium-channel blocker nifedipine on LV function, infarct 
size and infarct expansion was studied in a prospective double-blind, placebo- 
controlled trial of 132 low-risk Ml patients randomized to nifedipine (120 mg/day) 
or placebo (89). The patients were treated within 12 hours of symptom onset and 
had initial LV ejection fractions more than 35% and clinical Killip classes of less 
than II. Therapy was continued for 6 weeks, and evaluations made before
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treatment and at 10 days. There was no effect on clinical outcome or infarct size 
with nifedipine, although mean blood pressure decreased by 10% over the 10 
days. However, nifedipine limited infarct expansion on 2D-Echo. In a study of 
424 patients with successful reperfusion, within 12 hours of symptoms of acute 
Ml, a possible survival benefit was shown with beta-adrenergic antagonist but not 
calcium-antagonist therapy taken before reperfusion (221).
2.5.7. Digoxln
In theory, prolonged inotropic stimulation and increased contractility of the non­
infarct area after Ml would be expected to promote infarct expansion by increasing 
intra-mural traction on the infarct zone. The effect of digoxin therapy during 
healing over 6 weeks after Ml was therefore studied in the dog model of Ml (222). 
In this model of predominantly small infarcts, digoxin therapy increased infarct 
expansion, thinning and bulging as well as the frequency of LV aneurysms on 20- 
Echo (222). Digoxin also reduced global LV dilatation but preserved LV mass, 
global LV systolic function and infarct collagen (222).
2.6. Development of a chronic large animal model for studies of left 
ventricular remodelling during healing after myocardial infarction
Prior to 1980, there were no well-defined chronic large animal models for 
quantifying infarct size and remodelling or studying the long-term effects of 
interventions on LV function and remodelling during healing after Ml. Variability of 
coronary anatomy in dogs resulted in variable infarct size despite occlusions at a 
fixed anatomic site. Between 1976 and 1979, a chronic canine model was 
therefore developed for studying the effects of early interventions on the size of 
the infarct relative to that of the occluded bed 48 hours after LCX occlusion as well 
as regional collateral blood flow and haemodynamic variables (147). This model 
allowed the mapping of infarcts, occluded beds and regional blood flows from the 
base to apex of the left ventricle (147,149). The potential for pharmacological 
agents to modify the relation between the mass of the infarct and occluded bed 
was initially studied using vasodilators, such as NTG and prostaglandin (PG) 
inhibitors (which were also anti-inflammatory agents), in the conscious dog model 
(56,57,98,99). The end-points included haemodynamics, collateral blood flow and 
pathologic infarct size (56,57,98,99).
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The analysis of infarct size relative to occluded bed size at 2 days post Ml 
had at least 5 advantages (56,57,98,99,147). First, it provided a reliable baseline 
for studying the effect of therapies on infarct size. Second, it made allowance for 
the variation in coronary anatomy which leads to variation in infarct size despite 
occlusions made at a fixed site. Third, it allowed comparison of treatment groups 
using linear regressions showing the direct relation of infarct size to the occluded 
bed size. Fourth, it recognized the fact that no infarcts result with occluded beds 
smaller than 20% of the LV weight; this factor resulted in a dilution effect in 
studies that expressed the infarct weight in grams or as percent of LV weight, 
necessitating large numbers of dogs to detect significant differences with 
interventions. Fifth, It permitted the detection of increased or decreased infarct 
size using relatively small numbers of animals, by comparing the slopes of the 
linear regressions between infarct size and occluded bed size for treatment 
groups. Similar relationships between infarct size and occluded bed size were 
found in humans dying soon after acute Ml.
Post-mortem coronary arteriography had been used previously to visualize 
the coronary anatomy by Fulton in Glasgow (223) and Schaper in Mannheim 
(204). This technique was applied in the 2-day infarct model to measure the 
occluded bed size, which was defined as the boundary between the anatomic 
locations of epicardial and transmural vessels recorded on stereoscopic 
radiographs of transverse sections, after permanent opacification by a barium 
sulphate-gelatin mixture containing pigments (224). This method was shown to 
be reproducible and allowed the mapping of collateral blood flow relative to an 
anatomic reference base that was considered to remain fairly fixed over the first 
48 hours after Ml (225).
In 1980, I set up the first laboratory for studying LV function and 
remodelling after Ml at the University of Alberta. I introduced the chronic dog 
model that was developed at the Johns Hopkins Hospital (147) and adapted it for 
studying cardiac function and remodelling over several weeks after Ml rather than 
just 2 days (41,55). Since several studies suggested that anterior Ml had a worse 
prognosis that inferior Ml, I performed both LAD and LCX occlusions. Infarct size 
was quantified and topography was mapped using computerized planimetry 
(Hewlett Packard digitizer and computer, Seymour, Connecticut) (Figure 5). 
Regional myocardial blood flow was measured by the radioactive microsphere 
method using a flow program for multiple isotopes rather than just six (Tracor
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Northern 2250 gamma scintillation counter). Post-mortem coronary arteriography 
was used for quantifying the occluded bed size (Figure 6). Systematic 
pathological assessment of the post Ml hearts was carried out for infarction, 
cardiac dilatation, aneurysm formation, rupture, geometric variables and 
correlation with ante-mortem 2D-Echo imaging. Computer programs were 
developed (Hewlett Packard) for statistical analysis, the analysis of large volumes 
of haemodynamic, angiographic, pathological and CK infarct size, 2D-Echo, and 
clinical data.
The model of mid-LCX occlusions and 2-day infarcts was validated in a 
study of the effects of PGEi, PGE2 , and PGI2 (or prostacyclin) and drugs acting 
via apparently different mechanisms such as NTG and ibuprofen, on infarct size, 
collateral blood flow and post-infarction arrhythmias (226). Decreased infarct size 
as percent of the risk region was demonstrated with PGI2 , NTG, PGEi and 
ibuprofen but not with PGE2 . Interestingly, this beneficial effect was associated 
with decreased infarction arrhythmias and was more marked with PGI2 , NTG and 
PGEi, which also increased collateral blood flow, but was trivial with ibuprofen 
which did not increase flow. In addition, PGE2 exerted an anti-arrhythmic effect 
independent of beneficial effects on infarct size or flow (226).
The model was then modified by using i) artériographie injections distal and 
proximal to the occlusion site instead of relying on filling via collateral channels, 
and ii) 10 LV sections instead of 5, in order to reduce the error in marking the 
boundaries to 1±1 mm (SD). Collateral blood flows were mapped within the 
occluded bed from the base to apex of the heart. This approach allowed definition 
of a functional risk region based on regional blood flows.
Using this modified model, the effect of mid-LCX and mid-LAD occlusions on 
infarct size was studied in conscious and barbiturate-anesthetized dogs 
(227[Appendix 34],228[Appendix 35]). The results showed that for similar 
occluded bed sizes. I) LAD infarcts were larger than LCX infarcts (227,228), and 
ii) infarcts were larger for anesthetized compared to conscious dogs (227,228). 
The overall findings suggest that this effect was due to tachycardia in the 
anesthetized model (227,228). In a previous study, a single dose of thiopental to 
‘conscious’ dogs resulted in increased heart rate and bigger infarcts after LCX 
occlusions (229). Two conclusions were drawn from these studies. First, cardiac 
patients who receive barbiturate anesthesia and develop peri-operative Ml may be 
at increased risk for larger infarcts. Second, intervention studies should analyze
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Figure 6. Histopathological and topographical changes 
during infarct healing
A. A schematic of topographical changes from average maps of the 
transmural and non-transmural infarcts among those hearts for 
five selected time intervals.
B. The dynamic nature of histological changes in the infarct 
substrate during healing over 6 weeks in the dog model of 
myocardial infarction. Data from 194 canine hearts.
From Jugdutt {22[Appendix 4])
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infarct size data after LAD or LCX occlusions separately and pooling of infarct size 
data from anterior and inferior Ml should be avoided.
Subsequent studies tested various vasodilator therapies in the model of 
anterior Ml after LAD occlusion. The concern that excessive afterload reduction 
with vasodilator therapy after acute Ml might decrease perfusion pressure below a 
critical level and offset previously noted beneficial effects was first investigated. In 
the previous study, 6 hour intravenous infusion of the vasodilator NTG after LCX 
occlusion, in low-dose to decrease mean arterial pressure (an index of afterload) 
by less than 10% but not below 80 mm Hg, was demonstrated to decrease 
pathologic infarct size (98). This beneficial effect was associated with a marked 
increase in collateral blood flow and a marked decrease in LV filling pressure, an 
index of preload. In the new LAD occlusion model, collateral flow did not increase 
and no myocardial salvage was found when mean arterial pressure decreased by 
20% or more with higher NTG dosage (123), suggesting a narrow therapeutic 
margin for benefit with vasodilator therapy, such as intravenous NTG, in acute Ml. 
In the same conscious dog model, prolonged therapy after Ml with NTG 
(48,102,103), captopril and enalapril (126-129,131) were shown to further limit 
remodelling during healing after transmural Ml and improve LV function.
2.7. Assessment of left ventricular geometry and function during healing
after myocardial infarction
Since 1980, I focused studies in my laboratory on the natural history of LV 
geometry and function during healing after Ml using 2D-Echo and the effects of 
early infarct-limiting therapies on subsequent healing, LV geometry and LV 
function by 2D-Echo, and clinical outcome.
Since 2D-Echo provided tomographic images of the heart in real-time (230) 
and permitted repeated examinations to be made non-invasively, it became an 
effective tool for research studies in the early 1980’s. Between the mid 1970’s 
and the mid 1980’s, 2D-Echo was successfully applied to estimate regional LV 
function and LV asynergy (16,17,231,232:Appendix 36) despite some technical 
limitations (233), to estimate infarct size (62), to detect LV aneurysms (15,234), to 
detect post Ml complications (235), to measure LV volumes (236), to measure 
regional LV shape distortion (19,21,34), infarct expansion and remodelling in 
general (18,20,21,31,32), and LV hypertrophy (102,237).
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The relationship between LV asynergy on 2D-Echo and myocardial 
necrosis was validated in an earlier study in the dog model (62). The ability to 
quantify LV volumes by tomographic imaging using 2D-Echo was also validated in 
the dog model (238). Significant resolution of LV dyskinesis on 2D-Echo after 
LAD or LCX occlusion with normalization of transmural blood flow over 6 weeks 
was demonstrated in a small study of 13 dogs (239). This recovery of regional 
function was later ascribed to scar contraction during healing after Ml (240). 
Several studies applied 2D-Echo to measure the endocardial surface area of LV 
asynergy after Ml (21,28,34,36,241 -243) and demonstrated its expansion after Ml 
(244). Quantitative 2D-Echo was used to assess LV thrombi after Ml (245) and 
later to predict apical thrombus formation (246). The application of 2D-Echo to 
detect the viability of dysfunctional myocardium has been recently reviewed (247). 
Quantitative 2D-Echo has confirmed greater LV dilatation after anterior than 
inferior Ml (28) that was previously documented by echoventriculography (248). 
Quantitative 2D-Echo has also confirmed that LV ejection fraction may improve 
and the extent of LV asynergy may decrease in some survivors after Ml 
(21,28,34), as suggested in a previous study using gated blood pool scanning 
(249).
2.7.1. Assessment of infarct or scar size and remodelling in humans versus 
animals
In animal studies, direct ex-vivo demonstration of myocardial protection and 
reduction of ultimate necrosis and remodelling is possible. In contrast, clinical 
studies have had to rely on indirect methods that are often frustrating because of 
the lack of a single reliable standard for infarct size and difficulties in obtaining 
serial measurements before and after therapy. Multiple non-invasive techniques 
that permit serial measurements of different indicators of the extent of ischaemic 
injury have therefore been used to assess effects of therapy but each technique 
has its limitations (250:Appendix 37).
Because of the possibility that therapy merely delays the evolution of 
necrosis and prolongs the interval to its completion, assessment of infarct size 
needed to be repeated over several days to demonstrate persistent benefit. 
Quantitative 2D-Echo was therefore an attractive tool for quantifying LV geometry 
and function during healing after Ml in the dog model (102) and in patients
(21,28,34,35,132).
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2.7.2. Preliminary studies: validation of quantitative 2D-Echo for left 
ventricular remodelling and function
Although there was a paucity of information in the literature on the application of 
2D-Echo for repeated studies, beginning at the bedside in acutely ill or acute Ml 
patients in the early 1980’s, my laboratory validated the method in the first 500 
patients over the first 2 years and had performed over 1500 research studies by 
1985. As there was no standard protocol for quantifying wall motion abnormalities 
in acute Ml and to allow the application of repeated 2D-Echo imaging for 
assessing the effect of therapies in early Ml in 1980, a systematic approach for 
tomographic 2D-Echo imaging using a strict protocol (Figure 5), was applied both 
for studies at the bedside and in the laboratory (21,28,34,35). Against prevailing 
scepticism over the applicability of quantitative 2D-Echo in acute Ml studies, the 
necessary computer software programmes were developed for these studies in 
my laboratory (19-21,28,34,35,232). This innovative research approach in 
patients with acute Ml, while in the coronary care unit (CCU), revealed 
unsuspected complications on 2D-Echo imaging such as right ventricular 
infarction (251-253), LV thrombi and embolization (245), early RSD and infarct 
expansion (19-21,33-36), cardiac rupture (20), as well as large pericardial 
effusions and cardiac tamponade, and papillary muscle rupture.
The advantage of quantitative 2D-Echo studies using a strict systematic 
protocol, both for initial studies at the bedside and subsequent follow-up studies in 
the laboratory, with recording of patient positioning and angulation as well as 
transducer positions for repeated studies, has been confirmed in many 
laboratories (31,32,132). The ability to perform serial, non-invasive estimation of 
LV asynergy and RSD using quantitative 2D-Echo in experimental and clinical 
studies made it possible to objectively assess the effect of therapies on these 
parameters. Such studies contributed to the development of practical therapeutic 
strategies to preserve ischaemic myocardium as well as geometry and function in 
survivors, and thereby reduce morbidity and mortality post Ml (23). Systematic 
application of 2D-Echo in bedside studies in acute Ml patients between 1980 and 
1985 demonstrated the limitation of LV asynergy (232) and infarct expansion (28) 
by NTG.
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2.7.3. Assessment of global left ventricular shape and regional shape
distortion
The shape, size and structure of the normal left ventricle appear to reflect an 
adaptation to the dynamic requirements during systole and diastole. Adjustments 
ensure the optimal conversion of energy during contraction to the development of 
pressure and systolic ejection. Heart size has been shown to be directly related to 
its work load (254). Ventricular wall thickness is directly related to ventricular 
radius, and the ratio of wall thickness is directly related to systolic pressure (1). 
The Law of Laplace (255), which is crucial for understanding LV shape relative to 
LV load, states that wall stress (S) is proportional to pressure (P) and the radius of 
the curvature (r) for thin walled spheres. Thus, for wall thickness (t), the Law of 
Laplace states:
S = Pr /2t
Clearly, this only provides an approximation as the left ventricle is not a 
thin-walled sphere with uniform radius. Other investigators have modelled LV 
shape on a spheroid (256) or an ellipsoid (2,257), or on an egg shell with its top 
cut off (258), close to a truncated ellipsoid. More than 100 years ago, the LV wall 
was modelled on a curved membrane with two principal radii of curvature and a 
finite thickness (259). Modern cardiac imaging techniques, including 2D-Echo, 
support the idea of the normal LV shape being circular in the short-axis and close 
to a truncated ellipse in the long-axis (2).
It is important to note that mathematical models assume uniform LV shape 
and, often, uniform wall thickness as well. Calculations of LV wall stress are 
therefore flawed by over-simplified assumptions (260). Various mathematical 
approaches have been proposed for calculating wall stress (10,261,262). In 
pressure- and volume-overload hearts with LV dysfunction and LV dilatation, the 
transition from the normal ellipsoidal shape to a spheroidal shape represents an 
adaptation towards normalized wall stress (263-266). Global shape has been 
measured by a variety of indexes: the eccentricity index (267), Gibson index 
(268), shape-power index from Fourier analysis (269), curvature index based on 
quantitative regional curvature analysis (270), global LV shape index based on the 
ratio of major axis to minor LV axis at end-systole and end-diastole (271), a shape 
index based on the short- to long-axis ratio on 2D-Echo (265), a shape index 
based on width, length and area on 2D-Echo (266) and a sphericity index based
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on the long-axis length (12). Although these indexes were useful predictors, none 
involved left ventricles with marked regional shape distortions associated with Ml.
Numerous reports have described RSD of asynergic zones on end-diastolic 
short-axis and long-axis images on 2D-Echo, with further dilatation on end-systolic 
images (15-21,33-36,272). Several investigators have attempted to measure the 
areas and volumes of large chronic LV aneurysms on 2D-Echo. In patients with 
LV aneurysms, a residual myocardial index derived from 2D-Echo was shown to 
identify survivors after LV aneurysectomy (273).
I quantified RSD directly on short-axis 2D-Echo images in patients after Ml 
and showed that the degree of early diastolic RSD predicted subsequent outcome 
(21). In another study, I demonstrated that significant RSD preceded ventricular 
septal rupture after Ml (20). Importantly, the degree of RSD on the baseline 2D- 
Echo correlated with the degree of LV dilatation at follow-up, suggesting its role in 
progressive LV enlargement (274:Appendix 38). It is possible that increased wall 
stress in the border zone (275), especially in the presence of RSD, drives the 
progression to global LV dilatation and a global LV shape with normalized wall 
stress. Moreover, in 40 patients with LV dysfunction after anterior Ml, the 
sphericity index on LV angiography was elevated at a baseline study between 2 
and 4 weeks (12). In a study of 30 patients with anterior or inferior Ml from the 
SOLVD study (11 placebo, 19 enalapril), follow-up between about 1 year and 2 
years showed evidence of increased wall stress and progression of LV dilatation 
(276). In a subsequent study of 70 patients with anterior and inferior Ml, 
progressive dilatation was detected over 3 years after Ml (26). However, these 
studies did not assess RSD and the populations were fairly heterogeneous.
The collective evidence suggests that measurement of diastolic RSD in 
asynergic zones after acute Ml may identify a high-risk group of patients who 
might benefit from aggressive therapy.
2.8. The concept of adverse remodelling after myocardial infarction and
anti-remodelling therapy
The concept of infarct size limitation Implies existence of a functional border zone 
in the ischaemic region (88). In that concept, myocardium within the border zone 
is at jeopardy because of reduced flow but has sufficient flow for immediate 
survival. Subsequent increase in collateral flow, natural or drug-induced, provides
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for ultimate survival of this tissue. Flow In other areas is so low that necrosis 
results despite therapeutic efforts.
One major factor for survival of ischaemic myocardium is collateral flow, 
and this was confirmed in a previous study (149). It appears that during the early 
hours after coronary occlusion, there are varying amounts of normal, ischaemic 
and dead myocardial cells depending on a gradient of collateral flow from the 
peripheral to more central regions of the occluded bed (149). Other factors are 
also important, such as the myocardial oxygen demands and various cellular and 
metabolic factors (87). However, these are also linked to flow. Well-timed 
restoration of flow by reperfusion of the ischaemic myocardium may arrest the 
progression to necrosis (148). The timing of therapy is therefore critical and the 
early hours are of pivotal importance in therapeutic efforts to modify the extent of 
ultimate necrosis. This was also confirmed in experimental (153) and clinical 
(152) studies.
As discussed before. Ml is followed by adverse LV remodelling which 
contributes significantly to LV dilatation, LV dysfunction, disability and death (21- 
27). The aim of anti-remodelling therapy after Ml is therefore to prevent, limit, or 
reverse adverse structural remodelling and thereby interrupt the sequence of LV 
dilatation, LV dysfunction, disability and death (22).
As for the protection of ischaemic myocardium, the early hours are critical 
for therapy to limit early LV remodelling after Ml. The timing of anti-remodelling 
therapy after Ml may be staged to span the acute infarction phase, the healing 
phases, and the post-healing phase (Table 2) (22,37,39). Longitudinal studies 
have suggested that timing and duration of therapy are critical (22). Sequential 
changes during LV remodelling post Ml (Figure 6) span the phases of acute Ml, 
healing and repair over weeks to months (Figure 2), and beyond (22,23).
Since mechanical deformation forces and increased wall stress act on the 
infarct and non-infarct zones throughout these phases (Figure 7), thereby promo­
ting progressive LV dilatation (22,23,277) and stimulating fibrosis (277,278: 
Appendix 39), early and prolonged anti-remodelling therapy is favoured. Some 
potential anti-remodelling therapies based on the determinants (Table 3) are listed 
(Table 7). Since several of the anti-remodelling therapies exert pleiotropic effects, 
some of which may potentially impact on the supporting ECM and infarct healing, 
the assessment of regional remodelling in the infarct zone throughout infarct 
healing after Ml, using such tools as 2D-Echo, is highly pertinent.
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TABLE 7. P oten tia l pha rm aco log ica l therap ies fo r  lim itin g  rem ode lling  a fte r 
acute m yoca rd ia l In farction
M echanism Therapeutic in te rven tion
Decrease infarct size Nitroglycerin, Reperfusion (thrombolysis 
and/or mechanical)
Decrease preioad Nitroglycerin, ACE inhibitors
Decrease afterload Nitroglycerin, nifedipine, ACE inhibitors
Decrease chamber size Nitroglycerin, ACE inhibitors
Decrease heart rate Beta-adrenergic blockers, 
calcium channel blockers
Decrease contractility Beta-adrenergic blockers, 
calcium channel blockers
Increase coilateral flow Nitroglycerin
Modi I led ironi Jugdutt (22 [Appendix 4J)
2.9. Role of the extracellular collagen matrix during healing and left 
ventricular remodelling after myocardial infarction
During the 1980’s, several investigators have drawn attention to the ECM (see 
27,277,278 for review). A large body of evidence supports the role of an 
organized, intricate network of ECM in mediating several important functions in 
the normal heart, including mechanical support, coupling of cardiomyocytes, 
mechanical strength and resistance to distension (279). During early healing after 
Ml, the loss of the 3D organization of the matrix (74,280), mediated by matrix 
metallo-proteinases (MMPs), was postulated to result in cardiomyocyte disarray 
(281), which might explain why cardiac ruptures occur spontaneously 
(282,283:Appendix 40) or during acute pressure loading (283), infarct distension 
(284), and early aneurysm formation (74). Several studies support the concept 
that ECM dissolution promotes dilatation (279,285-289). Loss of ECM 1-2 hours 
after Ml in the dog is associated with regional dilatation of the infarct zone (290). 
Several studies have linked extracellular strut rupture (Figure 8) and 
cardiomyocyte slippage to early infarct dilatation post infarction (66,73,74) and 
progressive global LV dilatation in heart failure (291). Others have linked collagen 
loss to cardiac rupture (292,293).
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2.9.1. MMP and TIMP balance m remodelling post Ml
During the early hours after Ml, ECM degradation, mediated by MMPs (294), 
follows early rapid activation of latent MMPs and exceeds synthesis. Since 
degradation occurs rapidly and synthesis slowly (0.56% per day in dog left 
ventricle), replacement after degradation is slow (295). This implies that the early 
ECM degradation results in a window of increased susceptibily for adverse 
remodelling that may last for weeks after the acute event, so that its prevention is 
imperative (277). Once activated, MMP-1 degrades fibrillar collagen into 
fragments, and MMP-2 and MMP-9 degrade these fragments into smaller 
fragments (294). Within hours of Ml in rats, collagen content decreases (165) and 
MMPs increase (296). The tissue inhibitors of MMPs (TIMPs), which neutralize 
MMPs, also increase after Ml (296). A balance between MMPs and TIMPs 
appears to be necessary for normal ECM remodelling and function (296).
Since replacement of the ECM after damage is slow, it is doubtful whether 
therapy targeted on MMP/TIMP balance, given after the damage in the acute setting 
of acute post-ischaemic reperfusion or reperfused Ml, can significantly reduce or 
reverse the early disruption of the ECM after acute ischaemia-reperfusion and 
thereby improve LV geometry and function.
The mechanical and other forces that alter regional and global shape and 
function during structural LV remodelling after Ml (Figure 7) have been reviewed 
(22,37,39). Sequential changes (e.g. matrix disruption, LV dilatation, hypertrophy 
and fibrosis) span the phases of acute injury and subsequent healing (Figure 6).
Since early expansion of the infarct zone contributes to regional dilatation 
and RSD that precede global dilatation (21), early anti-remodelling therapy is 
needed. Since mechanical forces (“push, pull and stretch”) that increase wall 
stress influence remodelling throughout its course (Figure 7) (22,28), it follows that 
therapy should be continued for a prolonged period.
Several studies over the 1980’s have shown that the in-vivo changes in LV 
remodelling and function during post Ml healing (22) and beyond can be tracked 
using 2D-Echo in-vivo (21,26,130,132). These studies indicated that timing and 
duration of therapy are critical (22). Susceptibility to deformation has been shown 
to depend on characteristics of the substrate, stage of healing, the status of the 
ECM and the pharmacological milieu (21,22,60,73,74,297). Transmural infarction 
is especially prone to expansion and rupture (64,78,81,87-89). Long-term studies 
that tracked in-vivo changes in LV remodelling using 2D-Echo have shown that
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therapy with overall beneficial effects on global LV remodelling could also modify 
infarct collagen matrix and infarct zone remodelling (103,126,127,129). In addition, 
these studies showed that therapy targeted at one mechanism might be unsuitable 
for another and produce potentially harmful effects, such as those seen with nitrates 
(122), ACE inhibitors (123,129,276), and anti-inflammatory agents (35). Clinical 
studies using 2D-Echo after Ml have shown progressive LV dilatation up to 1 year
(28,105,132), or 3 years (26), or 10 years (298:Appendix 41). In rats with 
moderate infarct size, LV dilatation, assessed ex-vivo, progressed over months 
(120,299).
After acute Ml, regional mural damage provides the basic substrate for 
remodelling by mechanical forces (Figure 7). Early reperfusion therapy, which 
effectively reduces the transmural extent of damage (148), also impacts positively on 
overall LV remodelling after Ml (22). Paradoxically, this occurs despite ECM 
damage (164-166). Moreover, morphological evidence of irreversible injury has 
been shown to increase between 5 and 90 or 180 minutes of post-ischaemic 
reperfusion in the dog model, suggesting that late reperfusion is less beneficial 
(162). Studies In the 1990’s have shown that apoptosis contributes significantly to 
cell death in early Ml (188) and reperfused Ml (189), suggesting that apoptosis may 
also contribute to acute LV dysfunction and remodelling (190). Apoptosis has 
recently been implicated in long-term LV remodelling after Ml (300).
Cumulative evidence also suggests that reperfusion injury associated with 
post-ischaemic coronary reperfusion involves damage to the ECM, besides 
calcium overload, oxygen free radicals, microvascular obstruction, neutrophil 
leucocytes and peroxynitrite (ONOO) (163). Thus, in the dog, myocardial stunning 
is associated with ECM disruption, complete loss of the collagen weave and 
increased MMP activity (164,165). In the pig model of 90 minutes of ischaemia 
and 90 minutes of reperfusion without infarction or inflammatory cell infiltration, 
MMP-9 increased and MMP-2 did not change (301). MMP-9 is also increased in 
the pig model of acute Ml (302). In other animal models, MMP-9 deletion (303) 
and MMP inhibition (304) were shown to limit global LV dilatation after Ml.
In transmural Ml without reperfusion, the concept that extensive early 
damage to the ECM (Figure 8) results in rapid aneurysm formation (285) was 
confirmed (Figure 4). Early inflammation and the cellular responses after acute Ml 
and reperfusion (297) were linked with increased MMPs and collagen degradation 
by others (294). That non-transmural damage achieved by early reperfusion (148)
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is associated with less ECM damage in the spared epicardial rim of the 
myocardium (Figure 8), less infarct expansion when made 2 hours post occlusion 
in dogs (49), and better overall long-term prognosis in humans (21,28) and dogs 
(73,74), were confirmed. However, myocardial stunning with persistent LV 
dysfunction is still a common clinical problem after reperfused Ml (50). Although 
late reperfusion produces several important overall benefits in animal models, 
including non-transmural damage, less infarct zone remodelling and less global 
dilatation (49), and accelerated healing (43), it also results in decreased infarct 
collagen (49). In reperfused infarcts in the rat, the density of collagen cross-links 
(168) is reduced and ECM disruption is greater than In non-reperfused Ml (160). 
Clinically, late reperfusion is associated with persistent LV dysfunction (305), 
earlier ruptures (282), and increased ruptures when made after 17 hours of onset 
of Ml (306). Thrombolytic therapy with streptokinase after Ml was also associated 
with decreased myocardial collagen (307).
2.9.2. Effects of anti-remodelling therapies on the ECM and coilagen
The aim of anti-remodelling therapy after Ml is to prevent and limit adverse 
remodelling, and thereby interrupt the sequence of LV dilatation, LV dysfunction, 
disability and death (22). An important aspect of this goal is to protect the ECM 
during remodelling after Ml (27,279).
However, several of the anti-remodelling strategies currently used after Ml 
exert pleiotropic effects that can potentially affect ECM turnover in both the infarct 
and non-infarct zones (27,278). Thus, ACE inhibitors, angiotensin II type 1 
receptor blockers (ARBs) and aldosterone blockers decrease ECM (278, 295) and 
the aldosterone blocker spironolactone decreases collagen turnover (308). 
Angiotensin receptor blockers (ARBs) also decrease proline-4-hydroxylase, the 
major enzyme involved in synthesis of collagen, the major protein of the ECM 
(27,278). As discussed above, reperfusion disrupts ECM (27,278), increases 
MMPs and collagen degradation (294), decreases infarct collagen (49), and 
decreases collagen cross-links (168). Unloading with the LV assist device (LVAD) 
results in a down-regulation of MMPs, increased TIMPs, decreased collagen 
damage and increased collagen cross-links (278). Beta-blockers decrease MMPs 
(278). Nitrates preserve IZ collagen and prevent the decrease in collagen after 
reperfusion (278). DIgitoxin increases proline-4-hydroxylase activity although 
digoxin does not alter IZ collagen (278). Endothelins increase collagen synthesis
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and decrease MMPs (278) while endothelin blockade impairs healing after Ml 
(309). Bradykinin increases MMPs and decreases collagen (278). Agents such 
as adenosine, which elevate cAMP, nitric oxide (NO) and cGMP, decrease fibrosis 
(278).
Several studies in the 1980's suggested potentially harmful effects of some 
post-MI therapies (26,35,49,122,123,129,278), supporting caveats against inducing 
very early hypotension with vasodilators (122,123), or impairing early healing with 
powerful anti-inflammatory drugs post Ml (35). Other studies demonstrated 
progressive LV enlargement over 1 year (21) or 3 years (26) despite optimal post- 
MI therapy, and morbidity and mortality remain high (310). In addition, cardiac 
rupture remains a major cause of death after reperfused Ml (311) and the number 
of post-MI patients needing LV assist devices or awaiting transplantation is 
increasing, suggesting that additional protection against LV dilatation, adverse ECM 
remodelling, lowering of infarct collagen, and impaired healing is needed.
2.10. Epidemiology and relevance of ventricular remodelling after
myocardial infarction
In 1970, acute Ml was the major cause of mortality and morbidity in North America 
(312). Without therapy, 40% of patients died in the first few hours of onset of 
symptoms, a further 20% in the first 30 days and another 10% within the first year. 
Pump failure, cardiogenic shock, and cardiac rupture were major causes of death 
within the first month. Congestive heart failure was a major cause of suffering and 
death in early survivors. Since these complications were directly related to total 
infarct size, therapeutic strategies in the mid 70's were aimed at limiting infarct 
size (88). Remodelling during healing in survivors of acute Ml received little 
attention.
During the mid 1980’s, it became increasingly clear that complications after 
acute Ml were not only related to the total infarct size but also, to a large extent, 
on the severity of LV remodelling, dilatation and shape deformation that took place 
during healing and beyond, and in turn adversely affected LV function and 
outcome (18,20,22,23, 59,63). It was hypothesized that the profound changes in 
LV architecture and structure that occurred during remodelling contributed to LV 
aneurysm formation and set the stage for congestive heart failure (41,102,283). 
Several studies indicated that the severity of topographic deterioration was greater 
for large, anterior transmural AMI (18,21,23,28,35,78). Cardiovascular research
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was therefore aimed at developing therapeutic strategies directed not only at 
salvaging LV muscle but also at preserving LV geometry and function, especially 
in high-risk patients with large, anterior transmural Ml. Two pharmacological 
therapies were suggested to be potentially promising for limiting remodelling after 
acute Ml, namely the vasodilator NTG (28) and the ACE inhibitor captopril (29,30).
In the mid 1980’s, coronary heart disease and congestive heart failure 
became recognized as major public health problems in North America. In the 
United States, coronary heart disease was responsible for more than 550,000 
deaths per year (313). This translated to at least 1 death per minute. In 
perspective, it exceeded deaths from all types of cancer combined, which 
amounted to less than 500,000 persons per year. Coronary heart disease also 
resulted in as many as 1.5 million heart attacks per year or 2.9 per minute.
By the late 1980’s, at least 5.4 million North Americans had symptomatic 
coronary disease. Nearly 2 million had congestive heart failure and approximately 
250,000 new cases were diagnosed each year (314). Direct and indirect costs in 
the United States exceeded 60 billion dollars per year. Despite a steady decrease 
in the incidence of coronary heart disease since the late 1960’s, deaths from 
coronary disease still exceeded those from cancer. In 1968 and 1982, death rates 
from the following were, respectively: cardiovascular diseases, 54.3 versus 
49.0%; coronary heart disease, 35.0 versus 27.9%; stroke, 11.0 versus 8.0%; 
cancer, 16.5 versus 21.9%. While the exact figures might be different in other 
countries, it became apparent that the application of potentially successful 
preventive therapy after Ml might have considerable impact on the work force and 
the cost of continuing health care.
By the 1990’s, it was apparent that limitation of LV remodelling after Ml was 
likely to have important world-wide epidemiological and public health implications 
(23). This approach offered the potential for prevention by reducing the risk from 
infarct-related complications, especially aneurysm formation and congestive heart 
failure. An ultimate goal of translational, pre-clinical and clinical research became 
the prevention of adverse LV remodelling and dysfunction after Ml. In theory, 
therapy to limit LV remodelling should improve LV function, increase survival and 
decrease morbidity after Ml. However, the objective application of therapy to limit 
remodelling and salvage function not only requires an understanding of the 
pathophysiology of the substrate being remodelled but also how it changes in 
composition during healing after Ml (24,25,27). Since the remodelling process is
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progressive, it follows that therapy should be applied throughout its duration. An 
important prerequisite is the availability of a reliable and readily available tool such 
as 2D-Echo for repeated non-invasive evaluations of LV geometry and function 
over time.
In the 2000’s, anti-remodelling therapy is still far from ideal, as progressive 
LV enlargement, morbidity and late mortality remain significant despite improved 
therapy. Post Ml survivors who develop heart failure and need LV assist devices 
and transplantation are increasing.
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3. STATEMENT OF THE PROBLEM AND HYPOTHESES
3.1. The problem
In the early 1980’s, myocardial Infarction (Ml) was recognized as a major killer 
world-wide. Left ventricular (LV) myocardial infarct size and cardiogenic shock 
were the major contributors to mortality and morbidity after Ml. Early deformation 
of LV geometry, associated with early expansion of the infarct zone, was 
becoming recognized as a major contributor to early mortality and morbidity after 
Ml. Subsequent LV enlargement, with a departure from the normal global 
ellipsoidal to a more spheroidal shape, was becoming recognized as a major 
contributor to persistent LV dysfunction and late mortality and morbidity after Ml. 
Potential new therapies were being targeted mainly on the reduction of infarct size 
but progress was hindered by the lack of a quantitative non-invasive method for 
assessing effects of therapy on regional and global LV geometry and dysfunction. 
2D-Echo was just emerging as a potential tool for assessing changes in LV 
geometry and function after Ml but imaging protocols and quantitative 
methodologies had not yet been defined. The importance of healing after Ml and 
harmful effects of potentially beneficial therapies on LV geometry and function 
were just becoming recognized but the underlying pathophysiological mechanisms 
were unclear and the role of the ECM was not fully appreciated.
3.2. Hypotheses:
i) Myocardial Infarction (Ml) results in early regional distortion of LV geometry 
and LV dysfunction during the early infarction phase. This early regional 
shape distortion (RSD) is followed by progressive global LV dilatation, 
development of a more spheroidal shape and more LV dysfunction during 
and after the subsequent healing phase.
ii) The remodelling of LV geometry and structure after Ml is a dynamic 
process that spans the early infarction and healing phases, and is largely 
driven by increased wall stress as a consequence of the RSD and 
increased LV size. Mechanical forces acting on the infarct and non-infarct 
zones during healing, and other factors, play a significant role in the 
remodelling of these regions. Progressive LV remodelling, during and after 
healing post Ml, impacts negatively on outcome after Ml and may be 
modified by early and prolonged anti-remodelling therapies applied during 
the phases of infarction and post-infarction healing.
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These can be more simply stated as follows: since early RSD and thinning 
and subsequent scar formation are gradual processes, prolonged LV unloading 
during the healing phase or reduction of the pounding of mechanical forces should 
reduce the degree of thinning and bulging until the scar is formed. This scar 
should be thicker, stronger, less deformed. Pumping action of the heart should 
improve.
Conversely, agents that impair healing and decrease or adversely modify 
infarct collagen and the ECM, cause thinning, increase preload and afterload, 
increase contractile pull of the non-infarcted segment, increase wall stress and 
heart rate might enhance adverse remodelling, increase RSD and decrease 
performance.
3.3. Objectives
The main goal, between 1980 and 1988, was to gain better understanding of 
pathophysiological mechanisms of LV remodelling during healing after Ml and 
determine the effects of potential anti-remodelling therapies using non-invasive 
quantitative 2D-Echo imaging. A secondary goal was to determine the effects of 
therapies on the ECM and possible accentuation of adverse remodelling during 
healing after Ml.
The proposed algorithm was as follows: 
salvage ischaemic myocardium and maintain normal healing preserve LV  
structure, geometry and sha pes  improve LV systolic squeeze improve 
outcome and survival.
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4. METHODS AND PROCEDURES
Due to the complex nature of the field of research, it was necessary to take a 
multidisciplinary approach, involving biochemistry, pharmacology, physiology, 
histopathology, computing, imaging, radiation physics and biomedical 
engineering.
A bench to bedside approach was used, with animal and human studies 
being carried out in parallel. Both sets of studies involved two phases:
• phase 1, focused on.validations and the natural history, and
# phase 2, focused on modification by pharmacological agents.
4.1. Animal studies
The studies were approved by the institutional animal welfare committee and 
conformed with the guiding principles of the American Physiological Society, the 
“Position of the American Heart Association on Research in Animal Use” as 
adopted by the Association on November 11, 1884, and the Canadian Council on 
Animal Care guidelines on the use of animals in research. Animals were 
purchased initially through the institutional Medical and Surgical Research 
Institute and later through the new institutional Health Sciences Laboratory Animal 
Services.
A previously validated chronic dog model (62,147) was modified for 
studying healing over 6 weeks after acute Ml and established, standard and 
published methods were used (41,48,49,55,102,103,122,126). Mongrel dogs (18- 
20 kg) were surgically instrumented under general anesthesia (intravenous sodium 
pentobarbital, 30 mg/kg; endotracheal intubation; ventilation with room air enriched 
with oxygen) and sterile thoracotomy. In studies performed after 1988, general 
anesthesia with isofluorane was used to avoid tachycardia associated with 
barbiturates (227,228).
Polyethylene catheters were inserted in the jugular vein, carotid artery and 
right and left atria, filled with heparinized saline, and the distal ends exteriorized 
behind the neck. An occluding snare was inserted around the mid-LAD or mid-LCX 
coronary artery and the chests closed. All animals were given 1 million units of 
penicillin and 1 gram of streptomycin intramuscularly and returned to their cages.
A warm blanket was used during recovery and supplementary antibiotics 
administered as necessary. Post-operative monitoring and follow-up care were 
carried out in the institutional animal facility and included regular clinical assessment,
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catheter care, haemodynamic and 2D-Echo recordings for assessing LV function 
and remodelling over 6 weeks.
The coronary artery snare was pulled in the sedated but conscious animals 2 
days after the surgical preparation. In reperfusion experiments, the snare was 
released 90- to 120 minutes post-occlusion, while still anesthetized before chest 
closure and by random allocation. With late reperfusion, infarct sizes in this model 
averaged 25 ± 3% (SEM) LV mass and 49 ± 6% occluded bed mass at 7 days.
Although high LAD and LCX occlusions were used in anesthetized animals 
for some experiments focused on infarct limitation in 2-day infarcts, mid-LAD or 
mid-LCX occlusions were used in subsequent long-term studies focused on 
remodelling during healing in survivors post Ml. This was necessary because the 
high occlusions were associated with greater mortality compared to mid-coronary 
occlusions (30 % versus 10 %). The risk regions with the mid-LAD or mid-LG 
occlusions averaged 25 % of the left ventricles.
Serial 2D-Echo (either Diasonics V3400 R, or Toshiba SSH-65A or Hewlett 
Packard Sonos 1000; 3.5 or 5 MHz transducer) was recorded in-vivo, using the 
established protocol for obtaining tomographic images (Figure 5) and techniques in 
the mildly sedated but conscious animals (Figure 9). Standard views included: 
parasternal long-axis; five parasternal short-axis from base to apex at mitral, chordal, 
mid-papillary, low-papillary and apical levels; the apical four- and two-chamber 
views. Recordings were made before surgery, at baseline before occlusion, and 
again post-occlusion and/or reperfusion for up to 7 weeks, with careful attention to 
transducer position and angulation.
Sterile echo-opaque beads were sutured on the anterior and posterior LV 
surfaces at 3 levels from base to apex for better 2D-Echo orientation and consistent 
imaging post Ml. Although 2D-Echo image analyses routinely used anatomic 
landmarks, such as the papillary muscle, to identify the levels for measuring infarct 
segment lengths and infarct wall thickness, and shape changes during remodelling 
(Figure 10), repeated comparisons of the same area was often difficult. The 
opaque beads were therefore useful for regional comparisons of serial 2D-Echo 
data post Ml in animal studies. Pilot serial 2D-Echo studies in 30 infarcted dogs 
with sutured epicardial beads confirmed consistent 2D-Echo imaging (103,283).
In studies after 1985, 2D-Echo guided pulsed Doppler recordings of the 
mitral inflow velocity at the level of the mitral annulus were made concurrently with
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Figure 10. Quantitative analysis of echocardiographic images
Computer assisted measurements of:
A. circumferential extent of asynergy (Si) and regional bulging;
B. endocardial surface area of LV asynergy and volume from 3D 
reconstruction;
C. bulge of the asynergic zone,LV apical view;
D. the expansion index (x/y) and thinning ratio (a/b) from the papillary 
short-axis.
From Jugdutt (21 [Appendix 3])
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2D-Echo recordings (315:Appendix 42), as previously described in the dog (316) 
from the apical-2 or -4 chamber view parallel to flow, with optimal definition of the 
spectral envelope and a sample volume size of 3 to 6 mL. Three to five cycles 
were manually digitized and averaged for peak velocities and integrals of the LV 
inflow in early and late diastole. The 4 main parameters were the rapid filling 
velocity (E), the atrial filling velocity (A) and the atrial filling fraction (E/A) and the 
deceleration time (DT) (Figure 11).
In all dogs, serial haemodynamics were recorded on a Gould Recorder 
(Cleveland, Ohio), as described previously (122,126), and included: right atrial 
pressure (index of right ventricular filling pressure and hydration), left atrial pressure 
(index of LV end-diastolic pressure or filling pressure); phasic and mean arterial 
pressures (index of afterload), and ECGs (for heart rate, rhythm, and evidence of 
ischaemic injury and infarction).
After the final recordings, the dogs were re-anesthetized. In order to study 
LV topography, the hearts were arrested in diastole (1 molar potassium chloride 
intravenously), removed, washed In normal saline, and filled with gelatin to 
preserve diastolic relations before formalin fixation (41). The hearts were 
sectioned systematically along the transverse axis from base to apex after formalin 
fixation in distension to preserve diastolic relations and at the same planes where 
2D-Echo images were obtained (41). Occluded bed size was measured by post­
mortem coronary arteriography before formalin fixation (Figures 4 and 12).
Improved computerized planimetry techniques with recordings of all 
anatomic landmarks was used for more accurate definition of the location of 
infarcts and shape distortion, measurements of wall thickness (41) and correlation 
with 2D-Echo images (Figure 13). A successfully developed and validated 
computer program, executed on a Hewlett Packard 9835A computer and 9874A 
digitizer interfaced with a VAX 750 computer, was used for measuring RSD on LV 
short-axis 2D-Echo images (Figures 13 and 14 ) and similarly on pathologic 
transverse sections in the dog hearts.
Myocardial samples (100 to 200 mg) were taken from the infarct, border and 
non-infarct zones for assays of hydroxyproline (OHP), a marker of collagen content 
and histopathology (41), and immuno-histopathology for collagen subtypes I, III and 
IV (129), after making tracings of the weighed transverse sections, infarcts or scars, 
and occluded bed for computerized planimetry (Figure 13). Histology and
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SYSTOLIC FUNCTION 
Offline analysis (Disc method) versus automatic edge detection for volumes
DIASTOLIC FUNCTION 
Transmitral Doppler for E and A integrals
Normal E and A E and A equalization E and A reversal
Figure 11. Computer assisted quantification of LV global systolic 
and diastolic function by 2D-Echo
Upper panel: LV volumes (end-diastole shown) by the offline Disc 
method versus the automatic edge detection method for systolic and 
diastolic volumes and global LV ejection fraction. Lower panel: Typical 
recordings of transmitral Doppler velocity integrals for diastolic function. 
The early (E) amplitude exceeds the late atrial (A) amplitude in normals. 
The waves become equalized or reversed post Ml. In large Ml and 
severe diastolic dysfunction, the E wave is taller and the deceleration 
time (DT) is decreased (not shown).
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morphometric analysis was done on 5 mm slices from the middle of the occluded 
bed. Thin 5-pm sections taken in triplicate were stained with hematoxylin and 
eosin, Mallory’s stain, or Masson’s trichrome, respectively, and examined for 
infarction and collagen. The concentration of OHP, as mg/g of dry weight, was 
measured using spectroscopy, as described by Bergman and Loxley (317). 
Scanning electron microscopy for extracellular matrix evaluation was performed on 
fresh samples (74, Figure 8 ).
In animals undergoing reperfusion and sacrificed within 2 days, infarct size 
was measured using the triphenyl tétrazolium chloride (TTC) method and 
planimetry. Sections were incubated in TTC (1% in 0.09 molar phosphate buffered 
saline, pH 7.4) for 30 minutes at 37°C to delineate infarct tissue. In those animals, 
the LAD was re-occluded at the same site after final recordings and the left atrium 
injected with monastral blue to define the risk region.
Because infarcts in the dog are rarely 100% transmural, small transmural 
apical infarcts (< 25% LV mass) were produced by ligating the collateral feeders 
from the LCX into the bed below the standard mid-LAD ligation 
(73,74,31 B.Appendix 43). This results in marked remodelling with antero-apical 
aneurysm formation, avascularity and collagen matrix disruption (Figures 4 and 8 ). 
The finding lends support to the concepts that collateral flow protects ischaemic 
myocardium (203,204) and the ECM framework (279), ECM is disrupted during post- 
MI remodelling (284) thereby contributing to LV dysfunction (277) and shape 
deformation (22,73,74). Because healing takes 6  weeks in dogs and mortality from 
large infarcts is high over that time (about 35 %), we produced infarcts that are about 
25% LV for ensuring survival to 6  weeks. This modified model is closer to the 
"collateral-poor human model" (203,204) and shows more ECM disruption, regional 
bulging (RSD) and global LV dilatation than the standard model (73,74).
All data were coded for analysis and observers were blinded with respect to 
the details of the protocols and the treatment groups, as described in extensively 
published methods from my laboratory. Randomization into treatment groups was 
done by opening a sealed envelope that contained the pre-assigned group.
4.1.1. Analysis of echocardiograms for remodelling and functional data
As described previously (103,126), coded echocardiograms were analyzed double­
blind on video playback (0.5 inch tapes) by two independent observers for standard 
in-vivo 2D-Echo parameters of mechanical function, such as regional LV asynergy
64
and global LV ejection fraction, and topographic parameters such as expansion 
index, cavity areas, volumes, segment lengths, thinning ratios, and the area (Ad) 
and depth (rd) of RSD (Figures 10 and 14). Differences were resolved by 
consensus.
Briefly, endocardial and epicardial outlines of the LV images at end-diastole 
and end-systole were traced with a light pen (Diasonics CardioRevue Center), 
corrected over at least three consecutive cycles and copied on plastic overlays. 
Anatomic landmarks, such as papillary muscles and right and left ventricular 
junctions, were indicated on the tracings. Markings of asynergy, defined as akinesis 
(no systolic inward motion and thickening) or dyskinesis (systolic outward motion 
and thinning), or both, were made on each endocardial diastolic outline by careful 
visual assessment of motion and thickening on repeated video playbacks. 
Circumferential extents of asynergy on each short-axis view were then digitized and 
used to compute total endocardial surface area asynergy by a 3D reconstruction 
algorithm. Outlines from five short-axis and two long-axis views were also used to 
compute volumes by means of a modified Simpson's rule algorithm. Global ejection 
fraction was calculated as end-diastolic volume minus end-systolic volume divided 
by end-diastolic volume. The inter-observer error was less than 5% in marking 
asynergy, segment length, wall thickness and areas of outlines (103,126). As for 
post-mortem hearts, topographic measurements were made on end-diastolic 
outlines of short-axis images at the papillary level, and the expansion index (ratio of 
the lengths of the asynergy containing and the non-asynergy containing segments), 
thinning ratio (ratio of the average thicknesses of the asynergic and non-asynergic 
zones) and regional area ejection fraction (end-diastolic area minus end-systolic 
area divided by end-diastolic area) were computed.
The degree of regional bulging, or RSD, in the asynergic zone was 
characterized by its area (Ad) and depth (rd), as described previously 
(19,21,103,126,318). LV aneurysm was defined as the presence of a bulge in 
diastole and further bulging in systole. LV mass was calculated from the volume of 
myocardium (difference in volumes of epicardial and endocardial shells at end- 
diastole) multiplied by an assumed specific gravity of 1.05 g/ml (319). The LV mass 
and the RSD indices (Figures 10 and 14) for each set of 2D-Echo and heart-section 
outlines were compared using linear regression analysis. Wall thicknesses on 2D- 
Echo and heart sections were also compared at 5° angular intervals.
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4.1.2. Post-mortem measurement of scar size and geometry
As described previously (103,126), the risk region was measured on post-mortem 
coronary arteriograms. These were made by simultaneous pressure-controlled 
injections of the coronary arteries of fresh hearts with a mixture of barium sulfate and 
gelatin, followed by fixation of the hearts in distension (15 cm pressure head; 10% 
phosphate-buffered formalin solution or gelatin for 48 hours) to preserve diastolic 
proportions. Radiographs of the whole heart (in two perpendicular planes) and 
transverse sections (five equally spaced sections, 1-1.5 cm thick) were then made.
Boundaries of the risk region were then marked on section radiographs, by 
consensus, at the water-shed between the adjacent beds. The LV rings were 
weighed and outlines of the rings, occluded zones and infarct scars were made on 
plastic overlays. Computerized planimetry was then performed to measure infarct or 
scar size (masses and volumes of infarct, risk region, non-infarct myocardium) and 
ex-vivo topographic parameters, including "thinning" ratio (ratio of average thickness 
of infarcted wall to average thickness of the normal wall) and "expansion" index 
(ratio of endocardial lengths of infarct to non-infarct containing segments 
demarcated by papillary muscle landmarks) and generate average short-axis 
topographic maps for each treatment group (Figure 13).
Average maps of long-axis contours of the LV epicardium and endocardium 
were also made for each treatment group from digitized whole heart radiographs 
and direct measurements of the area and depth of the apical bulge or RSD (Figure 
15).
4.1.3. Sample size.
Calculation of sample sizes considering beta error was done for all remodelling 
experiments. Thus, defining a significant change in RSD as a 50% decrease, a 
doubly significant sample size (N) was calculated by Feinstein's method (320; 
Clinical Biostatistics, St. Louis, Mosby, 1977; p 329) as N=16 for a = 0.05 and (3= 
0.20. With N=16 in each group, a negative result would be associated with a 20% 
chance of falsely accepting the null hypothesis due to a sampling error. With this 
correction, n=10 for a = 0.05, (3 = 0.1. An increase in LV mass of greater than 7% 
was considered to be an indicator of significant LV hypertrophy (103,127,128,131). 
A mortality rate of 10% for mid-LAD occlusions was factored in.
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F igure  15. Computerized topographic maps: Long-axis remodeling ( anterior Ml ).
Postmortem maps of diastolic ventricular topography in the long-axis. 
Digitized epicardial and endocardial contours and average maps in the 
long-axis plane. Dots on the average contours indicate landmarks for 
quantifying the apical bulge. The maps show less apical bulging and 
smaller cavities in the enalapril group.
Jugdutt et al. (127[Appendlx 25])
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4.2. Clinical studies
All protocols were reviewed and approved by the institutional ethics committees 
and informed consents were obtained from all patients for the studies. The 
methodology for non-invasive assessment of regional and global LV function 
before and after therapy using 2D-Echo was developed in 3 stages:
First, the facility was developed for performing tomographic imaging by 
means of 2D-Echo in acutely ill Ml patients at the bedside in the COU and follow- 
up 2D-Echo recordings in the step-down cardiac recovery wards and the 2D-Echo 
Laboratory. Two 2D-Echo machines were acquired (Diasonics 3400) for the 
studies; one was dedicated for studies in the COU and the adjoining step-down 
ward and another for laboratory studies. The laboratory personnel in the early 
1980’s consisted of two sonographers, three fellows and a computer programmer.
Second, the methodology was developed for systematic 2D-Echo studies 
and computer-assisted quantification of right ventricular and LV asynergy (wall 
motion and wall thickening abnormalities), wall thicknesses, and LV shape at 
multiple short-axis levels from the base to the apex of the heart and multiple long- 
axis planes (251-253; Figures 10,14,16). As mentioned above, the computer 
software needed for the above was developed. Manually contoured LV 
endocardial and epicardial outlines were digitized for analysis using a Hewlett- 
Packard computer and digitizer as described for the animal studies. Computer 
programs were developed for measuring the circumferential extent and location of 
LV asynergy using a radial coordinate system (21) and for quantifying LV regional 
and global function (21,28,34,35).
Third, all 2D-Echo studies were performed systematically, according to a 
strict imaging protocol (Figure 5) to permit non-invasive evaluation of cardiac 
function and follow changes by repeated studies focused on LV remodelling and 
myocardial protection.
In addition, the following methodologies for the measurement of multiple 
indexes of infarct size were implemented:
i) Praecordial ST-segment and R/Q-wave mapping using EGG.
ii) Haemodynamic measurements of pulmonary capillary wedge pressure 
and cardiac output using the Swan-Ganz catheter with the 
thermodilution technique, and arterial blood pressure via arterial lines in 
the ecu .
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1, MITRAL
RV
2. CHORDAL
Cl
C. SURFACE AREA AND 
VOLUME CALCULATION
LV
3. PAPILLARY
4. APICAL
Figure 16. 2D-Echo evaluation of right ventricular infarction
A. Right ventricle (RV) is a crescent shaped appendage attached to the more 
conical left ventricle (LV).
B. Extents of abnormal wall motion (AWM) in 4 short-axis sections {thick lines) 
were expressed as ratios of circumferences for LV (S/C^ to SJC^) and as 
ratios of the arc lengths for RV (S /^L  ^ to S3/L3). LV diameters (D^  to D^ ) and 
RV septal chord lengths (I., to IJ were measured.
C. Surface area of AWM (stippled) in endocardial shells was computed from 
AWM in 4 serial short-axis views at the mitral, chordal, papillary and apical 
levels. Long-axis lengths (h.,, h^) of RV and LV were measured in the apical 
4-chamber views and slices assumed to be of equal thickness. Total LV AWM 
area was computed for conical shapes. The RV was opened out into 2 
trapezoids and a triangle to compute the total RV AWM area. Volumes were 
computed from areas and thicknesses of sections.
Jugdutt et al. (253)
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iii) Serial CK and CK-MB enzyme assays for cumulative CK infarct and 
CK-MB-infarct sizes in gram-equivalents based on method of Shell and 
Sobel (321), using customized computer software (Hewlett Packard).
iv) Thallium-201 myocardial scintigraphy and other radio-nuclide cardiac 
imaging.
v) The procedure for preparation of NTG solutions for intravenous 
infusions in acute Ml in initial studies, before commercial preparations 
became available, using glass bottles, special tubings and infusion sets 
in the COU.
vi) Use of computer for rapid statistical analysis, analysis of large volumes 
of haemodynamic, angiographic, CK and 2D-Echo data.
4.3. Statistics
Data were analyzed in blinded fashion. Stringent methodology was used (320-322). 
The statistical tests included: 1) analysis of variance (univariate) for differences 
within and between separate or combined groups; 2 ) repeated measures analysis of 
variance with orthogonal contrast for comparing serial data within groups and a 
multigroup repeated measures design for overall differences between groups; 3) 
multiple comparisons analysis of variance and the Student Newman-Keuls test for 
the significance between placebo and separate or combined therapy groups; and 4) 
chi-square and Fisher's exact tests for the significance of difference in event 
frequency among groups. Results are presented as mean values ± standard 
deviation (SD) or standard error of the mean (SEM) as stated. Statistical 
significance was set at P < 0.05 (two-tailed).
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5. RESULTS
5.1. ANIMAL STUDIES: NATURAL HISTORY
5.1.1. Temporal changes in infarct collagen and left ventricular topography
during healing after myocardial infarction in the dog (41: Appendix 12)
Background; Healing after acute Ml takes places over weeks. Collagen 
deposition in expanded and thinned infarct segments during healing might 
contribute to permanent RSD associated with ventricular aneurysms. The 
changes in collagen content In the infarcted and non-infarcted zones during 
healing over 6  weeks after Ml were studied in 132 hearts of untreated or control 
dogs with LAD or LCX occlusions between 1980-1983 (41).
Methods/Results: Hydroxyproline (OHP) was used as a biochemical marker for 
collagen. Over the 6  weeks, OHP content did not change significantly in normal 
non-infarcted regions but increased progressively in infarct zones (Figure 17). The 
data indicated that, compared to the non-infarct zone, the increase in OHP content 
in infarct zones became detectable by 7 days [9.94 ± 0.67 (SEM) versus 4.38 ± 
0.18 mg/g dry weight, n=25, P<0.001] and peaked by 6  weeks (55.55 ± 3.27 versus 
4.06 ± 0.20 mg/g dry weight, n=17, P<0.001). In contrast, over the 6  weeks in 
sham-operated dogs and dogs with no infarcts, OHP content in the two regions 
remained normal and similar (4.41 ± 0.25 versus 4.06 ±0.18 mg/g dry weight, 
n=21, P=NS). The changes in OHP were similar for LAD and LCX infarcts.
Importantly, significant ex-vivo changes (P<0.05) in LV geometry 
accompanied the changes in infarct collagen and included increased LV cavity 
area (5.0 versus 3.9 cm^), endocardial circumference (8 . 8  versus 7.4 cm) and 
expansion index (1.21 versus 1.02) by 7 days, and decreased thinning ratio (0.71 
versus 0.98). Compared to 2-day infarcts, the infarct area decreased by 6  weeks 
(1.8 versus 3.4 cm^) and the non-infarcted length increased (6.9 versus 5.4 cm). 
The overall findings indicated that healing over 6  weeks in the dog model is 
associated with infarct expansion and LV dilatation within 7 days, before 
significant collagen deposition occurs, and this is followed by infarct scar 
contraction and thinning at 6  weeks.
The findings suggested that collagen deposition in already expanded and 
thinned infarct zones might explain the permanent RSD associated with LV 
aneurysms. The peak RSD index, Pk, for the infarct zone in the LV apical section 
at 6  weeks in that study, was significantly greater in infarcted than non-infarcted or
71
A. NO INFARCT AND SHAM GROUPS n=11n=410
0
n=1780 INFARCT GROUPS n=9O
30
n -2 520
n -5 4
10
0
ctîliter m intafct comer
normal center kAa (iek zone
* p<0.001
1 DAY 2 DAYS 7 DAYS 2 WEEKS 4 WEEKS 6 WEEKS
B, I
I 6 WEEK INFARCT7 DAY INFARCTCONTROL
3  « 1500
ss
£ i  1000
z §
0
a. TIME IN WEEKS
Figure 17. Temporal changes in myocardial hydroxyproline
A. Temporal changes in myocardial hydroxyproline content.
B. Summary of changes in topography {top panel) and percent 
increase in infarct collagen (bottom panel) during healing in 
the canine model. Stippled area indicates infarct.
From Jugdutt (41: Appendix 12)
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sham hearts (4.57 ± 0.06 versus 1.12 ± 0.04, n=21, P<0.001) and greater for LAD 
than LCX infarcts (5:62 ± 0.05 versus 2. 13 ± 0.06, P<0.05).
Relevance: In applying these results, it is Important to remember five points with 
respect to the duration of therapeutic interventions to modify remodelling In 
humans.
First, the infarcts in the dog model were not all 100 % transmural, although 
this was apparent at the LV apex for the posterior Ml after LCX occlusion shown in 
Figure 170.
Second, the duration of healing of the infarct zone after Ml, from the time 
of an acute coronary occlusion to formation of the.final scar, differs among 
species (Figure 1) and takes place over a period of two to three weeks in rats 
(43,96), four to six weeks in dogs (41,96) and between six weeks and six months 
in humans depending on infarct size (40,44). Thus, the slower rate of healing in 
humans compared to rats and dogs should be taken into consideration.
Third, the rate of healing also depends on infarct size (44), in addition to 
other cellular, metabolic and biochemical factors involved in the healing process. 
It was also apparent, in this study, that the time to the collagen plateau was longer 
with large than small infarcts.
Fourth, further late remodelling takes place after collagen deposition has 
plateaued. This involves compaction of the infarcted segment, hypertrophy of the 
non-infarcted segment, and global LV dilatation due mainly to dilatation of the 
non-infarct segment (41) as confirmed by others (71,72,93,94). As shown in 
Figure 17C, the infarct scar at 6  weeks shows evidence of both endocardial and 
epicardial RSD, suggesting that collagen deposition fixes the endocardial and 
epicardial RSD associated with early infarct expansion before the collagen 
plateau. A subsequent report has confirmed an acute increase in both 
endocardial and epicardial surface areas with infarct expansion (323). The early 
window after infarct expansion and before the collagen plateau leaves the infarct 
zone vulnerable to adverse remodelling.
Fifth, late thinning of the infarct zone, with compaction of the scar after 
collagen deposition has plateaued at about 3 weeks in the dog, is associated with 
increased LV chamber distensibility which appear to contribute further to LV 
chamber and aneurysmal dilatation (102,283). However, the subsequent normally 
healed scar is relatively less distensible and more resistant to deformation (69).
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This resistance to further stretch appears to be related to connective tissue cells 
entering the myocyte compartment and connecting disrupted myocyte fibers 
(324). Since the infarct scar has now been recognized as a living structure 
containing myofibroblasts with contractile ability (325), some infarct remodelling 
may continue for years beyond the initial healing phases. Several studies have 
confirmed that lengthening of the non-infarcted segment plays a major role in the 
late cavity dilatation (7,31,68,194). Progressive LV dilatation has also been 
correlated to infarct size and continues long after the healing process is completed 
(26,76,298,299). In the rat model, a further 30% increase in LV volume occurred 
between 3 weeks and 3 months (77).
5.1.2. Two-dimensional echocardiographic characterization of topographic 
changes after transmural and non-transmural infarcts during healing 
after myocardial infarction in the dog
5.1.2.1. Transmurality (73: Appendix 19)
Background: The subepicardial rim of spared myocardium after subendocardial 
Ml might protect against infarct remodelling whereas its absence in transmural Ml 
might allow unrestricted infarct bulging and thereby contribute to LV dysfunction.
Method/Results: The effect of infarct transmurality on adverse in-vivo and ex-vivo 
LV remodelling during healing over 6  weeks after Ml was studied systematically in 
the dog model (73). Serial topographic and functional parameters on 2D-Echo 
and haemodynamics as well as post-mortem topography were measured in dogs 
randomized to standard l_AD ligation (group 1) or a modified lower LAD ligation 
plus collateral obliteration to decrease collateral inflow and increase infarct 
transmurality (group 2). Compared to group 1 at 6  weeks, group 2 had similar 
infarct weight [5.5 ± 2.0 (SD) g versus 4.7 ± 2.9 g] and slightly less infarct collagen 
(36.1 ± 7.7 versus 43.1 ± 17.1 mg/g dry weight, P<0.05). In contrast, group 2 had 
greater transmurality (94.8 ± 6.7% versus 6 6 . 6  ± 23.7%, P<0.001) (Figure 18) and 
was associated with more necrosis relative to the area at risk (54.9 ± 11.5% 
versus 35.3 ± 17.4%, P<0.001), Q-waves (8 6 % versus 36%, %^=12.88, P<0.0005), 
infarct expansion, infarct thinning, regional bulging or RSD (depth: 0.96 ±0.15 
versus 0.57 ±0.14 cm, P<0.001, and LV dilatation. At 6  weeks on 2D-Echo, group 
2 showed more infarct expansion (2.59 ± 0.32 versus 2.30 ± 0.25, P<0.001), more 
late thinning (0.56 ±0.15 versus 0.72 ±0.13, P<0.001) and RSD in the short-axis
74
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(Figure 18), larger LV diastolic (82 ±10 versus 75 ± 11 mL, P<0.05) and systolic 
(53 ± 14 versus 42 ± 11 mL, P<0.05) volumes, and more LV apical aneurysms 
and RSD (Figure 18) in the long-axis, reflecting greater topographic deterioration. 
Group 2 also showed more LV thrombi (79% versus 55%, %^=2.70, P<0.01), 
ventricular arrhythmias, and deaths (36% versus 12%, P<0.001). Infarct 
transmurality correlated with the severity of LV remodelling and dysfunction.
Also in that study, mean left atrial pressure was higher in group 2 but heart 
rate and blood pressure were not significantly different. Collateral blood flow was 
less in all regions of the risk region for group 2, infarct center flows being 0.05 ± 
0.01 versus 0.29 ± 0.10 mL/min/g (P<0.001). Importantly in group 2, 6 6 % of the 
infarct expansion occurred by 2 days while 84% of the infarct thinning occurred 
late, after the second week. The ECGs showed a greater frequency of 
pathological Q-waves in group 2, the frequencies at 6  weeks being 33% versus 
0% (x^=10.18, P<0.005). Premature ventricular contractions at 2 days were more 
frequent in group 2, 63% versus 24% (%^=6.93, P<0.01). The Lown score of 
arrhythmias at 6  weeks was also greater for group 2 (1.8 ± 1.2 versus 0.5 ± 0.7, 
P<0.001). The overall findings indicated that infarct transmurality is a major 
determinant of LV remodelling and dysfunction during healing after Ml (73).
Relevance; Since Infarct transmurality is a major determinant of the severity of 
adverse LV remodelling and dysfunction during healing after anterior Ml, early 
therapeutic interventions aimed at decreasing transmurality might limit 
remodelling. Furthermore, stratification on the basis of initial infarct transmurality 
might be useful in selecting high-risk patients for aggressive anti-remodelling 
therapy during healing after Ml.
5.1.2.2. Q-wave and non-Q-wave Ml (74: Appendix 20)
Background: The presence of anterior Q waves on the EGG might identify a 
group at high risk for adverse LV remodelling and severe LV dysfunction after Ml.
Methods/Results: Whether LV remodelling is more severe after anterior Q-wave 
than non-Q-wave Ml was addressed in another report (74). This study confirmed 
that the Q-wave group had greater infarct transmurality (8 8 % versus 58%, 
P<0.001), higher left atrial pressures, more infarct expansion, more infarct 
thinning, greater LV dilatation, more LV apical bulging (depth of RSD: 4.9 versus
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1.9 mm, P<0.001), more LV asynergy (18% versus 7%, P<0.001), lower global 
ejection fraction (40% versus 48%, P<0.001), more LV apical aneurysms (82% 
versus 36%, P<0.001), more LV thrombus (64% versus 0%, P<0.Q005) and 
ventricular arrhythmias.
Importantly, this study provided insight into the relation between infarct 
transmurality and the presence of Q waves over 6  weeks after Ml (74). The 
presence of Q waves correlated with greater transmurality at 2  days (87% versus 
52%), 7 days (8 8 % versus 53%) and 6  weeks (8 8 % versus 15%). The values of 
transmurality that separated the Q-wave from the non-Q-wave group were close 
at the three time intervals and averaged 76.6%.
Relevance; The association of anterior Q waves on ECGs with greater infarct 
transmurality and more adverse LV remodelling and dysfunction during healing 
after Ml suggests that the finding of an anterior Q wave on the initial EGG might 
be used to select high-risk patients after Ml.
5.1.2 .3. Resistance to distension and rupture (283: Appendix 40) 
Background: Healing after Ml is associated with progressive EGM and collagen 
remodelling. These may lead to changes in the distensibility and mechanical 
strength of the infarcted LV. The LV rupture threshold might provide a global 
measure of the mechanical strength of the infarcted heart.
Methods/Results: The mechanical resistance of the infarcted left ventricle to 
rupture, or rupture threshold, was measured using the balloon technique (Figure 
19) between 1 and 2 days in 70 fresh post-mortem hearts from dogs with LAD 
occlusion (283). The rupture threshold in infarcted hearts was lower than in non- 
infarcted hearts (754 ± 223 (SD) mm Hg versus 1168 ± 165 mm Hg, P<0.001). 
Over 6  weeks after Ml, the rupture threshold did not change in non-infarcted 
hearts but decreased after 14 days in infarcted hearts, the average value being 
less between 21-42 days than 1-14 days (577 ± 140 versus 867 ±191 mm Hg, 
P<0.001). Passive LV stiffness before rupture also decreased after 14 days in 
infarcted hearts. Infarct OHP increased during healing and 2D-Echo confirmed 
evidence of early infarct expansion and late infarct thinning. The late decrease in 
rupture threshold and pre-rupture stiffness of the infarcted left ventricle and late
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scar thinning suggests there is a late decrease in the mechanical strength and 
resistance of the infarcted left ventricle to distension during healing after Ml.
Relevance: The time-dependent changes in collagen content (and remodelling) 
and LV structural remodelling during healing after Ml are associated with changes 
in global LV distensibility and resistance to rupture. High, “non-physiologic”, LV 
pressures like those in this study can develop during activities such as heavy 
lifting and snow shovelling.
The overall findings of the first two studies (73,74) underscore 5 points:
First, anterior Q-wave Ml is associated with greater infarct transmurality, 
LV remodelling and dysfunction in the dog model.
Second, transmural or Q-wave Ml does not simply imply more than 50% 
transmural extent as previously assumed but about 77%. This implies that Q- 
wave infarcts may also have a subepicardial buttress of 23% or less. This factor 
contributes to heterogeneity in clinical studies.
Third, subendocardial or non-Q-wave Ml may be buttressed by a more 
significant subepicardial rim than Q-wave Ml. While this may be an advantage in 
preventing infarct expansion (Figure 20), an increase in this area due to 
myocardial salvage after reperfusion therapy may not be reflected in improved 
regional function on 2D-Echo. This is because systolic thickening is due mainly to 
thickening of the endocardium and to a lesser extent to thickening of the mid­
myocardium, but very little to thickening of the epicardium (326).
This factor is compounded by the fact that restoration of flow to near 
normal levels in epicardial vessels may not achieve 1 0 0 % transmural reperfusion 
because of reperfusion injury associated with microvascuiar injury and “no reflow” 
(305). The mismatch between restoration of flow and recovery of function has 
been an active area of study in several laboratories since the mid 1980’s.
Contrast 2D-Echo has been applied to better define the area at risk and the role of 
microvascuiar injury (327-331).
Fourth, it follows from the first two studies (73,74) that a significant number 
of patients who have non-Q-wave or subendocardial Ml may be expected to have 
significant necrosis between 21% and 75% in transmural extent and significant 
akinesis and dyskinesis. Furthermore, as post-MI survivors show loss of Q-waves 
and heterogeneity in the severity of LV dysfunction over time on serial 2D-Echo 
(21,35,74,75), the timing of the measurements after Ml becomes pertinent.
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Figure 20. Transverse sections for measurement of infarct size, 
expansion, thinning and bulging in anterior Ml.
A, B. Transmural infarction produced by mid-LAD ligation (arrow), barium- 
gelatin-polymer injection into distal LAD, and running suture around the 
occluded bed. All myocardium within the occluded bed below the ligation 
shows transmural infarction, with no sparing.
C. Computer-generated LV endocardial and epicardial contours from 
radiographs in the long-axis plane for the infarction and sham groups. 
Group 1, standard LAD occlusion. Group 2, LAD occlusion with collateral 
obliteration and increased transmurality. Points on the average contours 
indicate landmarks for quantifying the bulge.
From Jugdutt et al. (318; Appendix 43)
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Fifth, the third study (283) suggests that the infarcted left ventricle after 6  
weeks is weaker than the non-infarcted left ventricle, and the resistance to 
distension is diminished. It follows that the healing heart is vulnerable even in the 
late phase of healing after the collagen plateau has been reached.
The overall findings suggest that the infarcted left ventricle is susceptible to 
early regional dilatation and RSD during the first 2 weeks after Ml, before the 
collagen plateau, and significant progressive dilatation involving both the infarct 
and the non-infarct segment in the later phase of healing, after the collagen 
plateau and in part due to late infarct scar thinning.
5.2. ANIMAL STUDIES ON MODIFICATION BY PHARMACOLOGICAL AGENTS
5.2.1. Effect of infarct-lim iting therapies on infarct collagen, LV geometry 
and LV function during healing after Ml in the dog (55: Appendix 16) 
Background: Before embarking on clinical studies, it was necessary to
determine whether infarct-limiting therapies (Table 7) applied during acute Ml 
might influence early healing after Ml. Effects of LV unloading with NTG and 
ACE-inhibition were first studied (Figure 21).
Methods/Results: The hypothesis that early short-term therapy with 3 infarct- 
limiting drugs, given only during the first 6  hours of acute Ml might produce 
persistent or delayed effects on LV remodelling during early infarct healing over 1 
week was tested in the dog model (55). Measurements of regional OHP content, 
wall thicknesses, segment lengths and infarct size were made at 7 days in left 
ventricles from 69 animals with LAD ligation and 7 sham animals. The animals 
were randomized after LAD occlusion to 6  hour infusions of intravenous saline 
(controls, n=29), NTG (low-dose to decrease mean arterial pressure by 10% but 
not below 80 mm Hg, n=13), PGI2 (low-dose, 1 0 % decrease in mean arterial 
pressure, n=13), or ibuprofen (low-dose, 4 mg/kg/hour, n=14). Infarct size, 
measured by computerized planimetry of weighed LV rings, was less in therapy 
groups compared to saline, as percent of occluded bed size (P<0.001) and as 
percent of the left ventricle (P<0.005). Infarct expansion was less with NTG and 
PGI2 compared to saline and ibuprofen. However, infarct thinning was greater 
with ibuprofen compared to the other groups. Thus, the ratios of the infarct to the 
normal wall thickness were similar for saline, NTG and PGI2 groups [0.92 ± 0.02
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Figure 21. Determinants and therapeutic approaches in the 
remodelling of infarct and non-infarct zones
Potential therapeutic approaches. IRA = infarct related artery, 
NIRA = non-infarct related artery. White arrows = intramural 
contractile pull, stipples arrows = intracavitary distending forces, 
dark arrows = restraining forces opposing distension.
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(SEM) versus 0.94 ± 0.02 versus 0.96 ± 0.01, respectively] but significantly lower 
in the ibuprofen group (0.80 ± 0.02, P<0.001). The OHP contents (mg/g dry 
weight) were higher (P<0.001) in the infarct than normal zones in all 4 groups 
(saline: 9.9 ± 0.7 versus 4.4 ± 0.2; NTG: 14.9 ± 1.9 versus 5.2 ± 0.3; PGI2 : 12.9 ± 
0.9 versus 5.3 ± 0.6; ibuprofen: 10.6 ±1.4 versus 4.2 ± 0.2), and higher with NTG 
compared to saline (14.9 ±1.9 versus 9.9 ± 0.7 mg/g, P<0.02). The degree of 
RSD measured on short-axis outlines of sections and long-axis radiographic 
outlines was less (P<0.001) with NTG and PGI2 compared to saline and ibuprofen. 
The rupture thresholds were less in ibuprofen than NTG or PGI2 or saline groups 
(397 ± 37 versus 720 ± 67 mm Hg, P<0.005). There was no difference among the 
NTG or PGI2 or control groups.
These results indicated that early therapy with NTG, PGI2 or ibuprofen 
reduced infarct size but did not reduce infarct collagen by 1 week. NTG increased 
infarct collagen while ibuprofen increased infarct thinning, and NTG and PGI2 
limited infarct expansion and RSD.
Relevance; The overall findings support the concept that the application of short­
term infarct-limiting therapy during acute Ml may exert delayed, and sometimes 
unexpected effects and influence LV remodelling during the very early phase of 
healing, before significant collagen deposition. Appropriate therapies might have 
greater potential for limiting remodelling and aneurysm formation when 
administered early after Ml. This was subsequently confirmed in a study at the 
bedside (28: Appendix 6 ).
5.2.2. Effect of vasodilator-induced hypotension on infarct size, collateral 
blood flow, and LV geometry and function in 7-day old anterior 
infarcts in dogs (122: Appendix 28)
Background: The hypothesis that vasodilator therapy, previously shown to be 
beneficial in Ml in dogs (98) and humans (232: Appendix 36), might be 
deleterious and lead to adverse remodelling was tested in the dog model when 
given in excess (122). NTG therapy was delayed 2 hours post-occlusion to mimic 
the clinical scenario.
Methods/Results: The effect of NTG-induced decreases in mean arterial 
pressure on myocardial salvage was studied in 65 lightly sedated conscious dogs
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that were randomized 2 hours after LAD occlusion to receive 4-hour intravenous 
infusions of saline (group 1, n=19), or NTG in doses to decrease mean arterial 
pressure by 10% (group 2, n=18), 25% (group 3, n=14), and 50% (group 4, n=14), 
respectively. At 7 days, infarct size and occluded bed size (post-mortem coronary 
arteriography) were measured in 41 dogs using computerized planimetry. Over 
the first 6  hours, regional blood flow was measured using 7 to 10 pm radioactive 
microspheres in 24 dogs (98). Compared to saline infusions in group 1, NTG 
infusions produced sustained reductions (P<0.001) in mean left atrial pressure 
and mean arterial pressure in all dogs, but heart rate was unchanged. The 
decreases in mean arterial pressure achieved in groups 2, 3, and 4 were 10% 
(range, 5% to 19%), 23% and 39%, respectively, with average levels of 96 (range, 
83 to 113), 83, and 64 mm Hg, respectively. Infarct size was significantly smaller 
(P<0.025) in group 2  compared to groups 1,3, or 4, expressed both as percent of 
the left ventricle (6 % versus 14% versus 13% versus 15%) and as percent of the 
occluded bed (13% versus 37% versus 34% versus 44%) (Figure 22). Myocardial 
salvage (expressed as percent of the occluded bed) with NTG correlated inversely 
with the percent of decrease in mean arterial pressure (r = -0.77, P<0.001). 
Collateral blood flow increased (P<0.005) throughout the occluded bed in group 2 
compared to group 1 but was unchanged in groups 3 and 4. In contrast, coronary 
vascular resistance decreased (P<0.025) in all NTG groups. These results 
suggested that perfusion pressure is an important determinant of myocardial 
salvage during vasodilator therapy such as NTG. An increase in the dose of NTG 
to decrease mean arterial pressure by more than 10%, and to levels below 96 mm 
Hg, might offset its potential for myocardial salvage in the dog.
Relevance; The overall findings suggest the need for a caveat on avoiding 
hypotension during vasodilator therapy after acute Ml. The paradoxical J-curve 
effect (Figure 22C), whereby reduction in perfusion pressure beyond a critical 
level leads to more necrosis instead of salvage, can occur with other vasodilators 
(100). In this study, marked NTG-induced hypotension negated the beneficial 
effects on infarct size and collateral blood flow (122). This underscores the need 
for extreme caution and titration of the drug to a suitable haemodynamic end-point 
in the setting of acute Ml. The risk is further amplified in the presence of 
multivessel disease and coronary vasodilators that can potentially cause ‘coronary 
artery steal'. The short half-life of intravenous NTG and its rapid onset and offset
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of action makes the drug suitable for use in acute Ml (250). Long-acting nitrate 
preparations, such as ISDN, may be problematic if hypotension develops during 
infusions in acute Ml.
5.2.3. Effect of prolonged vasodilator and anti-inflammatory treatment on LV 
remodelling and LV rupture threshold during healing after Ml In the 
dog
The hypothesis that prolonged therapy during healing after Ml significantly 
modifies LV geometry and function was addressed in 3 studies using the dog 
model (48,102,103).
5.2.3.1. Effect of prolonged isosorbide dinitrate and ibuprofen on LV
topography and rupture threshold during healing after Ml (102: 
Appendix 22)
Background: Short-term pharmacological interventions applied during healing 
after Ml might modify LV remodelling during healing and the mechanical 
resistance of the healed infarcted LV to distension and rupture threshold. 
Although acute administration of nitroglycerin and ibuprofen has been shown to 
reduce infarct size, prolonged treatment with ibuprofen was reported to produce 
adverse infarct remodelling (54).
Methods/Results: The effect of ISDN and ibuprofen, given between 2 and 7 days 
after LAD ligation, on the mechanical resistance of the infarcted left ventricle to 
rupture or the rupture threshold (balloon technique) and LV topography 
(computerized planimetry) and function (2D-Echo) at 7 days (n=32) and 42 days 
(n=34) post-ligation was studied in 6 6  dogs (102). The animals were randomly 
allocated to sham (no infarction, n=22) and infarction sub-groups (15 controls; 15 
ISDN, 30 mg b.i.d. orally at 08:00 and 14:00 hours, followed by 10 mL of water at 
2 2 : 0 0  hours so as to allow a washout period of about 1 2  hours and avoid 
development of nitrate tolerance (332); 14 ibuprofen, 200 mg t.i.d. orally). ISDN 
decreased mean arterial and left atrial pressures, decreased diastolic cross- 
sectional area, and improved LV systolic function, while ibuprofen increased 
diastolic area. Infarction subgroups showed infarct shrinkage and more infarct 
OHP at 6  weeks. Compared to sham animals, all infarct subgroups showed early 
expansion and thinning, with further marked late thinning in controls. ISDN
8 6
produced less expansion and thinning both at 1 and 6  weeks, while ibuprofen 
produced marked early thinning. Rupture threshold was less at 6  weeks than 1 
week with controls and ibuprofen but remained unchanged with ISDN. Passive 
pre-rupture stiffness was less at 6  weeks than 1 week with controls but remained 
unchanged with ISDN and ibuprofen.
The overall results indicated that reduced expansion and thinning with 
ISDN during the first week after Ml was associated with improved LV function, 
mechanical strength, and resistance to distension at 6  weeks.
Relevance: The finding of beneficial effects of short-term nitrate therapy, given 
using an eccentric dosing schedule and allowing a nitrate-free interval during the 
first week after Ml, on LV remodelling, LV function, mechanical strength and 
distensibility measured at 6  weeks supported the concept that short-term therapy 
may have long-term benefits. Another pertinent finding was that therapy given 
before infarct collagen reaches a plateau (before significant fibroblast activity 
develops) did not seem to lead to a detectable difference in the collagen content 
of the healed infarcts. This finding suggests that drugs that inhibit collagen 
synthesis may not significantly affect infarct collagen during that time window.
Erratum: An error appears in the title of this publication in reference #102 
(Appendix 22); 'nitroglycerin' should be ‘ISDN’ as stated in the text.
Both ISDN and NTG are denitrated to release NO (333: Appendix 44). 
While NTG is short-acting, ISDN is long-acting (334). ISDN is denitrated at a 
much slower rate than NTG (334). In fact, ISDN is a prodrug that is denitrated in 
the liver (first pass) to liberate NO, which then stimulates guanylyl cyclase leading 
to the conversion of cGMP (guanosine triphosphate to cyclic guanosine 3 ,5 - 
monophosphate) which causes vasodilatation. ISDN is metabolized to isosorbide 
2- and 5-mononitrrate. The latter is the primary metabolite that is commercially 
available as ISMN. NTG, on the other hand, is metabolized to 1,3- and 1,2- 
glyceryl dinitrate, which are active metabolites with lower potency than NTG (334). 
Inactive metabolites are also produced. Further metabolism yields glycerol and 
carbon dioxide. Unlike NTG, ISDN and ISMN do not cause spontaneous release 
of NO and are less effective in raising platelet cGMP (333,335,336).
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5.2.S.2. Effect of prolonged 2-week versus 6 -week nitrate therapy regimens 
on LV remodelling after Ml in the dog (103; Appendix 23)
Background; Although the beneficial effects of LV unloading with low-dose NTG 
in acute Ml (limitation of infarct size) (123) and ISDN during short-term therapy 
before the infarct collagen plateau (limitation of LV remodelling and dysfunction) 
(102) had been demonstrated, the effect of long-term nitrate throughout post-MI 
healing had not been determined. This study tested the hypothesis that long-term 
therapy, given throughout healing over 6  weeks after Ml, might be more beneficial 
than short-term therapy given over the first 2 weeks after Ml (103).
Methods/Results; The effect of prolonged nitrate therapy between 2 days and 6  
weeks during healing after Ml on serial parameters of LV remodelling (scar 
expansion, scar thinning, LV dilatation, and hypertrophy) and LV function 
(asynergy or akinesis plus dyskinesis and ejection fraction) by serial 2D-Echo, 
haemodynamics, post-mortem topography (computerized planimetry, geometric 
maps, and radiographs), and collagen content (OHP) was studied in 64 dogs. 
The animals were randomized 2 days after LAD ligation to various nitrate 
regimens (n=32) over the first 2 weeks: sub-group 1, 2% transdermal NTG at 8  
AM and 4 PM (n=6 ); sub-group 2, 2% transdermal NTG plus 2.6 mg of sustained 
release oral NTG at 8  AM, 3 PM, and 10 PM (n=5); sub-group 3, oral ISDN, 30 mg 
at 8  AM and 4 PM (n=11) or 6  weeks: sub-group 4, ISDN (n=10); and matching 
controls (n=32).
Nitrate therapy reduced left atrial pressure, mean arterial pressure, and the 
rate-pressure product compared to controls over the 6  weeks. Post-mortem scar 
mass and OHP were similar in control and nitrate groups. However, scar 
stretching and thinning, cavity dilatation, non-infarct wall hypertrophy, and apical 
bulging (RSD) were less with nitrates, especially in the long-term sub-group 4. In- 
vivo remodelling parameters between 2  days and 6  weeks after ligation showed 
that, compared to controls, nitrate therapy prevented further stretching of the 
asynergic segment, decreased the expansion index, decreased further scar 
thinning, prevented the increase in LV volumes, reduced the frequency of LV 
aneurysm, prevented the increase in LV mass, reduced the extent of asynergy, 
and improved ejection fraction. Although the beneficial effect on topography and 
function was seen in all nitrate sub-groups, the overall benefit was greater with
8 8
long-term therapy over 6  weeks (sub-group 4) than short-term therapy confined to 
the first 2 weeks (sub-groups 1, 2, and 3).
The overall results indicated that prolonged nitrate therapy, in various 
regimens during healing after infarction, effectively reduced LV loading and 
prevented infarct thinning, further infarct expansion, progressive LV dilatation, and 
the increase in mass. These effects were associated with decreased LV asynergy 
and improved LV ejection fraction. The beneficial effects were greater with long­
term therapy over 6  weeks than short-term therapy over the first 2  weeks. ■I
Relevance: The benefits of long-term nitrate therapy given in an eccentric dosing 
schedule in this study supported the concept that prolonged LV unloading can 
limit adverse LV remodelling and dysfunction after Ml. j
5.2.3.3. Impact of LV unloading after late reperfusion of canine anterior Ml 
on remodelling and function using isosorbide-5-mononitrate (48: 
Appendix 13)
Background: Late coronary artery reperfusion was being reported to result in a 
mismatch with delayed recovery of function despite re-established perfusion 
(158). However, late reperfusion was also reported to limit infarct expansion 
independent of reduction of infarct size (83). Whether prolonged LV unloading 
after late reperfusion might improve recovery of LV function and limit remodelling 
during healing after anterior Ml had not been determined.
Methods/Results: The hypothesis that late reperfusion combined with prolonged 
unloading with isosorbide-5-mononitrate (ISMN) might produce greater functional 
recovery and less remodelling than late reperfusion alone was tested in the dog 
model (48). The rationale was that late reperfusion during acute Ml results in 
delayed recovery of LV function and less remodelling, whereas LV unloading with 
nitrates Improves function and attenuates remodelling.
In-vivo LV function and topography (2D-Echo), post-mortem topography 
(planimetry), and collagen content (OHP) were measured in dogs that were 
randomized to reperfusion 2 hours after LAD ligation plus ISMN (n=12) or placebo 
(n=12) given as 25 mg intravenously over 4 hours followed by 50 mg q.i.d. for 6  
weeks. ISMN had been reported to be associated with less nitrate tolerance 
(337). Compared to placebo, the ISMN group had similar heart rate but lower left
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atrial pressure, mean arterial pressure, and rate-pressure products. Although in- 
vivo remodelling and functional parameters were similar in the two groups, by 6  
weeks the ISMN group had smaller (P<0.05) infarct and non-infarct segment 
lengths, ventricular volumes, and mass; less (P<0.001) asynergy; and greater 
(P<0.001) volume ejection fraction. More importantly, by 2 days, ejection fraction 
was 18% greater (P<0.025) and asynergy 26% less (P<0.05) with ISMN. At 6  
weeks, the ISMN group showed less (P<0.05) scar size, scar collagen, cavity 
dilatation, non-infarct wall thickness, and apical bulging than the placebo group. 
In another 4 dogs, ISMN given acutely produced less improvement in LV function 
and remodelling than prolonged ISMN.
The overall results suggested that late reperfusion of acute anterior Ml 
combined with prolonged ISMN unloading results in greater and earlier recovery 
of LV function and less remodelling than late reperfusion alone.
Relevance: Prolonged LV unloading with ISMN (once daily) after late reperfusion 
results in earlier recovery of LV function and less remodelling.
The overall findings of the three studies (48,102,103) underscore 3 
important points.
First, both the timing and duration of interventions after Ml are important. It 
is evident that certain factors such as mechanical forces are operative throughout 
the period after Ml (Figures 7 and 21). It follows that prolonged application of an 
appropriate intervention throughout healing might be more effective than early or 
late therapy alone. These principles have been tested and found to be true with 
agents that: i) reduce preload and afterload, such as NTG (48,102,103,104-109), 
and captopril or enalapril (108,126-131); ii) increase contractile pull, such as 
digoxin (2 2 2 ); and iii) decrease contractility and heart rate, such as metoprolol 
(220).
Second, therapy during the healing phase with an agent such as NTG, 
which does not decrease infarct collagen, does not cause thinning, but decreases 
preload and afterload, would be expected to reduce the extent of RSD and 
improve myocardial performance after acute Ml. The effect of prolonged NTG 
therapy during the healing phase in the studies described above confirm beneficial 
effects on LV geometry, RSD and LV function after Ml with or without reperfusion 
in the dog model (48,102,103).
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Third, the long-acting nitrate, ISDN, proved to be safe and produced 
benefits when given during the period after completion of Ml, between 2 days and 
7 weeks and allowing a daily nitrate-free interval. Thus, the ISDN was 
administered using an eccentric dosage schedule to avoid the development of 
nitrate tolerance (332). It is possible that the healing infarct is less susceptible to 
the harmful effects of hypotension than the acutely infarcting myocardium.
5.2.4. Effect o f agents that decrease infarct collagen on LV remodelling 
during healing after Ml in the dog
The hypothesis that prolonged therapy with ACE inhibitors, that produce LV 
unloading and inhibition of angiotensin II formation, might limit LV remodelling and 
dysfunction after Ml was tested in the dog model (126-129,131). The effect of 
ACE inhibitors on collagen synthesis was not known at the time that the studies 
were done in the mid 1980’s. This unexpected finding led to additional studies 
with ACE-inhibition.
5.2.4.1. Effect of long-term captopril therapy on LV remodelling and 
function during healing after Ml in the dog (126: Appendix 29) 
Background: The effect of prolonged LV unloading with an ACE inhibitor on LV 
remodelling, function and infarct collagen during healing after anterior Ml in the 
dog model had not been determined.
Methods/Results: The effect of long-term reduction of preload and afterload by 
captopril during healing after Ml on LV remodelling and function was studied in 30 
chronically instrumented dogs with LAD ligation (126). The animals were 
randomized 2 days after Ml to oral therapy with placebo (n=15) or captopril, 50 mg 
ti.d. (n=15), for 6  weeks. Serial haemodynamic as well as topographic and 
functional variables (2D-Echo) were measured over 6  weeks. Scar topography 
(planimetry), occluded bed size (coronary arteriography) and collagen (OHP) 
content were measured at 6  weeks. Between 2 days and 6  weeks, captopril 
decreased (P<0.001) mean arterial pressure and mean left atrial pressure more 
than placebo, but did not influence heart rate. Infarct scar mass, transmurality 
and collagen content at 6  weeks were similar in the two groups but scars showed 
less (P<0.001) thinning and expansion with captopril than with placebo. The 
infarct scar weights were consistent with small infarcts (control, 5.7 ± 2.7 g;
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captopril, 6.4 ± 3.5 g). Echocardiograms showed similar infarct expansion and 
thinning in the two groups at 2 days but less aneurysm with captopril at 6 weeks. 
Between 2 days and 6 weeks, the expansion index (infarct-/non-infarct-containing 
segment length) decreased (P<0.001) with captopril but increased (P<0.001) with 
placebo. Also, thinning ratio (infarct/normal wall thickness) decreased (P<0.001) 
with placebo but did not change (P=NS) with captopril. By 6 weeks, LV asynergy 
and volumes showed a greater decrease (P<0.01) and global ejection fraction a 
greater increase (P<0.05) with captopril.
The results suggested that captopril therapy during healing after canine 
anterior infarction limits LV remodelling and improves LV function in a dog model 
of small infarcts.
Similar benefit was seen with captopril in the canine model of small 
transmural Ml (318: Appendix 43). Transmural Ml was induced by mid-LAD 
ligation plus a circumferential running silk suture around the central cyanotic zone 
(not penetrating more than 50% of the LV wall thickness and not applied with 
excessive tension that might distort or tear the wall) and, as added precaution, 
ligation of visible collateral feeders (318). The captopril-induced attenuation of 
RSD in that study was dramatic in some hearts (Figure 23).
Relevance: The findings established that the ACE-inhibitor captopril limits LV 
remodelling and dysfunction in small transmural Ml. Beneficial effects of captopril 
on LV remodelling and survival were previously reported in rats with small and 
moderate Ml (75-77). Captopril in that study did not significantly decrease 
collagen in the infarct center region (126). Of note, the dose of captopril in that 
study decreased both afterload and preload (126).
S.2.4.2. Effect of enalapril on LV remodelling and function during healing 
after anterior Ml in the dog (127: Appendix 30)
Background: In view of the results of the CONSENSUS II study (123), the 
hypothesis that prolonged ACE-inhibition with enalapril might produce similar 
benefits as found with captopril (77) was tested. The effect of prolonged ACE- 
inhibition with enalapril, given in a dose that does not produce prolonged decrease 
in blood pressure, on LV remodelling, function and infarct collagen during healing 
after anterior Ml in the dog model had not been determined.
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Methods/Results; The effect of enalapril, during healing between 1 day and 6 
weeks after Ml, on in-vivo changes in LV size, shape, mass and function 
(asynergy, or akinesis and dyskinesis, and ejection fraction) as determined by 
serial 2D-Echo, haemodynamics, post-mortem topography (planimetered short- 
and long-axis ventricular contours), and collagen content (determined by levels of 
OHP) was measured in 25 instrumented dogs (127). The dogs were randomized 
1 day after LAD ligation to a control group (no treatment) and a group receiving 
oral enalapril (2.5 mg b.i.d.). Compared to controls, enalapril produced a 
sustained lowering of left atrial pressure but no difference in heart rate and mean 
blood pressure over the 6 weeks.
Also compared to controls, enalapril modified in-vivo remodelling 
parameters between 1 day and 6 weeks, with less elongation of the asynergy 
containing segment, lower expansion index (ratio of endocardial lengths of infarct 
to non-infarct containing segments demarcated by papillary muscle landmarks), 
less scar wall thinning, lower thinning ratio (ratio of average thickness of infarcted 
wall to average thickness of the normal wall), smaller LV volumes, less regional 
bulging and aneurysm frequency, prevention of the increase in LV mass, less total 
extent of asynergy, and higher LV volume ejection fraction.
At post-mortem examination, scar mass was similar in the two groups, but 
topographic maps with enalapril revealed less infarct bulging, flatter infarct scars 
and less non-infarct wall thickness. In addition, post-mortem collagen was similar 
in the non-infarct zones of the two groups but lower in the infarct zones of the 
dogs given enalapril.
The overall results indicated that prolonged enalapril therapy, in a dose that 
did not lower blood-pressure, during healing after anterior Ml produced prolonged 
reduction of LV preload in dogs. This diastolic unloading was associated with 
limitation of remodelling parameters (infarct expansion and thinning, progressive LV 
dilatation and hypertrophy, regional bulging), less total asynergy and improved LV 
ejection fraction. Although ACE-inhibition was associated with lower infarct collagen 
and altered scar topography, these effects did not impact negatively on overall 
remodelling and function in the model of small infarcts.
Relevance: The findings established that the ACE-inhibitor enalapril, in a dose 
that produced prolonged reduction of preload but not blood pressure, limited LV 
remodelling and dysfunction in small transmural Ml. However, beneficial effects of
94
this non-blood-pressure lowering dose of enalapril on LV remodelling were 
associated with less infarct collagen and flatter scars (127). These findings 
suggested that the effects on collagen might be due to an inhibition of collagen at 
the tissue or cellular level.
5.2.4.3. Effect of combined captopril and isosorbide dinitrate during heaiing 
after Ml (131: Appendix 33)
Background; Because i) ACE-inhibition was suggested to decrease infarct 
collagen (127), ii) captopril can donate sulfhydryl radicals that are depleted during 
chronic nitrate therapy, iii) nitrates did not decrease infarct collagen (103), and iv) 
both nitrate and ACE-inhibition limit remodelling and exert local vascular effects, it 
was reasonable to suggest that the combination of a nitrate and captopril might be 
more beneficial than either given alone. The effect of prolonged ACE-inhibition 
and a nitrate on LV remodelling, function and infarct collagen during healing after 
anterior Ml in the dog model had not been determined.
The hypothesis that combination therapy with captopril and ISDN might be 
more beneficial than monotherapy in limiting LV remodelling and dysfunction during 
healing after Ml was therefore studied (131).
Methods/Results: In-vivo remodelling variables and function (2D-Echo),
haemodynamics, post-mortem topography (planimetry) and collagen (OHP) were 
measured in 48 chronically instrumented dogs that were randomized 2 days after 
lA D  ligation to 6 weeks of therapy with captopril, ISDN, captopril plus ISDN, or 
placebo. Compared to placebo, the three active therapies decreased blood 
pressure and left atrial pressure, limited infarct expansion, infarct thinning, non- 
infarct wall stretching and thickening, limited LV dilatation and the increase in LV 
mass, and decreased regional bulging, aneurysm frequency and LV dysfunction. 
However, the decrease in asynergy and increase in volume ejection fraction were 
less with captopril alone or captopril plus ISDN than ISDN alone. Infarct thinning 
and bulging at 6 weeks was also less with ISDN than captopril. Although initial LV 
asynergy, final scar sizes and non-infarct collagen at 6 weeks were similar among 
the groups, collagen in the center of the infarct scar was less with captopril or 
captopril plus ISDN compared to placebo and ISDN.
The results suggested that monotherapy with captopril or ISDN, or the 
combination improved all remodelling parameters but ISDN improved function more
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than captopril or captopril plus ISDN. Inhibition of infarct collagen content by 
captopril suggests that benefits with captopril represent a balance between positive 
and negative effects, and combination with ISDN might be advantageous.
Interestingly, the 6-week old scar weights in the four groups in this study 
(6.0 ±2.1 (SD) g, 4.0 ± 3.6 g, 5.9 ± 4.5 g and 4.8 ± 2.0) were all small (131) and 
similar to those in other studies with captopril (126,318).
Relevance: The overall findings supported the concept of added benefits of 
combination therapy and synergism between ACE-inhibitor and nitrate therapy 
with respect to LV function. However, the captopril-induced decrease in infarct 
collagen detected in this study was not attenuated by addition of the nitrate (131).
5.2.4.4. Effect of captopril and enalapril on LV geometry, function and 
collagen during healing after anterior and inferior Ml in the dog 
(128: Appendix 31)
Background: The effect of prolonged ACE-inhibition on LV remodelling, function 
and infarct collagen during healing after anterior and inferior Ml in the dog model 
had not been determined. The hypothesis that the beneficial effect of prolonged 
ACE inhibitor therapy on remodelling during healing after Ml might be greater in 
anterior than inferior infarction and with captopril than enalapril was tested in the dog 
(128). This was based on the findings that LV remodelling is more marked after 
anterior Ml (21,28,35) and enalapril decreased infarct collagen (127).
Methods/Results: The effect of 6 weeks of therapy with captopril (50 mg b.i.d.), 
enalapril (2.5 mg b.i.d.), or placebo on in-vivo parameters of LV remodelling, function 
and mass (2D-Echo), haemodynamic function, post-mortem topography (planimetry) 
and collagen (OHP) was studied in 36 instrumented dogs randomized to therapy 48 
hours after LAD or LCX occlusion. Compared to placebo, both captopril and 
enalapril decreased infarct expansion, infarct thinning, progressive LV dilatation, LV 
mass and asynergy, and infarct collagen in anterior and inferior infarction. Despite 
similar small scar sizes, the effects on remodelling and dysfunction were greater in 
anterior than inferior infarction. In addition, captopril produced greater attenuation of 
infarct expansion and LV enlargement, greater improvement in volume ejection 
fraction, and less decrease in infarct collagen than enalapril.
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Relevance; The overall results of that study (128) indicated, that on balance, 
captopril and enalapril attenuated LV remodelling and preserved function in small 
anterior and inferior infarction despite differences in the effects of the drugs on 
individual remodelling variables. The results also suggested that further studies 
were needed to determine whether inhibition of infarct collagen might be harmful, or 
differences between captopril and enalapril therapy might be important in large 
transmural infarctions.
5.2.4.S. Effect o f ACE-inhibition on infarct collagen deposition and 
remodelling during healing after transmural Ml in the dog (129: 
Appendix 32)
Background: The effects of the ACE-inhibitors captopril and enalapril on the 
temporal changes in infarct collagen during healing after transmural anterior Ml in 
the dog had not been determined. In view of the previous findings with captopril 
and enalapril in small and predominantly non-transmural Ml (127,128,131), this 
study focused on small but transmural anterior Ml.
The hypothesis that prolonged AC E-inhibition for 6 weeks after transmural 
Ml lowers the collagen content of infarct scars was studied in dogs (129). Since 
collagen deposition increases progressively during healing, the temporal changes 
in collagen content of the infarct zone with ACE-inhibition during healing over 6-7 
weeks and their possible relation to infarct remodelling was also addressed (129).
Methods/Results: Infarct collagen (OHP) content was measured over 6-7 weeks 
in dogs treated with captopril (50 mg b.i.d.), enalapril (2.5 mg b.i.d.) or placebo, 
beginning on day 2 after transmural anterior Ml or sham. In-vivo changes in the 
infarct and global LV remodelling, mass and function (2D-Echo) and 
haemodynamics among 6-week survivors were also measured. Compared to 
placebo over the 7 weeks, both inhibitors decreased infarct collagen (P<0.001). 
Among the 6-week survivors, both inhibitors lowered infarct collagen (P<0,001) 
and increased the collagen type 1/111 ratio, but preload was lower, increase in 
diastolic volume and mass were less, and systolic function improved. Although 
the doses of captopril (but not enalapril) decreased afterload, inhibition of infarct 
collagen was less, infarct bulging and global LV dilatation were less and systolic 
function was better with captopril than enalapril (Figure 24). Apical aneurysm 
frequency at 6 weeks was similar (P=0.9) for enalapril (13/18) and controls (31/40)
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but less with captopril (6/23) than controls = 6.9, P=0.0002) and less with 
captopril than enalapril = 13.9, P=0.0002). In all 3 Ml groups, deaths over the 
7 weeks correlated with greater infarct size, LV volume and dysfunction, and lower 
infarct collagen.
The overall findings suggested that ACE-inhibition suppresses the temporal 
increase in infarct collagen and attenuates infarct expansion, thinning and bulging, 
LV enlargement and aneurysm formation during healing after Ml.
Relevance; In light of the overwhelming evidence from clinical trials that ACE- 
inhibition decreases mortality in survivors after Ml (134), one must conclude that 
the benefits outweighed potential disadvantages in the study patients.
However, the effects of ACE-inhibition on collagen in the infarct zone 
during healing of transmural Ml observed in the last study (129), suggests the 
possibility that long-term inhibition of collagen deposition and hypertrophy may be 
excessive and allow more LV distension, dilatation and dysfunction. This may be 
especially true after large transmural Ml. The findings in this study may explain 
the persistent LV dysfunction after early ACE-inhibition observed in rats (338). 
However, large transmural Ml as found in rats could not be studied in the dog 
model for logistic reasons. Since the patient population with heart failure and 
marked cardiac enlargement has been increasing in the ACE inhibitor era, 
inhibition of collagen deposition may be an important factor to consider.
The dose of captopril and enalapril used in the canine model 
(126,127,129,131) deserves comment. As a general rule, doses of drugs used in 
animals should not be extrapolated to humans. The 50 mg BID dose of captopril 
in dogs weighing about 20 kilograms (126,129,131) translates to 5 mg/kg daily. 
This is higher, on a milligram per kilogram basis, than the final dose used in 
patients in the SAVE trial: escalation from 6.25 mg to 50 mg TID or 1.42 mg/kg for 
the 70 kg human (121). The 2.5 mg BID dose of enalapril used in the 
approximately 20 kg dogs (127,129) would translate to 0.25 mg/kg daily, which is 
similar to the final dose used in the SOLVD and CONSENSUS trials; escalation 
from 2.5 mg BID to 20 mg QD or 0.29 mg/kg for the 70 kg human (123,142, 
143,145). A major focus of the study was on the tissue effect of ACE-inhibition on 
infarct collagen. A higher dose of captopril relative to that used in humans was 
chosen so as to offset a possible bias against enalapril. Furthermore, a non­
hypotensive dose of enalapril was used for the same reason.
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5.3. CLINICAL STUDIES: VALIDATION AND NATURAL HISTORY
5.3.1. Preliminary clinical research studies: Feasibility and validation
5.3.1.1. Phase 1: Reproducibility and angiographic correlation 
Background; Although 2D-Echo was an attractive clinical tool for the non- 
invasive assessment of the effect of pharmacological interventions on adverse LV 
remodelling and dysfunction in repeated studies on the long-term, this was a novel 
application and there was a paucity of data on feasibility and reproducibilty. 
Publications on these applications of 2D-Echo were just beginning to appear (15- 
17,230,231,235-238,241,242).
Methods/Results; The first priority was to determine the inter-observer and intra- 
observer variability in quantifying wall motion abnormalities and global function in 
human Ml by contouring endocardial outlines and marking asynergic boundaries. 
These errors were found to be minimal, between 5 and 10% depending on the 
level of training of the observers and whether or not hypokinesis was included or 
excluded. Asynergic areas at 48 hours in 89 patients post-MI correlated with peak 
serum CK levels (r=0.88, P<0.001), in agreement with a report from Visser et al. 
(231) and other publications from my laboratory (232; Appendix 36; 251-253).
Correlative studies of LV volumes by 2D-Echo and biplane LV angiography 
in 31 patients, using 4 models (Figure 25) and the modified Simpson’s rule, were 
in agreement with observations of others (236). Results of correlative studies of 
LV asynergy on 2D-Echo and biplane LV angiography in 30 patients were in 
agreement with those reported by Kisslo et al. (16) and Gibson et al. (339) using 
smaller groups of patients. Early correlative studies between LV asynergy and LV 
ejection fraction calculations in patients with remote Ml by LV angiography 
(biplane) and 2D-Echo were also done and published in several abstracts as well 
as papers (251-253). Inter-observer reproducibility of 2-Echo steered M-mode 
measurements in infarct patients, positioning the M-mode beam perpendicular to 
the region of interest, was reasonable (error < 5 %). Although 2D-Echo and LV 
biplane angiographic estimates of ejection fraction were very good (r=0.91 to 0.96, 
P<0.001), attempts at quantifying LV volumes using 2D-Echo in patients with Ml 
uncovered the major problem of RSD in diastole and becoming more marked in 
systole (21 ; Appendix 3). It therefore became necessary to quantify RSD after Ml 
(19; Appendix 1; 33; Appendix 7).
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Relevance: This essential first step confirmed published data from other 
laboratories and the reproducibility and limitations of 2D-Echo for the assessment 
of regional and global LV dysfunction and topography after Ml in my laboratory.
5.3.1.2. Phase 2: Feasibility and detection of asynergy 
Background: Although some publications had appeared (15-18,230) on the 
feasibility of assessing asynergy using quantitative 2D-Echo, and others were just 
appearing (231,235,236,241,242,339), it was necessary to establish my own 
expertise and database. The second priority was therefore to establish the 
feasibility of our systematic 2D-Echo imaging approach (Figure 5) in patients with 
ischaemic heart disease, including acute and remote Ml and other diseases. This 
was done in the 3500 consecutive patients who were studied between 1980 and 
1985 in my clinical adult 2D-Echo laboratory (book in preparation).
Methods/Results: Serial systematic tomographic images (in parasternal long- 
axis, apical 4-chamber and parasternal short-axis views at mitral, chordal and 
papillary muscle levels), which were adequate for detailed analysis of endocardial 
wall motion and visual assessment of systolic thickening, were obtained in 85% of 
the patients. Asynergy was subsequently defined as akinesis (no motion, no 
thickening) and/or dyskinesis (paradoxical motion and systolic thickening). 
Hypokinesis was not included on the basis of the findings in previous reports 
(62,233) and difficulty with accurate visual quantification of hypokinesis.
In a subsequent clinical research study (only abstracts presented), the 
predictive value of an early 2D-Echo in acute Ml, performed at 2 days by the 
bedside, was evaluated in 40 consecutive patients with a first Ml. On EGG, 31 
patients had transmural or Q-wave Ml and 9 had subendocardial or non-Q-wave 
Ml. The EGG location was inferior in 16, anterior in 20, posterior in 2 and 
uncertain in 2. The conclusions of that study were as follows:
i) The early 2D-Echo detected LV asynergy, defined as akinesis and/or
dyskinesis in all patients (100%).
ii) The location of LV asynergy on 2D-Echo agreed with the EGG location 
of acute Ml in all patients.
iii) Anterior LV asynergy in 4 of 21 patients was associated with apical right
ventricular asynergy, and posterior LV asynergy in 6 of 12 patients was
associated with right ventricular free wall asynergy.
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iv) The early 2D-Echo detected LV thrombus in 13 of 21 patients with 
anterior LV asynergy and 2 of 16 patients with posterior LV asynergy, 
suggesting that thrombi are more frequent with anterior infarcts.
v) An estimate of the extent of LV asynergy, by summation of abnormal 
segment lengths as percent circumference (range 5-50%) from all 
short-axis views, correlated with peak CK levels (r=0.88, P<0.001).
vi) The location and extent of asynergy on 2D-Echo predicted early 
complications and detected late complications: acute ventricular septal 
defect in 2 patients; papillary muscle dysfunction in 3 patients or rupture 
in 1 patient; infarct extension in 3 patients and infarct expansion in 8 
patient.
Relevance; The overall findings indicated that serial 2D-Echo after Ml was 
feasible, provided reproducible diagnostic data in the early stages of infarction, 
and could detect unsuspected RV dysfunction and complications after acute Ml.
5.3.2. The natural history of LV asynergy after acute Ml by 2D-Echo 
Background: There was a paucity of data on the natural history of LV asynergy 
after Ml using 2D-Echo.
Methods/Results: Clinical and 2D-Echo data were collected on 89 consecutive 
patients with a first acute anterior Ml (only abstract presented). The 63 patients 
with adequate and quantitative initial 2D-Echo were entered in a longitudinal 1- 
year follow-up study. The echocardiograms were coded for double-blind, detailed 
analysis by two experienced observers (the author and a trained assistant).
On the basis of the extent of LV asynergy as percent of LV circumference 
on images at the papillary muscle level, and serial data over the first 3 months, the 
patients with first anterior infarcts could be classified into 3 groups (Figure 26):
1. Patients with a small area of LV asynergy initially had very small or no 
detectable asynergy at 3 months. These patients had subendocardial non- 
Q-wave infarcts on ECG and were in Killip class I on admission. They were 
in New York Heart Association (NYHA) functional class I at 3 months. 
These patients showed no regional or global LV dilatation.
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Figure 26. Natural history of LV geometry in survivors of a first 
anterior infarction over 3 months by 2D-Echo
Three main groups of patients after a first Q wave Ml on the basis of 
asynergy on the baseline study on day 2. Average LV outlines at 4 time 
intervals over 3 months are shown. Dark segments = asynergic zone 
(akinesis + dyskinesis).
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2. Patients with initial LV asynergic areas of 5-20% had persistent but slightly 
smaller areas of asynergy by 3 months, no significant change in LV cavity 
size or diastolic wall thinning. They had transmural or Q-wave infarcts on 
ECG and were in Killip class I to II on admission. At 3 months, they were in 
NYHA class l-ll. These patients showed very mild RSD and progressive 
LV dilatation.
3. Patients with initial LV asynergic areas of 20-30% had persistent asynergy 
at 3 months but showed significant dilatation in LV cavity size and wall 
thinning in diastole with paradoxical motion in systole. An example of 
expansion with 18% LV circumferential asynergy at the papillary level on 
the baseline 2D-Echo is shown (Figure 27). A proportion of these patients, 
especially those with >30% LV asynergy, had developed infarct expansion 
between days 6 and 10. All had been in Killip class lll-IV initially, with 
transmurai, Q-wave infarcts on ECG. They were in NYHA class III at 3 
months. These patients showed marked RSD and early aneurysm 
formation over the 3 months.
Relevance: The overall findings suggested that the extent of LV asynergy on an 
initial 2D-Echo in acute anterior Ml can predict outcome at 3 months and 1 year. 
This study first unmasked the problem of RSD in quantifying total LV asynergy 
and volumes in patients with moderate to large Ml.
5.3.3. Detailed analysis of 2D-Echo data and regional shape distortion (19: 
Appendix 1)
Background; Detailed analysis of 2D-Echo data was time consuming. However, 
the circumferential extent of LV asynergy in papillary and chordal short-axis 
sections and apical 4- and 2-chamber views could be quickly assessed at the 
bedside. Measurement of the extent of LV asynergy by manual contouring of 
these selected views could be made in 10 to 15 minutes.
Over the 198D’s, my laboratory used: i) multiple to and fro video playbacks,
ii) manual contouring of endocardial outlines and digitization using the HP 
digitizer, rather than the light pen system on the Varian system, iii) visual 
assessment of systolic thickening, as done by Gibson et al. (339), together with 
measurements of regional thicknesses on adequate images. It is important to
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remember that in 1981, when this work began, commercial systems for analysis of 
2D-Echo images were not available for off-line analysis of 2D-Echo images.
Methods/Results: As a first step towards more rapid analysis of 2D-Echo images, 
with the assistance of a computer assistant working in my laboratory and in 
consultation with the Information Systems, I explored the feasibility of acquiring 
digital images via the video recordings of the Varian system. I realized that a 
time-base corrector, a video-digitizer and software development were needed. 
These were implemented between 1984 and 1985. Digital images from selected 
patients were initially acquired via the digital RS-232 output port of the Varian 
system. Storage of a single frame on computer took 3 minutes (4800 BAUD), 
which was impractical from a therapeutic viewpoint although useful data could be 
obtained. Images were stored on floppy discs for additional processing on a 
larger computer (Computer Sciences). Subsequently, a Grinnel system with a 
frame-grabber was tested and found to be time consuming.
Manually contoured short-axis images were used for quantifying RSD (19; 
Figure 10) and wall thickness after Ml (Figure 14). Transformation of ‘manual 
contours’ into the computer-generated graphical representation facilitated storage 
of large volumes of data on videotapes and rapid acquisition of meaningful data 
for comparison with subsequent studies.
The characterization of RSD on diastolic short-axis 2D-Echo images (19), 
using the traditional index (P /^4tcA), with perimeter (P) and area (A), as described 
by Holt and Marjoram (340), yielded similar values for distorted LV outlines from 
patients with Ml and normal outlines from controls (1.042 versus 1.047, P=NS). In 
contrast, the 5 new indices of shape distortion, after the excision of the distorted 
segment (Figure 28), were markedly sensitive in detecting shape distortion of the 
asynergic regions in end-diastolic contours as well as greater distortion in end- 
systole (Table 8 , Figure 28). The new indices include the peak (P )^ of the angular 
distribution and the first four moments (Mi, M2 , M3 and M4) of the distance 
distribution between the risk segment of LV asynergy and the computed ideal 
segment of a circle (19). These new RSD indices at end-diastole in infarct 
patients compared to normals were as follows: Pk, 6.0 versus 0.7 mm, P<0.001; 
Mi (average), 3.8 versus 1.0 mm, P<0.001; M2 (variance), 20.0 versus 0 mm^, 
P<0.025; Ms (skewness), -216.8 versus 0 mm^, P<0.025; M4 (kurtosis), 19576.0 
versus 0 mm"^ , P<0.05.
107
TABLE 8. Traditional and new primary shape distortion indices in 
systole and diastole in the infarct group*
Parameter Diastole Systol e P value
P^/4wA 1.0402
+ 0,0266
1.0811 
1  0,0591
< 0,001
(mm) 4,447 
1  4.300
9,0175 
±  6.580
< 0.001
(mm) 2,556 
±  2.438
6,697 
1  4.307
< 0.001
#2 (mm )^ 4.1053 
1  7,6071
13,8832 
+ 20.2275
< 0,001
Mg (mm3) .1,2304 
1 14.518
-23.787 
1  59.307
< 0.005
(mm )^ 129.550
±  39.324
1050,200 
±  2851.000
< 0,025
Values as mean f  standard deviation, 
* H 58 sections
Relevance: Three points need emphasis:
First, in this method, RSD is measured directly and is applicable to Ml at 
any location. The expansion index, which is based on the ratio of infarct to non­
infarct segment lengths, gives very different (reciprocal) values for anterior and 
posterior Ml. In addition, it depends on anatomic landmarks that may shift with 
expansion after infarction of antero-septal, infero-septal or postero-lateral regions.
Second, the distorted asynergic segment is replaced by a derived risk 
segment, which is a more accurate measure of the original segment of the LV wall 
that underwent infarction. The alternative approach of deriving the mass of the 
asynergic segment from its area required clear definition of both endocardial and 
epicardial borders. The epicardial border was less adequately visualized on 2D- 
Echo systems in the 1980’s.
Third, in subsequent studies, the derived risk segment was used to 
compute LV asynergy, and the distorted native segment to quantify infarct 
expansion and RSD. Since the derivation of the new indices of RSD was time- 
consuming using the developed computer system, the depth and area of the RSD 
were used in later studies and found to be more practical.
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5.3.4. Regional shape distortion as a predictor of adverse remodelling after
Ml (20: Appendix 2; 21: Appendix 3)
Background: Early detection of potential expanders (patients who develop 
clinically significant infarct expansion with acute regional LV dilatation and LV 
failure but no additional necrosis) after Ml (18) is necessary in order to apply 
preventive therapy. Although stretching and thinning of the infarct segment had 
been used as measures of infarct expansion on 2D-Echo (18,31,32), direct 
measurement of RSD or dilatation of the infarct zone had only just been attempted 
in my laboratory (19,20). The hypothesis that the degree of RSD on an early 2D- 
Echo after acute Ml may allow identification of patients prone to infarct expansion 
was therefore tested (21).
Methods/Results: To determine whether the degree of RSD or dilatation on early 
2D-Echo after acute Ml can identify potential expanders, serial clinical and 20- 
Echo data were studied prospectively in 244 consecutive patients with a first Q- 
wave Ml (Tables 9A, 9B). Initial (mean 2 days) and final (mean 10 days) 
echocardiograms were compared for regional LV asynergy (Figure 10), RSD 
(Figure 29) and conventional indices of expansion (Figure 11) measured on 
endocardial diastolic outlines of mid-LV short-axis sections.
Analysis of clinical and 2D-Echo data revealed 51 expanders and 193 non­
expanders (Tables 9A, 98, 10, 11). Expanders showed greater LV dysfunction 
and more In-hospital deaths (27% versus 8%, P<0.001) compared to non­
expanders (Table 98). Conventional indices of expansion showed more marked 
increase between initial and final 2D-Echo in expanders, but initial indices were 
not predictive. In contrast, the new RSD index Pk, a measure of outward bulge 
(Figure 29D), was markedly greater in expanders than non-expanders on both 
initial (16.5 versus 2.4 mm, P<0.001) and final echo (Table 11). Furthermore, 
expanders with > 30% increase in Pk (to 21 mm) developed rupture of the 
ventricular septum (n=10) or free wall (n=2). Also, 50 of 51 expanders compared 
to 3 of 193 non-expanders had a Pk > 10 mm on the initial echo. A simpler index, 
the depth of RSD (ry), provided similar discrimination as Pk (Table 12, Figure 30). 
The overall findings suggested that the degree of diastolic RSD on an early 2D- 
Echo after acute Ml can identify potential expanders.
The relation between RSD and rupture of the ventricular septum was 
demonstrated in a parallel study (20: Appendix 2; Figure 31).
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Table 9A. Initial patient data
Characteristic
Expanders
(n=^51)
Nonexpanders
(n-193) p Value
Age (yr) 60±12 57±14 NS
Sex (% male) 73% 78% NS
Body stiiface area (m^j 1.9±0.2 l,9±0 .2 NS
History o f hypencnsion Cn) 13 (25%) 42 (22%) NS
Kistor>' o f angina (n) 17 (33%) NS
Anterior M i (n) 31 (61%) 109 (56%) NS
Heart rate (beata/min) 82 ±20 77 ±20 NS
Systolic BP tmmHg) 129 ±25 NS
Diastolic BP (mmHg) 83±17 &5±15 NS
Mean BP (mrnHg) 9 8 ± I9 99±1? NS
RPF (tnmHg xbeats/min X lOB 8.0±2.2 7,8±2.6 NS
Killip class score 2,1x0.8 !.8±0 .7 0.025
EST: anterior M l (mV) ll .4 ± 7 .0 8 .l±5 .0 &W5
EST: inferior M I (rnV) 7,0±5.0 3.0±3.0 & W I
Peak CK level (lU/l) 2445 ±1574 175611412 0.01
CK infarct size (gEq) 72 ±60 43±30 0.005
Total asynergy (%) 29±7 20 ±9 O.tXH
Ejection fraction (%) 34 ±9 43±9 0.001
AhhnMüîiom: BP-blood piessure; CK -  creatine kinase; Ml-niyocapdia! infatelion; E f 
rale % mean blood pressure product.
T-.sum of ST-segment ekvt tions; RPF-heart
Table 9B. Pertinent clinical findings and drugs during hospitalization
Parameter
Expanders
(n -5 1 )
Nonexpanders 
(n = 193) p Value
In-hospital deaths (n) 14 (27%) 15 (8%) 0,001
Maximum K illip  score 3.3 ±0.8 2.2±0 .9 0.001
Asynergy at 10 days (%) 25±8 W ^9 0,001
Ejection fraction at 10 days {%) 42±10 47 + 8 0.005
Infarct extension (ti) 17 (9% ) NS
Cardiogenic shock (n) 10 (20%) 0.001
Cardiac arrest (n) 7 (14%) 16 (8%) NS
Free wall rupture (n) 0 NS
Ventricular septal rupture (o) 10 (20%) 0 0.0W5
Congestive failure (n) 37 (73%) 70 (36%) 0.0005
Pericarditis (ii) 24 (47%) 20 (10%) 0.0005
Drugs
Indomethacin (n) 19 (37%) 27 (14%) 0.000.5
Ibuprofen (n) 9 (18%) 22 01% ) NS
Prediii.sotie (n) 0 NS
Nitroglycerin, oral/paste (n) 40 (78%) 164 (85%) NS
Captopril (n) 5 (10%) 0 0,0005
Beta-blocker (n) 20 (39%) 65 (34%) NS
Calcium-blocker (n) 9 (18%) 31 (16%) NS
Diuretic (n) 39 (76%) 95 (49%) 0.001
Inotrope (n) 30 (59 %0 65 (34%) 0,005
Amiurrhythrnic (n) 38 (75%) 125 (65%) NS
Anticoagulant (n) 49 (96%) 161 (83%) 0.05
Antiplatelet drug (n) 8 (16%) 28 (15%) NS
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From Jugdutt (21 : Appendix 3)
TABLE 10. Changes in topographic and functional parameters
Expanders (n=51) Nonexpanders (n =  193)
Initial Firtai Initial Final
ASL (cm)
Anterior M I 10.4±3.0" 16.0+4.0*' 9.9 ±1 .7 “ 10.5+2.1
Inferior M I 6.7 ±0 .9 “ 9.8±3,0*’ 6.9 +1.2" 7.8+1 ,6
NASL (cm)
Anterior MI 7,0±1.3“ 7.9+1.1 6 .8 + 1 .2 6.9+1.3
Inferior M I 9 .6±1.8“ 10,7+2.0 9.6+1.5 9.8+1.7
Expansion intlex
Anterior M I 1.50±0.36“ 2.28+0.43*’ 1.48+0.30 1.53+0.30
Inferior M l 0 .70±0 ,!1 " 1.01+0.46*’ 0.73+0.12“ 0.81+0,17
Thinning ratio
Anterior M I 0.76±0.1S” 0.51 ±0.15'’ 0.76+0.19" 0 ,6 8 + 0 .2 1
Inferior Ml 0 ,7 4 ± 0 . i r 0.46+0.14*’ 0.74+0.14" 0.63+0.17
A ll 0.75±0.14" 0,49+0,14*’ 0.75+0.17" 0.66+0.19
LV ID p (mm)
55±5“ '’Anterior 58+7*’ 50+6" 52+5
Inferior 53^7»,i 58+9*’ 50+6" 54+8
A ll S4±6“ '*' 58 + 8 " 50+6“ 53+9
LVEDV (cmb
Anterior 126±40" 165+61*’ 127+38" 138+38
Inferior 117±44“ 168+78" 120+36" 131+36
A ll 122±4I" 166+6?" 124+37" 135+37
LV asynergy {%)
2 9±8 “ -''Anterior M I 24+9" 20+9" 18 + 9
Inferior Ml 2 9±7 “ -*’ 25+6" 21+9" 19 + 8
A ll 2 9 j . 7 a.fc 25 +  8 " 20+ 9“ 18+9
L V E F {%)
33 +  10“ *’Anterior M I 41 +  12" 42 + 8 " 47 + 8
Inferior MI 36+7“ -*’ 45+6 43+10“ 47 + 8
A ll 3 4±9 “ -*’ 42 + 10" 43+9" 47+8
"p<0 .05 , significance of difference comparing date at 2 and 10 days within groups (ANOVA).
*’p:S0.05, significance of difference comparing expander with nonexpander groups at coircspondittg times.
Abbrev ia iiom : ASL = infarct-containing segment lengtit; NASL=non-infarct-containing segment length; LV==ieft ventricular;
LVEF=left ventricular ejection fraction; LV ID p= le ft ventricular internal diastolic dimension; L V E D V v e n t r ic u la r  end-diastolic
volume.
TABLE 11. Indices of global and regional diastolic shape distortion
Expanders Nonexpanders
Parameter Timing (n=51) (n=193) p Value
Traditional global shape indc.'t
P /^4 trA a 1.06+0.08 1.03+0.08 0.025
b 1.06+0.09 1,03+0.03 0.025
Regional shape distortion indices
Peak distortion, Pj, (mm) a 16.5+6.1“ 2.4±2,6“ 0.001
b 5.7+6.1 34+4.9 0 .0 0 1
Ml, Average (mm) a 1 0 .8  + 1 0 .6 " 1 ,6 + 1 .6 " 0.003
b 4.S+5.6 2.3±4.4 0.005
Mj, Variance (ntm^) 50.7 + 111" 1.9+3.9" 0.025
b 19.9+57 3.7 ±9.2 0.05
Mj. Skewness (mm') a -21.2+78.8 -1 .1  ±4.7 NS
b -65.3+421.6 -11.0+114.4 NS
M,,, Kuitosis (ntnr*) a 2531 ±8795 35 + 122 0.05
b 1047+3443 260 + 2165 NS
Nonnalized distortion, iV q 0.71+0.34" 0.09+0.10“ 0 .0 0 1
b 0.21+0.24 0.13+0.18 0.05
Idea! area, A; (cm9 a 21.4+7.0" 22.2+7.8 NS
b 24.8+12,6 22.6+7.7 NS
Area of distortion, A;, (cm’ ) 5.3±2.6" 0.9 ±1.2" 0 .0 0 1
b 2.3+2.8 1.2 + 1 .7 0 ,0 1
Area ratio, A,i/A| a 0.28+0.16" 0.05+0.13 0 ,0 0 1
b 0 . 1 0 + 0 .1 2 0.06+0.14 0.05
Actual asynergic segment, s, (cm) 5.6+2.6 4.4 ± 2.0 0.005
b 5.6±2.7 4.6+4.Ô NS
Depth of distortion, r^ (mm) a 16.6+7.3" 2.3+2.B" 0 .0 0 1
b S.8+5.7 3.1+4.4 0.005
“p<0.05, significance of difference between initial (a) and final (b) echocardiograms.
113 From Jugdutt (21 : Appendix 3)
TABLE 12. Ranking of echocardiographîc parameters by ability to 
distinguish expanders from non-expanders using 
multivariate analysis of variance
F value
Overall discrimination
F ratio Fo,05 (20,223) =  56.8I
Critical F ratio F0 0 5  (20,200)= L62
Univariate discrimination
Peak distortion, 603 .14^ ^
Normalized distortion, Pj^ /q 485.20''
Depth of distortion, 483.34"
Area of distortion, A j ' 315.44"
M l, Average 120.95"
Area ratio, A^j/A] 110.94"
Infarct-containing segment length 59.77"
Total LV asynergy 48.77"
Mz, Variance 38.87"
Global LV ejection fraction 36.16"
Global shape index, P /^4?rA 25.71"
M 4, Kurtosis 15.71"
M 3, Skewness 1 2 .8 8 "
Actual asynergic segment, 12.45"
Perimeter, P 10.06"
Long-axis height, h 1 . 6 6
ideal asynergic segment, S; 0.55
Expansion index 0.31
LV end-diastolic volume 0.18
Thinning ratio 0.04
Critical F ratio Fo.05 (1 ,200)=  3.89
‘'Strongest discriminators; level of F test set at 95 % confidence
limits (p<D.05).
Jugdutt 21 : Appendix 3
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Figure 30. Discriminators of expanders and non-expanders by the
degree of RSD
1. Four highest ranking discrim inators of expanders (E) and non-expanders (NE).
2. Discrim inators of expanders (E) and non-expanders (NE) in anterior and inferior Ml
subgroups. Dotted lines and arrow Indicate cutoff values. P,^  and in mm, A^ , in cm^.
Jugdutt (21 : Appendix 3)
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Relevance: Three points need emphasis:
First, the early detection of RSD might permit rational therapy for limiting 
adverse LV remodelling after Ml and the objective assessment of the effects of 
therapy during healing after Ml.
Second, a practical estimate of early RSD or diastolic bulging using the 
depth of distortion, ra, might be useful in clinical studies to assess the efficacy of 
interventions.
Third, it may be possible to stratify patients on the basis of their 
topographic status after Ml using RSD on 2D-Echo, in addition to their clinical and 
haemodynamic profiles.
5.3.5. The effect of a cardiac rehabilitation programme on 2D-Echo LV 
asynergy and RSD (34: Appendix 8)
Background: Enthusiasm about cardiac rehabilitation early after Ml coincided 
with the introduction of various exercise programs in many clinics. However, the 
effects on LV remodelling, infarct topography and RSD in high-risk patients with 
anterior Q-wave Ml undergoing exercise training had not been determined.
Methods/Results: A prospective pilot study was undertaken to determine the 
effect of a cardiac rehabilitation programme on LV asynergy by 2D-Echo in 20 
patients surviving acute Ml (10 subendocardial, 10 transmural). Resting 2D-Echo 
and exercise testing were done before and at the end of the program (6 weeks 
and 3 months). The rehabilitation programme, was conducted under the 
supervision of the director of the cardiac rehabilitation and exercise laboratory. 
The programme consisted of a 10-minute voluntary exercise at home (jogging) 
and participation in a group (volleyball once a week). At the beginning of the 
program, LV asynergy ranged between 5-15% in the subendocardial group versus 
16-30% in the transmural group. After 3 months, 16 patients had improved 
exercise tolerance: 10 patients with subendocardial Ml and 6 patients with 
transmural Ml had initial LV asynergy between 16 and 24%. However, 4 patients 
with initial LV asynergy between 25 and 30% were in NYHA class II on 
medications (digoxin and diuretic) showed evidence of regional LV dilatation 
(Figure 32). The findings suggested that 2D-Echo might be useful in the selection 
and follow-up of patients on the post-infarction rehabilitation program.
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A subsequent prospective study was therefore undertaken to determine 
whether the extent of LV dysfunction and degree of RSD might predict outcome in 
survivors of moderate anterior Q-wave Ml who underwent exercise training 15 
weeks after Ml (34). Left ventricular function and RSD were measured by 2D- 
Echo before and after 12 weeks of the low level exercise programme in 13 
patients with Ml (begun 15 weeks post Ml) and 12 weeks apart in 24 matched Ml 
patients without training (controls). The exercised Ml patients were stratified on 
the basis of the response to exercise. Compared to baseline, the NYHA 
functional class score at the end of exercise training increased from 2.25 to 2.67 
(P<0.005) in 6 patients (group 2) but did not change in 7 (group 1). Further 
discrimination of groups 1 and 2 was provided by an initial asynergy (akinesis or 
dyskinesis, or both) < 18% or > 18%. Compared to group 1, group 2 had greater 
initial asynergy (32 versus 6%, P<0.001), expansion index (asynergic/normal 
endocardial segment length; 1.8 versus 1.6, P<0.025), and peak RSD index (12.2 
versus 1.0 mm, P<0.005) but lower LV ejection fraction (43 versus 59%, P<0.05) 
and thinning ratio (asynergic/normal wall thickness: 0.61 versus 0.74, P<0.05).
These variables did not change with training in group 1. However, in group 
2, training caused significant increase in asynergy (from 32 to 40%, P<0.05), 
expansion index (from 1.8 to 2.0, P<0.01) and peak RSD (from 12.2 to 20.9 mm, 
P<0.05) associated with a decrease in thinning ratio (from 0.61 to 0.51, P<0.001) 
and ejection fraction (from 43 to 30%, P<0.005). Initial values for these variables 
were similar for corresponding control groups but did not change over the 12 
weeks. Thus, patients with > 18% LV asynergy on the initial 2D-Echo showed 
more RSD, expansion and thinning before exercise training and developed further 
functional and topographic deterioration with training.
Relevance: These studies suggest that survivors of Ml may be stratified before 
starting exercise programs on the basis of LV asynergy and RSD on a screening 
2D-Echo. Patients with Q-wave Ml, LV asynergy greater than 18% and 
significant RSD might be at risk of topographic deterioration during exercise 
training.
In a large study in the reperfusion era, Giannuzzi et al reported that 
exercise training, initiated 4-8 weeks after anterior Q-wave Ml and continued for 6 
months, did not appear to cause further LV dilatation or dysfunction (341). in 
contrast, a study in rats showed that endurance training after large Ml results in
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more adverse remodelling with severe global LV dilatation, LV shape distortion, 
and scar thinning, and decreased survival (342). The reasons for the disparate 
findings are not clear. It is possible that reperfusion played a role in Giannuzzi’s 
study (341). Moreover, none of those studies evaluated infarct expansion or RSD.
5.3.6. importance of early regional shape distortion in progressive LV
dilatation after Ml
5.3.6.1. Progressive changes in regional and global LV dilatation during 
remodelling after Ml 
Background; There was a paucity of data on the relation between early RSD and 
late global LV dilatation after Ml.
Methods/Results; To determine the relation between early bulging of the 
asynergic zone and late global LV dilatation after Ml, serial 2D-Echo studies from 
800 patients with a first Q-wave Ml, between 1980 and 1988, were analyzed 
(274). Four shape algorithms (rocket, bullet, grenade, spaceship) were 
systematically applied for calculating LV endocardial surface area, area of LV 
asynergy (akinesis + dyskinesis) and volumes from 4 short-axis and one base to 
apex image (Figure 25), with special attention being given to regional diastolic 
bulging (274; Appendix 38; only abstract presented; book chapter in preparation).
Analyses were done by 2 observers who were blinded to patient data. 
Areas and volumes computed using the 4 algorithms differed by < 6% and 11%, 
respectively. Results from the first 2D-Echo in 43 patients (28 anterior, 15 inferior) 
with CK infarct size data and 11 normal controls showed no difference in CK 
infarct size (45 versus 44 g-Eq) and mean LV asynergy 31% versus 37% surface 
area) for anterior and inferior Ml. In contrast, mean LV surface area (133 versus 
94 cm^, P<0.001) and mean LV volume (155 versus 92 mL, P<0.001) were 
greater for anterior than inferior Ml. The controls had no LV asynergy and normal 
mean LV volumes (111 mL) and surface area (124 cm^).
Despite similar infarct size and asynergy on the initial 2D-Echo post-MI, the 
surface areas and volumes were greater in anterior than inferior groups indicating 
marked remodelling in the anterior but not the inferior group. Importantly, serial 
2D-Echo revealed a progressive decrease in the bulge as global LV dilatation 
developed over 6 weeks and I year. The smoother LV outline of the dilated
1 2 0
ventricles after anterior Ml was associated with increased sphericity, remodelling 
of apical shape from a gothic to a roman arch, and global thinning.
Relevance; This study underscores the important role of early RSD in 
subsequent global LV dilatation in survivors of moderately sized Ml and more 
severe remodelling after anterior Ml. Since estimates of infarct size from LV 
dysfunction by 2D-Echo tend to summate circumferential extents on diastolic 
short-axis images without attention to regional bulging, this important aspect of the 
pathophysiology of LV remodelling post-MI may be overlooked. Improved 2D- 
Echo systems with harmonic imaging allow changes in regional and global 
dilatation as well as dysfunction to be more easily appreciated and quantified. In 
addition, LV opacification with injection of Echo-contrast material may be used to 
enhance endocardial deformation at the LV apex in difficult cases.
5.3.6.2. Overestimation of infarct size on 2D-Echo due to RSD of the 
asynergic zone (36: Appendix 10)
Background: On 2D-Echo imaging, the infarcted area is detected by the extent of 
regional LV asynergy, and infarct expansion results in an increase (‘expansion’) of 
the asynergic area and dilatation. Since estimation of infarct size is based on the 
circumferential extent or surface area of LV asynergy, outward bulging of the 
infarct zone might be expected to result in overestimation of infarct size by 2D- 
Echo.
The effect of early RSD or bulging of infarct zones due to infarct expansion 
on estimates of regional LV dysfunction and infarct size by 2D-Echo imaging was 
therefore studied (36).
Methods/Results: Quantitative 2D-Echo’s from patients with a first Q-wave Ml 
and CK infarct size data, and normal subjects, were subjected to detailed analysis 
of regional LV dysfunction and RSD in short-axis images. Regional LV asynergy 
(akinesis and dyskinesis) and RSD indices [e.g. peak (Pk)/radius (n)] were 
measured on endocardial diastolic outlines of short-axis images in 43 post-MI 
patients (28 anterior and 15 inferior, 5.9 hours after onset of symptoms) and 11 
normal subjects (controls). In the infarction group, the endocardial surface area of 
asynergy was calculated by 3D-reconstruction of the images and infarct size from 
serial CK blood levels.
12 1
Diastolic bulging of asynergic zones was found in all infarction patients. 
The RSD indices characterizing the area between the ‘actual’ bulging asynergic 
segment and the derived ‘ideal’ circular segment (excluding the bulge) on indexed 
sections were greater in infarct than control groups (Pk/n 0.31 ± 0.23 versus 0.03 ± 
0.02, P<0.001) and greater in anterior than inferior infarction sub-groups (Pk/ri 
0.39 versus 0.16, P<0.001). Importantly, the degree of RSD correlated with 
overestimation of asynergy (r=0.89, P<0.001) (Figure 33), and the relation 
between infarct size and total ‘ideal’ asynergy showed a leftward shift from that 
with ‘actual’ asynergy.
Relevance: Early regional diastolic bulging of the infarct zone results in
overestimation of regional ventricular dysfunction, especially when assessing 
effects of therapy on infarct size, remodelling and dysfunction using tomographic 
imaging.
5.3.6 .3. Volume of RSD by 3D reconstruction of 2D-Echo images (33: 
Appendix 7)
Background; Several laboratories, including mine, were interested in 3D- 
reconstruction of 2D-Echo images. These algorithms were tested for volumes and 
the surface area of LV asynergy in my laboratory (Figure 25). The volume of LV 
global RSD may be estimated using 3D-reconstruction.
Methods/Results: The hypothesis that 3D reconstruction of 2D-Echo images can 
be used to estimate the volume of RSD was therefore tested (33). Accepted 
models of LV geometry that assume circular endocardial outlines in the short-axis 
and elliptical outlines in the long-axis give erroneous estimates of regional and 
global LV asynergy and LV volume in the presence of RSD after acute Ml.
However, LV models reconstructed on computer from digitized 2D-Echo 
images in which the distorted segments have been excised and replaced with 
ideal circular (or elliptical) segments give improved correlation between total LV 
asynergy and CK infarct size (Figure 34). The distortion can be quantified and 
normalized to allow comparisons among treatment populations. RSD indices 
[area of distortion (Ad), peak distortion (Pk), depth (ra)] measured on 2D-Echo 
images, and global RSD parameters (volume of distortion) measured on 3D 
reconstructions allow correction of infarct size estimates based on the endocardial
122
A. ■  ANTER IO R  ( n = 28 ) 
□  INFERIO R ( n a 13 )
A C T U A L
B.
a .
ËOH*COo
hd<wCL
QC3I
g
LLo
CO2a<
1.0'
ID E A L
*  p < 0 .01 , AN TE R IO R  vs  IN F E R IO R  
t  p < Û.Û1. A C T U A L vs  ID E A L
A C T U A L  - ID E A L
50
40
30
20
10
T
TOTAL LV ASYNERGY (%)
O INFERIOR #
e  ANTERIOR
[ ACTUAL -  IDEAL } CIRCUMFERENTIALEXTENT OF ASYNERGY
Figure 33. Overestimation of infarct size on 2D-Echo due to 
remodelling of the infarct zone
A. Actual and ideal left ventricular (LV) asynergy
B. Relation between the degree of distortion and the degree of 
overestimation of asynergy. SEE = standard error of estimate.
From Johnston and Jugdutt (36: Append ix 10)
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area of LV asynergy (Figure 34).
This approach was applied to 39 subjects (28 with a first Q-wave anterior 
Ml; 11 normal controls). 2D-Echo’s were recorded at a mean of 7 days post-MI. 
The computed and fitted volumes were in close agreement (Table 13, Figure 34).
This approach was applied to 39 subjects (28 with a first Q-wave anterior 
Ml; 11 normal controls). 2D-Echo’s were recorded at a mean of 7 days post-MI. 
The computed and fitted volumes were in close agreement (Table 13, Figure 37).
Relevance: The approach can be applied to compute the volume of RSD from 
various forms of tomographic cardiac imaging.
Other approaches have been proposed previously and are more 
cumbersome (343).
TABLE 13. Comparison of computed and ellipse fitted volumes in computer 
generated synthetic data
Volume
Model # compLited e llipse  f i t % difference
Actual (D istorted)
1 88.6 8A9 -0.80
2 476.2 474.0 -0.45
3 82,3 8 L 8 -0.55
4 232,0 230.4 -0,69
5 78.4 7A8 -0.78
Ideal
1 84.8 86.3 +1.74
2 452,4 460.4 + 1,77
3 75.1 7^^ +L39
4 211,5 215.3 +1.76
5 74,5 76.0 +2.05
Jugdu tt (33: Append ix 7)
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5.4. CLINICAL STUDIES: MODIFICATION BY PHARMACOLOGICAL
AGENTS
5.4.1. The effect of short-term anti-inflammatory therapies after acute Ml on
LV geometry and function during early healing (35: Appendix 9) 
Background; The fact that acute infarct expansion and pericarditis are both 
common complications of high-risk patients with transmural or Q-wave Ml 
provided the opportunity to the assess the effects of two NSAIDs, that were 
commonly prescribed for pericarditis, on LV remodelling.
Methods/Results: Evidence of acute infarct expansion on serial 2D-Echo and the 
frequency of the acute infarct expansion syndrome occurring at 2 days or more 
after a first Q-wave Ml were therefore studied in 221 consecutive patients (100 
anterior, 121 inferior) (35).
Patients with symptomatic pericarditis were treated with indomethacin 
(group 1, n=73) or ibuprofen (group 2, n=49) and those without symptomatic 
pericarditis received neither drug (group 3, n=99). The patients were followed for 
1 year.
The overall frequency of the acute infarct expansion syndrome was 13%, 
and 69% of these were among the pericarditis groups. The infarct expansion 
syndrome was significantly more frequent in group 1 (22%) than group 2 (8%) 
(P<0.05) or group 3 (9%) (P<0.025).
Serial 2D-Echo (day 2, day 10) revealed more expansion with greater 
percentage increase in the infarct containing segment length in group 1 than 
groups 2 or 3 (18% versus 9% versus 9%, P<0.005). However, the decreases in 
infarct segment thickness were similar in group 1 (24%) and group 2 (25%) but 
greater (P<0.001) than in group 3 (7%).
Despite similar infarct size and infarct thinning in groups 1 and 2, the 
degree of infarct expansion on 2D-Echo was greater and the infarct expansion 
syndrome more frequent in group 1. However, when allowance was made for the 
potential protective effect of prior use of intravenous NTG and concomitant use of 
nifedipine, indomethacin and ibuprofen had similar effects on expansion.
The frequency of LV aneurysms was greater with indomethacin (group 1) 
than in groups 2 or 3 (33% versus 20% versus 17%, = 6.09, P<0.05). RSD
was also more marked in group 1 patients.
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Relevance: The overall findings suggested that indomethacin or ibuprofen should 
be used with caution after Q-wave infarction so as to avoid further infarct 
expansion. The fact that short-term use of other drugs might modify infarct 
remodelling should be considered in studies attempting to assess efficacy of one 
particular drug.
The possibility exists that the difference in remodelling in that study may 
have reflected the fact that patients with pericarditis had larger transmural infarcts 
than those without symptoms of pericarditis. Thus, although all patients had 
transmural or Q-wave Ml, the CK infarct size was larger (P < 0.05) in patients 
receiving indomethacin (51.2 g-Eq) and ibuprofen (52.4 g-Eq) compared to the 
non-pericarditis group. Magnetic resonance imaging which allows the 
measurement of infarct transmuratity may help to resolve the problem. Although 
new cyclo-oxygenase-2 (COX-2) inhibitors may be an alternative to NSAIDs for 
the treatment of pericardial pain, they have recently received increased publicity 
for increasing cardiovascular events.
5.4.2. Therapeutic interventions in acute myocardial infarction
Initial studies focused on LV unloading after Ml using low-dose intravenous NTG. 
Patients with angina were studied before embarking on studies in acute Ml.
5.4 2.1. Preliminary study of NTG infusions during pacing-induced angina in 
the cardiac catheterization laboratory 
Background. There was a paucity of data on the effect of low-dose NTG infusion 
on LV asynergy assessed by 2D-Echo.
Methods/Results; To determine whether a 10 minute intravenous NTG infusion 
would decrease LV asynergy induced by atrial pacing in patients with chronic 
stable angina (< 6 months duration and no LV asynergy on a resting baseline 2D- 
Echo), asynergy was measured after atrial pacing to the angina threshold, or a 
maximum rate of 150 bpm, on biplane LV angiograms after 10 minute infusions of 
saline and again after 10 minute infusions of NTG (n=10).
NTG was infused in doses of 35 to 200 pg/min, to produce a detectable 
decrease in mean arterial pressure by 5%. In a control group, the second infusion 
also consisted of saline (control, n=10). In all patients receiving NTG, the LV 
filling pressure and pulmonary vascular resistance decreased before a decrease
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in systemic vascular resistance was detected. Angiographic LV asynergy after 
NTG was less or absent compared to saline infusions. There was no 
improvement in LV asynergy in the control group. The improvement after NTG 
appeared to be related to i) decreased filling pressure, ii) decrease LV size (and 
wall stress), iii) the mild decrease in afterload (< 5%), and iv) possibly improved 
collateral blood flow.
Analysis of haemodynamic recordings, the time course of changes in LV 
filling pressure, arterial pressure, cardiac indices and vascular resistances, 
suggested that LV filling pressure might be a better guide for therapy in Ml. In 
these studies, 2D-Echo recorded simultaneously as the LV angiograms confirmed 
the effects on LV asynergy. Similar effects were found in 6 patients given 
prostacyclin (PGI2 , gift from Upjohn). No significant RSD was detected in these 
patients.
The dose of NTG required to produce a 5-10% reduction in mean systolic 
blood pressure (but not below 100 mm Hg) varied widely in patients after acute 
Ml, the range being 35 pg/min to 180 pg/min. Some patients were resistant to 
dropping arterial pressure despite high doses, while others were very sensitive in 
that respect. The pulmonary capillary wedge pressure decreased promptly in all 
patients.
Relevance: The findings of these preliminary studies (data not published) 
provided the basis for low-dose NTG infusions in subsequent studies.
S.4.2.2. Preliminary study of short-term low-dose NTG infusions during 
acute Ml in the CCU (232: Appendix 36)
Background: Whether acute short-term low-dose NTG infusions in acute Ml 
decreased measures of infarct size and LV asynergy on 2D-Echo had not been 
determined.
Methods/Results: Twenty-two patients with a first acute anterior Ml and no 
contraindications were randomized between control and NTG therapy over 2 days 
(232). All patients had complete haemodynamic monitoring, praecordial ST- 
segment mapping, CK-MB and serial 2D-Echo studies (days 1, 2 ,4  and 10). 
Haemodynamic measurements and cardiac index improved in all despite a 5% 
reduction in mean arterial pressure. The LV filling pressure decreased markedly
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from a mean of 18 mm Hg to 5 mm Hg. The sum of ST segment elevations (or 
1ST) on 16 lead praecordial maps decreased sharply. Cumulative CK infarct size 
also decreased. Four short-axis 2D-Echo views were analyzed. The extent of LV 
asynergy decreased in all. LV chamber size also decreased. The incidence of 
arrhythmias and complications over the acute phase were less in these NTG 
treated patients. The decrease in LV asynergy on 2D-Echo was persistent at 10 
days (232).
Relevance; In that study (232), early low-dose NTG infusion for 39 hours after 
acute Ml decreased LV asynergy, infarct size and complications. Retrospective 
analysis suggested that NTG also decreased RSD. The study also underscored 
the effect of the acute decrease in volume during NTG therapy on the assessment 
of RSD and infarct expansion. Additionally, the study led to the recognition of 
RSD with dilatation, stretching and thinning of the infarcted segment but no 
clinically evident ‘infarct expansion’. This suggested that pathologic expansion of 
the infarcted segment was common, and that there might be a threshold beyond 
which acute dilatation, aneurysm and/or rupture occur.
5.4.3. The effect of short-term NTG infusion therapy during acute Mi on LV 
geometry and function during healing after Ml and beyond (28: 
Append ix 6)
Background: Until 1988, eight randomized clinical trials had clearly shown that 
low-dose intravenous NTG in acute Ml i) improves haemodynamics, ii) decreases 
CK infarct size, iii) Is more beneficial in early Ml, iv) decreases LV asynergy, v) 
decreases remodelling, and vi) decreases other infarct related complications 
including mortality. These early studies of short-term low-dose intravenous NTG 
in acute Ml have been reviewed (100[Appendix 21],101,250[Appendix 37]). The 
effect of low-dose NTG infusion after a first Q-wave Ml on measures of infarct 
size, infarct-related complications, and LV asynergy and remodelling on 2D-Echo 
had not been studied.
Methods/Results: The effect of timing, dosage and infarct location on the 
response to intravenous NTG therapy during acute Ml was therefore studied in 
310 patients: 154 NTG, 156 controls (28).
Several points in this study (28) need emphasis.
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First, it was a prospective single-blinded study of 310 patients with acute 
Ml randomized to NTG or placebo. NTG was titrated to lower mean blood 
pressure by 10% in normotensives and 30% in hypertensives (but not below 80 
mm Hg) and was maintained for a mean of 39 hours. Measurements included 
clinical variables, CK infarct size, and indexes of LV function and expansion on 
2D-Echo.
Compared to placebo, NTG: i) reduced overall CK infarct size [41 versus 
55 g-Eq (gram-equivalent), P<0.001] and in both anterior (44 versus 58 g-Eq, 
P<0.05) and inferior infarction (39 versus 53 g-Eq, P<0.025) sub-groups, with 
greater benefit if given early (< 4 hours) and if average mean blood pressure was 
above 80 mm Hg in the first 12 hours; ii) decreased regional LV dysfunction, 
improved LV ejection fraction and decreased infarct expansion and thinning 
(Figure 35); iii) improved clinical functional status and haemodynamics; iv) 
decreased in-hospital complications, including the infarct expansion syndrome 
(2% versus 15%, P<0.0005), cardiogenic shock (5% versus 15%, P<0.005), LV 
thrombus (5% versus 22%, P<0.0005), and infarct extension (11% versus 22%, 
P<0.025): and v) decreased mortality in the acute anterior infarction sub-group, in- 
hospital (14% versus 26%, P<0.01), at 3 months (16% versus 28%, P<0.025) and 
at one-year (21% versus 31%, P<0.05).
Second, in that study (28), short-term NTG therapy after Ml decreased 
both the frequency of clinically significant expansion (as manifested by the clinical 
syndrome and marked evidence on 2D-Echo) and purely echocardiographic 
expansion itself (2D-Echo measurements of infarct stretching, thinning and RSD). 
NTG therapy also decreased LV size.
Third, nitrate tolerance was detected in less than 25% of patients but did 
not result in significant loss of efficacy (28,118).
Fourth, these findings support the concept that the application of 
appropriate expansion-limiting therapy in the very early phase of healing, during 
and after Ml, and before significant collagen deposition, might have greater 
potential for limiting remodelling and aneurysm formation (28,118).
Fifth, the greatest benefit from low-dose NTG was seen in the early sub­
group with mean arterial pressure >80 mm Hg and > 30% improvement in EST, 
LV asynergy and LV ejection fraction during the early stages of therapy, 
regardless of the infarct location.
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Relevance: This study (28) was the largest randomized trial of low-dose
intravenous NTG in acute Ml. It established that early and prolonged (> 48 hours) 
low-dose NTG infusions can be given safely to patients with Ml to limit infarct size 
and also to improve LV function and geometry. Both infarct expansion and 
mortality were reduced in the high-risk group with Q-wave anterior Ml (Figure 35). 
A meta-analysis of the pooled data from all 9 studies confirmed that NTG therapy 
decreased mortality, with a 35% reduction in the odds of death ratio (2P<0.001) 
(344).
5.4.4. The effects of prolonged NTG therapy, given during acute infarction
and healing phases after acute Ml, on LV geometry and function
(105[Appendix 24],109[Appendix 26])
Background: Following the demonstration of the benefits of that low-dose 
intravenous NTG infusion, given over the first 48 hours after acute Ml, on infarct 
size and LV remodelling, the next logical step was to study the effect of this 
intervention applied during the entire healing phase after Ml. There was no 
published data on LV remodelling during the entire healing phase at the time.
Methods/Results: The hypothesis that prolonged NTG therapy, given throughout 
the infarction and healing phases after acute Ml, may further limit deterioration of 
LV topography, reduce infarct expansion, improve LV function, and prevent 
aneurysm formation was therefore tested as the next step (104-107,109). 
Whether the beneficial effects persisted up to one year after therapy was also 
studied (106,107).
Briefly, to determine whether the effect of prolonged NTG therapy (low- 
dose infusion for the first 48 hours followed by buccal NTG for 6 weeks) versus 
placebo was studied in 43 patients with a first acute anterior Q-wave Ml (Table 14, 
Figure 36). Buccal NTG (1-3 mg) was given every five hours with a daily 8-hour 
washout period to avoid the development of vascular tolerance. Left ventricular 
function and topography were assessed by serial 2D-Echo over 12 weeks. 
Prolonged NTG therapy decreased infarct expansion, thinning and RSD, improved 
haemodynamics, decreased LV volume and asynergy, and increased LV ejection 
fraction compared to placebo.
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The overall findings suggested that prolonged LV unloading with low-dose 
NTG limited LV remodelling and improved LV function and clinical parameters 
when initiated early after Ml (data not fully published; book chapter in preparation).
TABLE 14. Patient characteristics in the BNTG and placebo groups
P a ram e ter BNTG G roup Placebo G roup P
(n=23) (n=20) Value
Sex 20 M, 5 F 20 M, 5 F NS
Age (yr) 5 9 + 1 0 57 ± 7 NS
Body surface area (m^) 1.9 ± 0 .2 1.9 ± 0 .2 NS
Pain to adm iss ion 1 0 + 1 3 1 0 ±  14 NS
Adm. to  first 2D-Echo (h) 2 4 + 1 8 2 2 ±  18 NS
Pain to NTG infus ions (h) 1 2 + 1 5 1 2 ±  14 NS
Dose: Average (|ig/min) 71 + 5 3 77 ± 6 5 NS
Range (|ig/min) 5 -2 3 2 1 0 -2 2 0 NS
Duration o f NTG infusion (h) 61 + 19 66 ± 2 9 NS
H istory of:
Hypertens ion (n) 7 8 NS
Heart fa ilure (n) 0 0 NS
Infarction (n) 0 0 NS
2-day BP (mmHg):
systo lic 111 + 13 1 1 5 ± 1 7 NS
d iastolic 74 + 9 7 4 ± 1 1 NS
mean 8 7 + 1 0 8 8 ±  12 NS
2-day HR (bpm) 8 4 + 1 0 8 7 ±  10 NS
2-day RPP
(mmHg x bpm x 10^) 7 .6 +  1.5 8.0 ± 1.9 NS
Adm iss ion K illip Class 2 .2 +  0.3 2.1 ± 0 .2 NS
Creatine kinase:
Peak (lU/L) 2583 +1664 2 1 7 4 ± 1791 NS
Infarct s ize (g-Eq) 52 + 60 46 ± 3 3 NS
NYHA at: 24 weeks 1.3 ± 0 .4 1.8 ± 0 .6 0.005
52 weeks 1.4 ± 0 .5 2.0 ± 0 .3 0.001
Deaths at 52 weeks 0 0 NS
A b b re v ia tio n s : BNTG, buccal n itrate; BP, blood pressure; bpm, beats per m inute;
F, female; M, male; RPP, rate pressure product; NYHA, New York Heart Association.
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Relevance: Four points need emphasis. First, the beneficial effects of prolonged 
NTG therapy on early and late remodelling in that study suggested that therapy 
may have interrupted the vicious cycle leading to LV aneurysm, LV dilatation and 
congestive heart failure.
Second, low-dose intravenous NTG therapy was rapidly becoming routine 
therapy for the management of acute Ml (345). Although NTG is widely used for 
the treatment of angina (346), low-dose NTG was proposed for the limitation of 
infarct size and early remodelling (28) and not for the relief of continuing chest 
pain as in unstable angina where high doses are used.
Third, although prolonged nitrate therapy for angina, especially at high 
doses, is associated with the development of nitrate tolerance (117), tolerance 
was not significant with low-dose NTG after Ml (118: Appendix 27).
Fourth, since tolerance during chronic nitrate therapy for angina can be 
partially combated by intermittent or eccentric dosing and new formulations that 
permit a low nitrate interval beyond the first 48 hours (337), an eccentric regimen 
was used in this study. This precaution was also justified by the mechanisms that 
were proposed for tolerance at the time, namely: i) a cellular mechanism involving 
depletion of sulfhydryl groups or alteration of the guanylyl cyclase pathway (117), 
and ii) a systemic mechanism, whereby haemodynamic changes trigger off a 
counter-regulatory neurohumoral activation with stimulation of the renin- 
angiotensin pathway and fluid retention (346). Importantly, the eccentric NTG 
dosing regimen used in that study was associated with beneficial anti-remodelling 
effects.
5.4.5. The effects of prolonged NTG and captoprii therapy, given during
healing after acute Ml, on LV geometry and function (108: Appendix
25;298: Appendix 41)
Background: On the basis of data available in the mid-1980 s, two major
approaches could be formulated to combination therapy for the limitation of 
remodelling after Ml. The firs t approach was to use low-dose intravenous NTG 
acutely followed by either prolonged nitrate or prolonged AGE-inhibition therapy. 
The second approach was to use a combination of nitrate and an ACE inhibitor 
in the chronic therapy phase. In theory, sulfhydryl-containing ACE inhibitors such 
captoprii could donate these groups as well as block neurohumoral activation, and 
thereby reduce nitrate tolerance. The combination of ACE inhibitors with
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vasodilators such as nitrates in the management of congestive heart failure had 
already been suggested to be effective in inhibiting vasodilator-induced 
vasoconstriction (346). It should be noted that although chronic continuous nitrate 
therapy resulted in tolerance with attenuation of the anti-anginal effect, eccentric 
dosing was believed to provide protection against painful ischaemia (337).
Several significant advances brought nitrates into prominence in the late 
1980’s. Endothelium-derived relaxing factor (EDRF), one of the most active 
endogenous vasodilators (347), was identified as nitric oxide (NO) by Palmer et al. 
in 1987 (348) and proposed to represent endogenous nitrate. Nitrates were 
thought of as NO donors. It was proposed that NO might also act as a free radical 
scavenger and explain the beneficial effect of NTG during reperfusion. However, 
Myers et al. (326) suggested that the vasorelaxant property of EDRF more closely 
resembled S-nitroso-cysteine than NO.
Methods/Results: As the logical next step, the hypothesis that prolonged anti­
remodelling therapy with acute NTG over 48 hours followed by the combination of 
NTG and captoprii, might be more beneficial than monotherapy with NTG or 
captoprii was tested in patients after Transmural Acute Ml or TAMI (108: 
Appendix 25;298:Appendix 41).
Between 1989 and 1991, 160 consecutive patients who were admitted to 
the CCU with a potential first anterior or inferior TAMI and were treated with 
standard therapy consisting of thrombolysis followed by intravenous low-dose 
NTG infusion for 48 hours, and had an adequate 2D-Echo and evidence of Q- 
wave Ml on ECGs at 48 hours were entered into the prospective, double-blind, 
placebo-controlled randomized study (Figure 37).
A factorial design (n=20/cell) was used and the patients with anterior 
(ATAMI) or inferior (ITAMI) TAMI were started on 6 weeks of oral placebo, 
captoprii (25 mg t.i.d.), NTG (buccal 3 mg t.i.d., 5-hourly with an 8-hour washout) 
or NTG+captopril. The patients were followed for 1 year after therapy, with serial 
complete quantitative 2D-Echo. The 2D-Echo remodelling indices at 2 days, 6 
weeks, 6 months, and 1 year as well as serial clinical data (complications, 
cardiovascular events and other drugs as per questionnaire) and ECGs were 
recorded (Figure 37).
At randomization, the demographic and clinical data for the 4 groups were 
similar (Table 15A). Average values were: 88% male gender; age 57 years;
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TABLE 15 A. PATIENT CHARACTERISTICS (Mean ± SEM)
P A R A M E T E R P L  (n=40 ) C L  (n= 4 0 ) N G  (n= 4 0 ) C L + N G  (n -4 0 )
Sex (% Male) 96 91 76 88
A ge (Years) 59±2 57±2 53±2 57±2
W e igh t (kg) 81 ±2 81±2 82±2 84±2
ES A  (M^) 1.9±0.02 1.9±0.02 1.9±0.02 1.9±0.02
A n te r io r  (%) 50 50 50 50
K illip  C lass: A d m iss io n 1.6±0.08 1.7±0.06 1.7±0.09 1.7±0.08
K illip  C lass: Day 2 2.1 ±0.03 2.2±0.03 2.1 ±0.05 2.2±0.03
Peak CK (lU /L) 2060±233 2767±303 2138±218 2756±332
CK In fa rc t S ize (gEq) 44±7 57±9 42±7 67±11
T h ro m b o lys is  (%) 43 43 52 55
S ys to lic  BP (mm Hg) 103±2 108±3 110±2 108±3
D ia s to lic  BP (m m Hg) 67±2 69±2 70±2 69±2
Mean BP (m m Hg) 79±2 82±2 83±1 83±2
Heart Rate (bpm ) 77±2 78±2 72±2 77±3
RPP (m m H gxbpm xIO ^) 6.1 ±0.2 6.4±0.3 6.0±0.2 6.3±0.2
NTG In fus ion  (%) 100 100 100 100
Dose (m g/m in ) 75±9 68±9 77±10 71±8
Past Hx: H ype rtens ion  (%) 25 27 30 28
Past Hx: In fa rc tio n  (%) 0 0 0 0
Past Hx: Heart Failure  (%) 0 0 0 0
P = NS fo r  a il co m p a r ison s
A b b re v ia tio n s : BP, blood pressure; BSA, body surface area; CK, creatine kinase; CL, captoprii; 
Hx, history; NG, nitrate; PL, placebo; RPP, rate pressure product
TABLE 15 B. FOLLOW-UP DATA (10 years: 1990-2000)
ATAMI Group (n =  80) ITAMI Group (n =  80)
PL CL NG NG+CL A L L  %) PL CL NG NG+CL A L L  (%)
PTCA 7 8 7 3 25 (31) 8 8 3 10 29 (36)
Rec Ml 0 1 1 2 4 (5 ) 2 2 0 2 6 (8 )
CHF 5 2 1 4 12 (15 ) 1 1 1 3 6 (8 )*
CABG 3 2 4 4 13 (16 ) 7 3 5 7 22 (28)*
Death 4 3 2 6 15 (19 ) 0 1 0 1 2 (3 )*
HTx 0 1 0 0 1 (1) 0 0 0 0 0 (0 )
ACE-i^ 3 3 2 5 1 3 (16 ) 3 1 3 4 11 (14)
BB 3 6 4 3 1 6 (20 ) 6 7 4 9 26 (33)*
Abbreviations: ACE-I, ACE-inhibito r; BB, beta blocker; CABG, coronary artery bypass graft; CHF, 
congestive heart failure; CL, captoprii; HTx, history; NG, nitrate; PL, placebo; PTCA, percutaneous 
translum inal coronary intervention; Rec Ml, recurrent Ml.
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A. PROTOCOL
Consecutive patients with potential first TAMI 
Admission to CCU
Factorial Design
ATAMI
ITAMI
intravenous Nitroglycerin 
for 48 h/ Tl^ombolysis
TAMI on ECG (Q-wave) at 48h
Randomized 
1^  /  >  \
Clinical Data 
Serial CK/CK-MB 
ECG
ECHOyOOPPLER
Placebo 
n = 20
Captoprii 
n = 20
Nitrate 
n =20
Captoprii+Nitrate n = 20
Placebo 
n = 20
Captoprii 
n = 20
Nitrate 
n = 20
Captoprii+Nitrate
..... ............
Captoprii 25 mg t.i.d. oral Nitrate3 mg t.i.d. buccal
6 weeksFoIlow-up on Therapy*r i|'
6 Months & 1 Year Follow-Up After Therapy* Annual Follow-up for 10 years
Clinical Data Serial CK/CK-MB ECGECHO/DOPPLER
9 2
B . INFARCT EXPANSION 
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150
PSO.01 «
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PLACEBO 
— NITRATE (NG)
— CAPTOPRIL
NG+CAPTOPRIL
Figure 37. Effect of prolonged 
combination therapy versus 
monotherapy with nitroglycerin 
/nitrate and captoprii.
A. Protocol, B. Infarct expansion,
C. End-diastolic volume, D. LV 
ejection fraction.
Jugdutt et al. (108; Appendix 25, 
315: Appendix 42)
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weight 82 kg; 50% ATAMI; Killip class 2.1 ± 0.03; peak CK 2430 lU/L; CK infarct 
size 53 ± 8 g-Eq; thrombolytics 48%; mean blood pressure 82 ± 2 mm Hg. 
Compared to the placebo group, all active therapy groups showed preservation of 
global LV ejection fraction and limitation of remodelling (as assessed by the infarct 
expansion index, wall thinning ratio, RSD, and diastolic and systolic volumes) 
between 6 weeks and 1 year (Figure 37). Follow-up data at 10 years (Table 15B) 
showed that most of these patients survived 10 years (book chapter in 
preparation).
The sample sizes in the cells of the factorial template were carefully 
calculated for the 2D-Echo end-points on the basis of previous 2D-Echo data in 
my laboratory which was dedicated to research on remodelling after Ml in humans 
(19-21,28,33-36,50,104-107,109,118,130,180,220,232,245,251-253,274,298) and 
the dog model (48,55,62,73,74,96,103,126-129,131,181,222,283,318,319).
Feinstein's method was used (320) for calculation of sample size considering beta 
error (322). Defining a significant change for in-vivo LV function as a 25% 
increase in ejection fraction, or 25% improvement in remodeling parameters (LV 
end-diastolic volume), a doubly significant sample size (N) calculated after 
correcting for the chance of falsely accepting the null hypothesis due to sampling 
error, was n = 6 for a  = 0.05, p = 0.1. This was trebled to allow for inter-observer 
error and other factors.
Relevance: Monotherapy and combination therapy with NTG (eccentric dosing) 
and captoprii, given during healing after transmural Ml, produced similar anti- 
remodelling effects which persisted up to one year. It is clear from the 
pathophysiologic determinants of remodelling (Figure 7; Table 3) and the stages 
of remodelling (Figure 6; Table 2) that therapy applied very early and throughout 
the early phase of healing before collagen deposition, and continued throughout 
the late phase of healing and beyond, might result in greater benefits in the 
absence of negative factors. Potential therapies, reviewed previously (67; Figure 
21), included nitrates, ACE inhibitors and beta-blockers and were included in 
management guidelines (345). While the beneficial effects of long-term therapy 
with ACE inhibitors in post-MI survivors are established (27), long-term therapy 
with nitrates is not recommended in post-MI survivors.
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6. DISCUSSION
The period between 1980 and 1988, during which the studies outlined in this 
thesis were conducted and/or initiated, were exciting years in the development of 
the novel concepts of adverse remodelling after Ml and its potential modification 
by anti-remodelling strategies. Importantly, that period witnessed the development 
of 2D-Echo as a powerful tool for the assessment of the dynamic changes in LV 
geometry and function after Ml and the effects of potential therapeutic 
interventions. The studies have contributed to knowledge of the pathophysiology 
of healing and gross mechanisms of LV remodelling after Ml (21,22) that triggered 
several clinical trials of potential anti-remodelling agents post-MI (23).
Rapid progress and developments during that period (1980-1988) made 
changes in the initial objectives and approaches necessary, with several to-and- 
fro leaps from bench to bedside research. Three landmark advances during that 
period triggered changes in the protocols for studies in this thesis. The first was 
the discovery that coronary thrombosis was the major culprit causing acute 
coronary occlusion in Ml (349), which led to the use of widespread early 
thrombolytic therapy. The second was the discovery that LV unloading and 
inhibition of the renin-angiotensin pathway with ACE-inhibition limited progressive 
LV dilatation after Ml (77), which led to the widespread use of ACE inhibitors after 
Ml. The third was the discovery that reperfusion induced damage to the ECM 
(164), which rekindled previous interest in the role of the ECM (277) and collagen 
in cardiac remodelling (277,295) and also led to the concept of anti-fibrotic therapy 
in cardiovascular disease (295), with implications for Ml.
6.1. Major findings
There are five major findings stemming from the studies in this thesis that are 
pertinent to the topic of ‘modification of LV geometry and function during healing 
after acute Ml’ and might have profound therapeutic implications still pertinent in the 
2000’s.
First, the LV remodelling process is complex, involving multiple 
determinants and diverse mechanisms that are potentially modifiable (21,28,37,39, 
50,103,126), and quantitative 2D-Echo and 3D reconstruction can be applied to 
measure the in-vivo regional and global structural, geometric and functional changes 
associated with LV remodelling post-MI (19-22,28,34,67,102,103,283). The
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sequence of acute Ml followed by early regional and subsequent progressive global 
LV dilatation and progressive LV dysfunction suggested that bad remodelling 
outweighs the good, a concept that is now generally accepted.
Second, LV remodelling and infarct healing are dynamic processes that 
progress in parallel over time (22) and the effects of interventions on LV 
remodelling during healing after Ml can be tracked by serial quantitative 2D-Echo.
The studies showed that remodelling spans phases of infarction and healing, 
before and after infarct collagen deposition reaches a plateau, to scar formation 
(22,39,41,55) and anti-remodelling therapies can influence healing (22). The results 
supported the concept that organized collagen deposition and scar formation in the 
infarct zone and cardiomyocyte hypertrophy in the non-infarct zone are important for 
preserving structural and functional integrity after Ml, especially since 
cardiomyocyte regeneration is insufficient to compensate for its loss. Studies 
of the rupture threshold indicated that the left ventricle after Ml is mechanically 
weaker and more susceptible to distension (102,283). The results also indicated 
that therapy targeted at one mechanism or phase might be unsuitable for another 
and have unexpected effects that might be potentially deleterious (22). This was 
illustrated in the studies with NTG (122), anti-inflammatory agents (35,102), and ACE 
inhibitors (127-129,131).
Third, ECM and collagen deposition in the infarct zone protect against LV 
remodelling (41,74,279,284,291) and interventions that disrupt the ECM or decrease 
IZ collagen may promote adverse remodelling.
Since early reperfusion causes ECM disruption (164) and late reperfusion 
after 2 hours of occlusion causes more structural disruption of ECM than permanent 
occlusion (160), induces myocardial stunning and reperfusion injury whereby 
salvage of muscle and geometry might not salvage function (158,159,161), the 
possibility of another double-edged sword was a concern. However, the overall 
benefits of early reperfusion are undeniable and late reperfusion was shown to limit 
acute expansion in dogs and limit RSD on 2D-Echo despite slightly lower infarct 
collagen (49). Late reperfusion also accelerates healing (46) which appears to be 
beneficial. Taken together, the final outcome of reperfusion appears to depend 
on a balance of effects. Importantly, NTG infusion after late reperfusion resulted in 
earlier recruitment of LV function and preserved LV geometry in patients after Ml 
(50).
141
Since angiotensin li mediates remodelling and failure (350) and stimulates 
fibroblast proliferation, ECM and collagen deposition, myocyte hypertrophy and 
fibrosis, thereby leading to increased resistance to LV distension, hypertrophic 
remodelling and impaired diastolic function (295), decreased angiotensin II formation 
with ACE-inhibition was expected to decrease ECM and collagen deposition, and 
decrease hypertrophy. A subsequent report showed decreased collagen with ACE- 
inhibition after Ml in rats (351). Captoprii was found to limit LV dysfunction and 
hypertrophy in patients with anterior Q-wave Ml (130). Clearly ACE inhibitor-induced 
limitation of LV dilatation, hypertrophy and heart failure is beneficial.
However, the possibility that early ACE-inhibition after Ml might decrease 
ECM and collagen deposition in the infarct zone and thereby promote infarct 
expansion, regional and global LV distension, impair IZ healing and act as a 
double-edged sword, was actively pursued. Although the ACE inhibitors were 
found to markedly decrease collagen in the infarct zone (127,128,129,131) and to 
a lesser extent in the non-infarct zone (129), and showed increased RSD on ex- 
vivo LV sections and in-vivo quantitative 2D-Echo in some studies, overall 
beneficial effects on global LV remodelling and function were found in survivors 
with small to moderate Ml (108,130,298). Since late coronary reperfusion can 
damage ECM (160), whether reperfusion and ACE-inhibition might potentially 
result in double jeopardy raised concern. However, this was not found to be the 
case in survivors with small to moderate Ml (108,130,298). Another study found 
that ACE inhibitors given early after reperfusion were beneficial (352), although RSD 
and detailed data on remodelling were not available.
Other researchers have shown that ACE inhibitors (338) and ARBs (353) 
block collagen deposition in the non-infarct zone in rats. Since ACE inhibitors also 
block bradykininase (354) (Figure 38), thereby increasing bradykinin, PGI2 and 
NO which contribute to LV unloading, anti-trophic and other pleiotropic effects, the 
final outcome may represent a balance of effects. The recent finding that 
volume overload in dogs, where chymase dominates over ACE, results in loss of the 
collagen weave that is not attenuated by ACE-inhibition (355), suggests that 
chymase-induced ECM degradation (356) may be an important factor during ACE- 
inhibition.
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Although acute administration intravenous low-dose NTG for 48 hours was 
effective in reducing infarct size and LV remodelling and dysfunction after Ml (28), 
and prolonged NTG in eccentric dosing during healing after Ml also limited LV 
remodelling and dysfunction (104-109) without decreasing infarct collagen or 
impairing healing (55,102,103,131), large clinical trials did not show a significant 
survival benefit (135-137). This negative result may have been due to the use of 
long-acting nitrates such as ISDN acutely, use of higher doses acutely often to 
control chest pain, continuous oral dosing subsequently resulting in the development 
of tolerance, and the administration of nitrates to other groups resulting in flawed 
statistics. A subsequent study showed benefit with prolonged transdermal NTG 
patch therapy (357).
Fourth, infarct size and transmurality are major determinants of adverse 
early and late remodelling after Ml. Moderate transmural Ml was shown to induce 
marked RSD and adverse remodelling after Ml in the dog and patients. In 
addition, infarct location influenced the severity of early remodelling whereby the 
degree of RSD and severity of LV dysfunction was greater with anterior than 
inferior Ml.
In the 1970’s, limitation of infarct size was the therapeutic strategy of 
choice for reducing cardiovascular deaths because pump failure was directly 
related to infarct size (312). By the late 1980’s, the increasing use of thrombolytic 
agents with or without PTCA, beta-blockers and nitrates had decreased early 
post-MI deaths to nearly 7% (28,121,134-141). The improved therapies increased 
the number of survivors but many still remain at risk of further adverse LV 
remodelling and its consequences (22). These include infarct expansion and 
thinning, LV aneurysm, LV dilatation, LV rupture, heart failure, LV volume 
overload, LV hypertrophy, arrhythmias and death.
Several studies in the 1980’s, including those presented in this thesis, 
indicated that acute infarct expansion, LV dilatation, LV dysfunction, disability and 
death are directly related to infarct size and infarct transmurality (21-23,28,88). 
The 2D-Echo studies of Ml in the dog and humans indicated that infarcting tissue 
undergoes early remodelling, with an expansion (stretching, thinning, and bulging) 
that sets the stage fo r further adverse LV remodelling (21,28,34,35,102,103, 
127-131,283). In dogs, LV unloading with nitrates over the first 6 weeks produced 
greater benefit on LV dilatation and LV mass than over the first 2 weeks (103). 
Early and prolonged anti-remodelling therapy after Ml therefore seems to be
144
a logical therapeutic strategy (22). Because patients with large anterior 
transmural (or Q-wave) Ml are at highest risk for early expansion and LV 
remodelling (18,21 -23,28,34,35,67,78,102,283), this high-risk anterior Ml group 
should be targeted fo r therapy.
Studies with different pulses of anti-remodelling agents, such as captoprii 
(22,23,121,126,132,134-141,145,318) and nitrates (28,55,102,103,318,357) in 
dog and human Ml, support the idea that salvage of geometry, function and 
lives might be greater with exposure to LV unloading throughout healing 
post-MI. ACE inhibitor trials after Ml showed a further small decrease in mortality 
(< 7%) and morbidity in selected patients (121,125,134-141,145). Comparison of 
captoprii and nitrate in dogs showed benefit on LV dilatation, mass and function with 
both agents, but infarct collagen was less with captoprii and thinning less with nitrate 
(131). Also in dogs, enalapril decreased infarct collagen more than captoprii (129) 
and made the scars flatter (131). This finding suggested that all ACE inhibitors were 
not equal.
There is general agreement that hypotension should be avoided when using 
vasodilators for LV unloading during Ml (28,122,123). A paradoxical J-curve effect 
was demonstrated with high doses of NTG (100,122). This may also be important 
for salvage of muscle and healthy healing after Ml. The concept that a border zone 
is potentially salvageable if flow is restored (149), or oxygen demands are 
decreased, or cellular and metabolic factors are improved (87), is still pertinent since 
early therapy is needed to optimize myocardial salvage during Ml (153) and 
attenuate early expansion (22,23,67).
The negative results of the CONSENSUS II trial (123), the lack of early 
separation of survival curves in other trials with ACE inhibitors (121,135,136), the 
persistent LV dysfunction after early captoprii in rats (338), and the persistent 
mortality after captoprii in rats with large Ml (77), might have been related to 
negative effects of early ACE-inhibition on blood pressure and collagen and ECM 
deposition in the infarct zone (55,354,358).
Fifth, the timing of anti-remodelling therapy relative to the infarct collagen 
plateau is an important factor for outcome during healing after Ml.
The progressive and dynamic nature of the remodelling process during 
healing after Ml suggests that timing and duration of therapy is important (22,338). 
The remodelling substrate also changes drastically during healing. The results 
presented in this thesis suggested that early and prolonged therapy should be used
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(21). Early short-term therapy was shown to exert profound late effects on 
remodelling via effects on infarct size and early healing (28,55,103). Several reports 
in the 1990’s indicated disease progression while on ACE-inhibition and favoured 
prolonged therapy beyond healing (26). Others suggested higher doses of ACE 
inhibitors.
The pathophysiological data presented in this thesis suggest that anti- 
remodelling therapy, applied before and after the infarct collagen plateaus, may 
produce different outcomes by modifying the determinants of remodelling and/or the 
substrate (22), such as the infarct size, healing process, deformation forces, LV 
loading conditions and wall tension. It may also modify the process during very early 
(first 24 h) and early remodelling (first 2 weeks) before infarct collagen plateaus, and 
late remodelling (3 to 6 weeks) after infarct collagen plateaus in dogs. Processes 
occurring before the collagen plateau include ECM degradation, infarct expansion, 
myocyte slippage, inflammation and fibroblast proliferation. After the collagen 
plateau, processes include compaction of infarct collagen, scar thinning, 
hypertrophy, formation of connections between collagen fibrils in the infarct and 
myocytes in the non-infarct zones (284) and fibroblast transformation to 
myofibroblasts containing actin filaments that mediate scar contraction (359).
6.2. Caution with the use of anti-fibrotic agents after Ml
The aim of anti-fibrotic therapy is to inhibit or reverse cardiac fibrosis and its 
adverse effects on LV function (278). Potential approaches have been reviewed 
elsewhere (278). Anti-fibrotic therapy may be beneficial for non-infarcted hearts 
with chronic LV pressure overload (278) and possibly for ischaemic 
cardiomyopathy and the non-infarct zone after remote Ml (360). However, caution 
might be advisable in idiopathic dilated cardiomyopathy without Ml, because of the 
altered MMP/TIMP balance with increased MMPs and decreased TIMPs, and 
reduced cross-linking (277). Collective evidence emerging from experimental and 
clinical studies using anti-remodelling strategies after Ml suggest that careful 
attention should also be given to timing, especially because anti-fibrotic agents 
exert global actions that can affect both the infarct and non-infarct zones. 
Experimental data on the temporal evolution of healing and ECM remodelling (22, 
278,291) suggest that these agents could potentially enhance adverse ECM 
remodelling in the infarct zone during the highly vulnerable periods of very early
146
and early stages of healing after Ml. It might also be prudent to exercise caution 
during the phase beyond scar formation (27).
6.3. Protecting the ECM in the infarct zone after Ml
There is now consensus that LV remodelling after Mi contributes significantly to LV 
dilatation and dysfunction, disability and death (23). Two paradigms, pertinent to 
anti-remodelling therapy, have evolved over the last 3 decades (27). The first 
paradigm, that LV remodelling is a major mechanism for disability and death 
(22,23) has received a great deal of attention. In contrast, paradigm 2, that 
remodelling of the ECM plays a major role in LV remodelling (277,278,291,293), 
whereby decrease, disruption and/or defective composition of the ECM promote 
LV dilatation and rupture (277-279,293) has received little attention. This is 
despite acknowledgement that myocardial collagen and the supporting ECM play 
protective roles in adverse LV remodelling during healing after Ml (22,23,41,73,74, 
129,164,277,294,295,308,) and should be preserved (22,23,27).
Many clinical trials have shown that ACE inhibitors with or without 
aldosterone antagonists, ARBs, beta-adrenergic blockers or reperfusion improve 
outcome in survivors of Ml (134,308,361). However, the antl-fibrotic action of 
ACE inhibitors, aldosterone antagonists and ARBs on ECM in the infarct zone and 
non-infarct zone (277,278,295,308) and the reperfusion-induced damage to the 
ECM in the infarct zone (164,278,293) still need to be reconciled with the benefits 
(49,134,308,361). Although growth hormone was shown to stimulate post-MI 
repair, increase IZ scar collagen and reduce LV aneurysm formation (278), such 
approaches have not been actively pursued. Strategies to protect the ECM after 
Ml, especially in the infarct zone, might further limit post-MI morbidity and 
mortality. Several factors could be targeted (27,278). In contrast to global 
approaches that target both the infarct and non-infarct zones with systemic 
delivery of adjunctive agents, regional strategies couid be applied to 
seiectiveiy protect the infarct zone against adverse ECM remodelling. 
Monitoring using protein markers could be systematically applied to detect 
potentially adverse ECM remodelling during therapy (27,278). In addition, on the 
basis of the results presented in this thesis, monitoring of the RSD and other LV 
remodeliing indices by sériai 2D-Echo may be helpful.
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6.4. Merits and lim itations
There are several merits of the studies described in this thesis. A major strength 
is that the studies spanned the eras before and after the introduction of 
reperfusion therapy. They contain valuable data on moderate and large 
transmural Ml that are less often seen in the 2000's. However, a significant 
number of patients still do not benefit from early reperfusion and optimal therapy 
as suggested in the latest ACC/AHA management guidelines (362), and present 
with large transmural Ml or ST-elevation Ml (STEMI), cardiogenic shock and 
significant RSD on 2D-Echo. Many patients receiving reperfusion therapy show 
RSD on endocardial contours and sub-epicardial aneurysms.
The results provide improved understanding of the pathophysiological 
mechanisms of LV remodelling during healing after Ml. They also provide the 
rationale for the timing of anti-remodelling therapy. Importantly, they indicate that 
the effects of anti-remodelling therapy may be objectively assessed using non- 
invasive quantitative 2D-Echo imaging. 2D-Echo may also be used to stratify 
patients according to their topographic status and select high-risk patients for 
aggressive therapy.
As with all studies, there were several limitations in the research studies 
described in this thesis, but four deserve mention. First, it was necessary to 
select patients with a first Ml for evaluation by 2D-Echo. Second, the 2D-Echo 
methods need to be applied in large clinical trials of potential anti-remodelling 
therapies. However, this has not been possible to date due to the lack of funds 
and support from the pharmaceutical industry, although the data from the studies 
were made available to the executive committees of several megatrials (23). 
Third, the computer software for the rapid analysis of quantitative 2D-Echo for the 
remodelling indices including RSD needs to be converted for general use. Despite 
the ability of 2D-Echo to provide quantitative data of robust remodelling indices, 
several trials have used areas to assess benefit (132), and have not taken 
advantage of the full potential of 2D-Echo imaging (125). Fourth, we focused on 
gross mechanisms of remodelling of LV shape and function between 1980 and 
1988. Further studies are needed to address the biology of remodelling involving 
cells, proteins and molecules (27,190, 278).
148
6.5. Advances pertinent to the thesis
To place the thesis in perspective with current knowledge, it is necessary to 
consider pertinent advances that have impacted current strategies to limit, prevent 
or reverse remodelling after Ml over nearly two decades. These advances may 
be considered under 3 headings: i) RAAS-inhibition; ii) nitrates and nitric oxide; 
and iii) novel concepts, approaches and technologies.
6.5.1. RAAS-inhibition
As mentioned previously, survivors of Ml are at risk for death and disability. This 
is largely due to infarct-related complications such as adverse LV remodelling with 
progressive LV dilatation, dysfunction, heart failure, hypertrophy, and arrhythmias. 
Since heart failure is the end result of adverse remodelling among post-MI 
survivors and this group is increasing as a result of improved therapies for acute 
Ml, the frequency of heart failure is also increasing. Finding improved therapies 
for heart failure in chronic Ml is therefore an important goal (27).
The pertinent aspects of RAAS-inhibition in post-MI remodelling have been 
reviewed (363). As discussed before (pages 18-22, section 2.5.3.), angiotensin II, 
the primary effector molecule of the RAAS, is a major contributor to post-MI 
complications. Cumulative evidence indicates that angiotensin II is produced in 
both the circulation and tissues via ACE and non-ACE pathways (Figure 38), and 
has important physiological as well as pathophysiological actions, such as 
activation of other neurohumoral agonists including norepinephrine, aldosterone, 
endothelin and vasopressin that can be harmful (Figure 39). Although angiotensin 
II acts on both the angiotensin II type 1 (ATi) and type 2 (AT2 ) receptors 
(363,364), most of Its effects are mediated through the ATi receptor (350). 
However, under certain conditions such as Ml, healing post Ml, heart failure, 
myocardial hypertrophy and vascular injury, the ATg receptor is up-regulated and 
may mediate some important cardiovascular effects of angiotensin II (363).
6 .5.1.1. ACE inhibitor Trials
The original rationale for using ACE inhibitors was to inhibit ACE and thereby 
decrease angiotensin II formation (Figure 38a). This was supported by 
experimental studies in rats showing that chronic captopril therapy reduced LV 
dysfunction, LV remodelling and mortality in chronic Ml (120).
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Over the last two and a half decades, several randomized clinical trials 
have established ACE inhibitors for the treatment of Ml, heart failure, and 
hypertension. Several trials (Table 16) showed that ACE inhibitors improve the 
survival of patients with Mi (121,122,125,134,135,137-139,365, 366) and heart 
failure (122,142,143,145). The ACE inhibitor trials showed a survival benefit in 
over 100,000 patients with acute (367) and chronic (368) Ml. The greatest 
benefits were found in the high-risk patients with LV dysfunction (369). ACE 
inhibitors in the SAVE (121,368), AIRE (139) and TRACE (365) trials reduced all­
cause mortality, non-fatal cardiovascular events such as hospitalization for heart 
failure and recurrent Ml, providing strong evidence that ACE inhibitors reduce 
mortality and morbidity in post-MI survivors.
TABLE 16. Trials of ACE inhibitors in heart failure and myocardial infarction
Year
(Reference)
Trial Number of 
patients
ACE-inhibitor Disease
1987 142) CONSENSUS 253 Enalapril HF
1991 143) SOLVD, symptomatic 2,569 Enalapril HF
1992 145) SOLVD, asymptomatic 4,228 Enalapril HF
1992 123) CONSENSUS 11 6,090 Enalapril Ml
1992 121) SAVE 512 Captopril Ml
1993 139) AIRE 2,006 Ramipril Ml
1994 136) GISSI-3 19,394 Lisinopril Ml
1995 135) ISIS-4 58,050 Captopril Ml
1995 140,365) TRACE 6,676 Trandolapril Ml
1995 137) CCS-1 13,634 Captopril Ml
1995 138) SMILE 1,556 Zofenopril Ml
1996 366) GISSI-3 19,394 Lisinopril Ml
1997 124,125) HEART 352 Ramipril Ml
Abbreviations: HF, heart failure; Ml, myocardial infarction. Other abbreviations 
as in the text and Abbreviation List (pages xxi to xxiii).
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6.5.1.2. ARB Triais
The rationale for using ARBs w as that they provide specific and selective 
blockade of angiotensin II at the A T i receptor. In view  of the previously 
established benefits of A C E  inhibitors, three other reasons w ere subsequently put 
forward for using an ARB. These included: i) more com plete blockade of the 
effects of angiotensin 11 derived from all sources; ii) absence of inhibition of 
kininase II or increase in bradykinin which cause side-effects associated with AC E  
inhibitors, such as cough, angio-oedem a, and hypotension; and iii) unopposed 
stimulation of the A T 2 receptor that m ay augm ent its beneficial effects (Figure 39).
Subsequent studies revealed that the cardioprotective effects of A C E- 
inhibition are not only related to blockade of angiotensin II formation via ACE but 
also the inhibition of breakdown of bradykinin via kininase II activity (Figure 38b). 
Thus during ACE-inhibition, the am ount of angiotensin II presented to ATi and 
A T 2 receptors is decreased, at least initially, so that decreased A T i and A T 2 
effects would be expected. However, the increase in bradykinin stimulates NO, 
P G I2 , EDHF, and tissue-thromboplastin activator (t-PA), thereby contributing to 
the vasodilatation, cardiovascular protection and other favourable vascular effects 
associated with ACE-inhibition (370). O f note, increased bradykinin during A C E- 
inhibition may also contribute to the hypotensive effect o f A C E  inhibitors.
In contrast, the cardioprotective effect of ARBs is mediated largely by A T i 
blockade and only partly via A T 2 receptor activation and via release of kinins and 
stimulation of kinin Bi and B2 receptors (371 ,372 ) or direct A T 2-mediated signaling 
via protein kinase C (PKCe), NO, and cG M P  (373-375) (Figure 38b). Evidence to 
date suggests that this bradykinin-dependent protective pathway involving NO and 
PG I2 is quantitatively greater with A C E  inhibitors than A R B s.
The finding that angiotensin II levels persist during long-term therapy with 
A C E  inhibitors (376,377) drew attention to the fact that A C E  inhibitors do not block 
the formation of angiotensin II from angiotensin I via chym ase or other non-ACE  
enzymes, or that from angiotensinogen via non-renin pathways (Figure 38). This 
finding promoted the idea that the combination of an A C E  inhibitor and an ARB  
may achieve more complete blockade of the deleterious effects of angiotensin II 
and produce greater benefits. Som e support for this concept was provided by 
experimental (378) and clinical (379) studies in heart failure.
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Over the last nearly two decades, several randomized clinical trials (Table  
17) have investigated the benefits of blocking the effects of angiotensin II via the  
A Ti receptor using selective A Ti receptor blockers (ARBs) in patients with Ml 
(380,381), heart failure (382-387), and hypertension (388-390). Because ARBs  
w ere introduced after A C E inhibitors had been shown to be beneficial, it becam e  
necessary to dem onstrate that ARBs w ere either superior to A C E  inhibitors or 
equally effective in patients who were intolerant to A C E  inhibitors and receiving 
other background therapies rather than relative to a true placebo group.
TA B L E  17. T ria ls  o f A R B s in heart fa ilu re  and m yocard ial in farctio n
Y ear
(R eference)
Tria l 1N um ber of 
patien ts
A R B D isease
1997 (382) ELITE 722 Losartan HF
1999 (392) R E S O LVD 768 Candesartan HF
2000  (383) ELITE II 3 ,152 Losartan HF
2001 (361) V a l-H eF T 5,010 Valsartan HF
2002 (380) O PTIM A A L 5,477 Losartan Ml
2003  (384) CHA RM -O verall 7,601 Candesartan HF
2003  (385) CHA RM -A dded 2,548 Candesartan HF
2003  (386) C H  ARM-Alternative 2 ,028 Candesartan HF
2003  (387) C H  ARM -Preserved 3,023 Candesartan HF
2003  (381) V A LIA N T 14,703 Valsartan Ml
A b b rev ia tio n s : H F, heart failure; Ml, myocardial infarction. Other abbreviations 
as in the text and Abbreviation List (pages xxi to xxiii).
6 .5 .1 .3 . E L IT E  and C H A R M
In the evaluation of ‘tosartan in the elderly' (ELITE) study of chronic heart failure 
patients (382), losartan showed an unexpected reduction in the secondary end­
point of all-cause mortality by 46%  relative to captopril. Although the study was  
small and not designed to assess mortality, this effect was felt to be due primarily 
to a reduction in sudden cardiac death. However, the ELITE II heart failure trial
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(383), which was designed to assess superiority of losartan over captopril in 
reducing mortality, showed similar survival rates.
In the large candesartan in heart failure assessm ent of reduction in 
mortality and morbidity’ (C H A R M ) trials (384-387 ), the ARB candesartan improved 
cardiovascular death or heart failure hospitalization in patients taking A C E  
inhibitors as well as those intolerant to A C E  inhibitors. Importantly, compared to 
placebo in patients not receiving AC E inhibitors, candesartan reduced the  
composite primary end-point of cardiovascular death or admission for heart failure 
(P =0.001) although overall mortality did not improve (P =0 .11) (386). In a sub­
study of patients with low LV  ejection fraction (< 40% ) in the C H A R M  trial, 
candesartan reduced all-cause mortality, cardiovascular death and heart failure 
hospitalizations (391).
6.5.1.4. RESOLVD pilot study
In the ‘randomized evaluation of strategies for left ventricular dysfunction’ 
(R ESO LVD ) pilot study, candesartan w as compared to enalapril and the  
combination (392). This small study suggested that combined therapy more 
effectively prevented LV remodelling than monotherapy. However, the study was  
prematurely terminated because of an early trend in increased mortality and heart 
failure hospitalization (secondary end-point) in the candesartan and combined 
therapy groups (392).
6.5.1.5. OPTIMAAL
In the ‘optimal therapy in myocardial infarction with the angiotensin II antagonist 
losartan’ (O PTIM AAL) trial (380), which was designed to test for superiority of an 
ARB on survival and other major cardiovascular outcomes in high-risk post-MI 
heart failure patients with captopril as comparator, losartan did not show  
superiority over captopril. Cardiovascular death was clearly less with captopril 
(P=0.035) while other outcomes were similar in the two groups. However, a non­
significant trend favoured captopril for the primary end-point o f all-cause mortality 
(P =0.069) but did not satisfy the criteria for non-inferiority.
6.5.1.6. VALIANT
In the ‘valsartan in acute myocardial infarction trial, (VALIANT) (381), which was  
designed to assess superiority of the A RB valsartan over the A C E  inhibitor
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captopril as comparator on top of background therapy, the efficacy and safety of 
long-term treatment with valsartan, captopril and their combination was compared  
in 14,703  high-risk patients with Ml and LV systolic dysfunction (ejection fraction < 
40% ) and/or heart failure (381). The patient selection matched that in the SAVE, 
A IR E and TRAC E studies. The patients were randomized 0.5 to 10 days after 
acute Ml and followed for a median period of 24 .7  months. There w as no 
difference in the primary end-point of all-cause mortality. Comparing valsartan  
with captopril, the upper limit of one-sided 97.5%  confidence interval was within 
the pre-specified margin for non-inferiority for mortality (P =0.004) and the 
composite end-point of fatal and non-fatal events (P <0.001). Thus, valsartan was  
non-inferior to captopril. However, adverse events w ere greater with the 
combination of valsartan and captopril. Valsartan monotherapy was associated  
with more hypotension and renal dysfunction, and captopril monotherapy with 
cough, rash and taste disturbance.
This study established quite conclusively that valsartan was as effective as 
captopril in reducing mortality in high-risk patients after Ml. However, the authors 
also performed a statistical comparison of the VA LIA N T results with those of 
SAVE, A IR E  and TR A C E  using an imputed placebo, and showed that the 25%  
risk reduction in all-cause mortality in VALIANT was comparable to those in the  
AC E inhibitor trials.
T h e  finding that the  valsartan plus captopril combination increased adverse  
events including hypotension underscores the need for careful monitoring of blood 
pressure when combining RAAS inhibitors after Ml and supports the caveat 
regarding vasodilator-induced hypotension in acute Ml.
An interesting finding in VA LIA N T was the disproportionately high rates of 
heart failure, re-infarction, and stroke which accounted for more than 50%  of the 
early mortality (381). In a sub-study (393), 21.5%  of the 14,703 patients were  
elderly (age > 75 years) and their outcomes remained poor. In fact, with 
increasing age in 4 sub-groups, the 3-year mortality quadrupled, composite end­
points doubled, and heart failure admissions tripled. Adverse events from 
captopril and valsartan, or both, w ere also more common in the elderly. In 
another sub-study (394), 1.5%  of patients with post-MI heart failure developed  
stroke and the stroke victims had greater in-hospital mortality (27.2 versus 6 .5% , 
P <0.001) and more frequently had atrial fibrillation.
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6.5.1.7. V a l-H eF T
In V al-H eFT  (361), which randomized 5 ,010 patients with heart failure to  treatm ent 
with valsartan or placebo on top of standard therapy consisting of A C E  inhibitors 
(93% ), digoxin (67% ), beta-blockers (35% ), and the aldosterone blocker 
spironolactone (5% ), valsartan did not reduce the primary end-point o f all-cause  
mortality. However, valsartan reduced the composite end-point of mortality and 
morbidity, improved clinical signs and symptoms of heart failure, and decreased  
heart failure hospitalizations.
A  post-hoc analysis of the combined end-point revealed that valsartan had 
a favourable effect in patients who did not receive A C E  inhibitors or beta-blockers, 
but an adverse effect in the 30%  of patients who received the combination of 
valsartan, A C E inhibitor and beta-blocker (361). In a sub-study of V a l-H eF T  
(395), valsartan improved LV size and ejection fraction in all groups except those 
taking valsartan together with an A C E  inhibitor and a beta-blocker.
However, this negative finding with triple therapy differs from those of the 
CHARM  trials (384-387) and should not detract from the important benefits in Val- 
HeFT. For example, valsartan decreased mortality by 33%  (P =0 .017) and the 
combined end-point by 44%  (P <0 .001) in patients not taking ACE inhibitors, (395), 
supporting the use of valsartan as an alternative in patients intolerant to A C E  
inhibitors. Valsartan also improved the secondary end-points in V a l-H eF T .
Sub-studies of V al-H eFT  provided further support for RAAS-inhibition. In 
one sub-study (396), the addition of valsartan on top of background therapy for 
heart failure including beta-blockers and AC E inhibitors, was associated with a 
37%  reduction in atrial fibrillation, which has been linked to adverse atrial 
remodelling and poor clinical outcome. In another sub-study (397), valsartan  
reduced levels of brain natriuretic peptide (BNP) and plasma norepinephrine, 
which have been linked to poor outcome. Another sub-study showed that 
valsartan reduced aldosterone in all sub-groups despite different outcomes (398). 
In yet another sub-study, valsartan decreased plasm a aldosterone and 
norepinephrine in chronic heart failure patients, and those receiving 4  w eeks of 
standard ACE inhibitor therapy had “physiologically active levels of angiotensin II” 
which did not rise with co-administration of valsartan (399).
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6.5.1.8. RALES and EPHESUS
The rationale for using aldosterone blockade in heart failure is two-fold. First, 
angiotensin II stimulates the re lease of aldosterone (Figure 39), thereby activating 
the mineralo-corticoid receptor. Second, activation of the mineralo-corticoid 
receptor persists despite the use o f A C E inhibitors, ARBs and beta-blockers (400).
Apart from increasing sodium retention and potassium loss, aldosterone 
causes myocardial and vascular fibrosis, vascular dam age and baroreceptor 
dysfunction, and inhibits myocardial norepinephrine uptake (400). Aldosterone 
also generates oxygen free radicals and aldosterone blockade decreases vascular 
N ADPH oxidase activity and reactive oxygen species, and improves availability of 
N O  and endothelial function (400). Aldosterone blockade has been shown to limit 
LV remodelling, fibrosis, M M P  activation and angiogenesis in the coronary 
embolization model of heart failure in dogs (401), and limit collagen synthesis and 
LV remodelling as assessed by LV  volumes on 2D-Echo in post-MI patients (402).
Two large trials have shown that aldosterone blockade reduces total 
mortality and hospitalization for heart failure in post-MI patients with LV systolic 
dysfunction (310). In the ‘random ized aldactone evaluation study’ (RALES), 1,663  
patients with chronic heart failure (LV ejection fraction < 35% ) received the  
aldosterone blocker spironolactone or placebo on top of background therapy with 
an AC E inhibitor, diuretic, digoxin and beta-blocker (403), This trial w as  
prematurely term inated due to the  finding of a 30%  reduction in all-cause mortality 
(P<0.001). In the ‘epierenone post acute Ml efficacy and survival study’ 
(E P H E SU S), 6 ,642  patients with acute Ml, LV ejection fraction < 40%  and heart 
failure were randomized to receive the selective aldosterone blocker, epierenone  
or placebo on top of optimal background therapy (310). Epierenone reduced all­
cause mortality by 15 % (P = 0 .008 ) and cardiovascular mortality by 17% (P =
0.005). Although serious hyperkalem ia increased by 1% and 1.6%, respectively, 
in these studies, this did not result in deaths.
In a sub-study of R A LES  (308), spironolactone was associated with 
increased levels of markers of cardiac fibrosis or collagen synthesis, suggesting 
that limitation of excessive EC M  turnover m ay have contributed to the benefits. In 
a sub-study of E P H E S U S  (404), epierenone begun at a mean of 7 .3  days after 
acute Ml was shown to reduce the 30-day all-cause mortality, supporting the  
initiation of epierenone in hospital.
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6.5.1.9. RAAS-inhibition and prevention of LV remodelling in trials
The discovery that LV remodelling leads to progressive LV dilatation, a m ajor 
determinant of post-MI survival and outcome that can be limited by R A A S- 
inhibition, represented a major paradigm shift that triggered several large  
randomized clinical trials. Despite these trials, however, there is to date (January  
2006) a paucity of comprehensive data on effects of anti-remodelling agents on 
regional and global changes in topography, structure and function using 2D -E cho  
or other cardiac imaging modalities. Som e reasons for this discrepancy have  
been the lack of funding and rapid methods for quantification.
Several post-MI trials, such as SAVE and HEART, used 2D-Echo evidence  
of a decrease in LV size (dimensions, areas, volumes) and increase in LV ejection  
fraction to support the beneficial effect of AC E inhibitors on LV remodelling 
(121,124 ,125 ,132 ,405). Thus, in a sub-study of SAVE (512  patients), 2D -Echo  
measures of LV cavity areas and the change in cavity area w ere shown to be  
predictors of adverse cardiovascular events and captopril decreased these areas  
and improved outcome (132). In HEART (312 patients), 2D -Echo measures of LV  
cavity area and volume ejection fraction improved with ramipril (125).
In a recently published sub-study of VALIANT (610 patients), 2D-Echo data  
showed similar changes in LV volume, ejection fraction, combined cavity areas, 
and infarct segment length over 20 months in groups receiving an ARB, A C E  
inhibitor or both (406). Importantly, baseline measures of LV  volume, ejection  
fraction, and infarct segment length predicted outcome. To  date (January 2 0 0 6 ) 
and to the best of the author’s knowledge, no 2D -Echo data on post-MI LV  
structural remodelling from RALES or E PH ES U S  have been published.
Several heart failure trials have reported beneficial effects of therapy on LV  
structural remodelling. In the Vasodilator-heart failure trials’ (V -H eFT) I and II 
(407), the mitral E-point septal separation (EPSS), LV  internal diameter in systole 
(LVIDs), and the systolic radius to wall thickness ratio (R s/TH s) on 2D -Echo  
steered M-mode Echo in 642  patients w ere shown to predict mortality and reflect 
treatment effects In heart failure. These A C E  inhibitor studies supported the use  
of the combination of a decrease in LV size and an increase in LV ejection fraction 
as a marker of regression of LV remodelling.
In V al-H eFT sub-studies (395,408), ARBs w ere suggested to limit adverse  
LV remodelling in heart failure on the basis of LV internal dimensions (2D -Echo  
steered M-mode Echo) and volume ejection fraction. Thus, in 5 ,010  patients with
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m oderate heart failure, valsartan added to an ACE inhibitor or beta-blocker was  
associated with improvement in LV size and function but this benefit was not 
found in patients taking valsartan and both A C E  inhibitor and beta-blocker (395). 
Also in V al-H eFT, patients with the most LV dilatation (LV end-diastolic dimension 
> 7 .5  cm) and worse ejection fraction (less than 22% ) benefited the most from the  
anti-remodelling effect of valsartan (408).
In RESO LVD , data on LV volum es and ejection fraction using radionuclide 
angiography in 768 patients with heart failure showed that the combination of 
candesartan and enalapril more effectively prevented LV remodelling (392).
To date (January 2006) and to the best of the author’s knowldege, no 2D - 
Echo data on LV structural remodelling in heart failure from sub-studies of 
C H A R M  in heart failure have been published.
6.5.1.10. Expanding the RAAS-inhibition paradigm
In addition to infarct-related complications and progressive LV remodelling 
(27 ,37 ,247), post-MI survivors are at risk for further vascular remodelling, 
progressive atherosclerosis, myocardial ischaemia, recurrent Ml, restenosis after 
coronary artery bypass surgery, metabolic syndrome and type II diabetes meilitus, 
peripheral artery disease, ventricular arrhythmias, ventricular dyssynchrony, atrial 
fibrillation and stroke. This risk may be partly due to genetic factors and continued 
exposure to the cardiovascular risk factors so that comprehensive secondary 
prevention is an important aspect of long-term therapy in survivors of Ml.
Fifteen years ago, the treatm ent and prevention arms of SO LVD  
established that RAAS-inhibition with the A C E  inhibitor enalapril offers protection 
against the development and progression of heart failure (143,145). Collective 
evidence from H O P E -TO O  (409), the extension of the Heart outcomes protection 
evaluation’ (H O P E ) study (410), the 12 year extension of prevention SO LVD  or 
S O LVD  follow-up’ (X -S O LV D ) study (411), the ‘extension of the A IR E ’ (A IREX) 
study (412), the losartan intervention for end-point reduction in hypertension’ 
(L IFE ) study (413) and its sub-study (414), suggest that prolonged RAAS- 
inhibition with A C E inhibitors and ARB s can effectively prolong life expectancy  
(415).
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6.5.1.11. Summary and future directions {
The totality of the evidence, from randomized clinical trials to 2005, supports the 
use RAAS-inhibition in post-MI survivors, with A C E  inhibitors as first line therapy 
and ARBs and aldosterone antagonists as proven life-saving alternatives or add­
ons. For patients intolerant to A C E  inhibitors, results of trials support the use of 
valsartan and candesartan for post-MI and heart failure patients, respectively. 
Other potential indications for RAAS-inhibition include: i) limiting LV  and atrial 
remodelling in Ml survivors; ii) preventing atrial fibrillation and stroke, especially in 
Ml survivors; iii) improving blood pressure control, cardiovascular protection and 
outcomes in hypertensive patients with LV hypertrophy; iv) reducing new onset 
diabetes and insulin resistance; v) preventing progression of atherosclerosis and 
its complications. Aggressive measures, including comprehensive RAAS- 
inhibition with A C E  inhibitors, ARBs and aldosterone antagonists or on top of 
approved background therapies, may be needed for reducing risk in high-risk 
patients who do not achieve treatm ent targets recommended by evidence-based  
guidelines.
6.5.2. Nitrates and nitric oxide
Nitrates have formed part of cardiovascular therapeutics eversince Sir Lauder 
Brunton used amyl nitrate for therapy of angina pectoris in 1867. Nearly 12 
decades later, work by Furchgott, Palmer, Ignarro, Moncada and others clarified 
that nitrates w ere NO donors and NO  was the biological m essenger that causes 
dilatation of coronary arteries. It w as proposed that activation of N O  synthase 
(N O S ) leads to synthesis of endogenous NO from L-arginine w hereas organic 
nitrates release NO via intracellular bioconversion. In that concept, NO  then 
activates guanylyl cyclase, thereby increasing intracellular cG M P which mediates 
smooth muscle relaxation. In 1998, Nobel Prizes in Medicine w ere awarded to 
Furchgott, Ignarro and Murad for the discovery of N O  as a signalling molecule in 
the cardiovascular system.
6.5.2.1. Nitrates in myocardial infarction and heart failure
The story of nitrates and NO  is fraught with reports of both beneficial and 
deleterious effects (416,417). The  evidence for the anti-ischaemic and 
cardioprotective effects of nitrates and the pathobiology of NO  have been 
reviewed (38 ,100,101,333 ,418) and discussed (pages 17; 130-139) in this thesis.
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In 1888, Stewart (419) first reported a case of nitrate tolerance in a patient 
who needed 20  grains of N TG  to achieve the sam e decrease in blood pressure as 
induced by an initial dose of 1 /100  grain, representing a 2000-fold increase. In 
1932, Prodger (420) w arned that too much nitrate resulted in hypotension. 
Currently, there is consensus that short-term nitrates are effective for the 
treatment of myocardial ischaemia and acute Ml (100 ,101 ,333 ,418 ) but efficacy is 
markedly reduced with long-term nitrates due to the development of tolerance  
(333). This nitrate tolerance is partly related to continuous dosing, high dosage  
and potency of the preparation.
Experimentally, nitrate given in low dose and eccentric dosing with a 
nitrate-free interval has been shown to be beneficial after Ml (48,103). Clinically, 
chronic nitrate in low dose w as shown to be effective in one published trial 
(357,421), one published study presented in this thesis (105-107 ,109) and one 
unpublished study described in this thesis (109 ,298 ). In all these studies, the 
nitrates improved LV function and prevented remodelling post Ml (105-109,298). 
Also clinically, low-dose intravenous NTG infusion for 48  hours in high-risk 
patients reduced LV dysfunction, acute infarct expansion, subsequent adverse LV 
remodelling, infarct-related complications and one-year mortality after acute Ml 
(28). This effect w as dose, blood pressure and preparation sensitive 
(28,118,122). A  m eta-analysis of various random ized clinical trials in M l using 
different nitrate preparations confirmed the benefits (344).
However, subsequent comparison of various nitrates and ACE inhibitors 
after Ml in large trials did not show significant lasting benefit (135-137), probably 
because of hypotension and nitrate tolerance. In addition, a study of 1,002  
patients with ‘healed’ Ml (> 7 days post Ml) treated with long-term sublingual or 
intravenous ISDN as well as N TG  showed an increase in cardiac events (422). A  
meta-analysis suggested that nitrates might be harmful post Ml (423). In a study 
of transdermal NTG in patients with angina pectoris, NTG reduced anginal attacks 
but did not prevent silent ischaem ia (424). In the ‘transderm-nitro trial’ of chronic 
angina, some patients experienced increased angina during the patch-off intervals 
(425). Collectively, these studies suggest that the long-term nitrates as primary 
therapy after Ml and a daily nitrate-free interval might not be prudent.
6.5 2.2. Mechanisms of nitrate action and tolerance
Our understanding of nitrate action and tolerance has increased over the last
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decade (see 426  for review). In the prevalent NTG /N O  hypothesis, NTG-induced  
vascular relaxation is due, in sequence, to activation of soluble guanylyl cyclase, 
increase in cGM P, activation of cGM P-dependent protein kinases and/or cyclic 
nucleotide-gated ion channels (427). NTG and other nitrates appear to share the 
same signalling pathway as NO generated via NOS. Although NTG bioconversion 
appears to be essential for cG M P formation, precisely how NTG  activates  
guanylyl cyclase remains controversial.
The  studies that favoured the N TG /N O  hypothesis used very high NTG  
concentrations. Recent studies from M unzel’s group (426) suggest that NTG  
activates the guanylyl cyclase/c-GM P protein kinase pathway independently of 
bioconversion to NO. Importantly, different activation pathways seem  to be 
involved for low (therapeutic) and high (pharmacological) concentrations of NTG. 
The pathway used at the low anti-ischaemic and vasodilating concentrations 
generates low amounts of NO. At the low concentrations, the biotransformation of 
NTG appears to involve the mitochondrial isoform of aldehyde dehydrogenase 
(ALDH-2) (428). In contrast, high doses of high potency nitrates, such as NTG , 
and low potency nitrates, such as ISDN and ISM N, generate higher and 
m easurable amounts of NO (426). Recently, M oncada’s group used confocal 
microscopy to observe endothelium-synthesized NO and suggested that high 
concentrations of NTG do not release free NO, so that the action of NTG m ay not 
be related to its bioconversion to NO but rather to a different species that does not 
inhibit oxygen consumption by vascular mitochondria (429). The authors 
speculated that this may explain ‘the long clinical success’ of NTG (429).
M unzel’s group has made various major contributions to the understanding 
of nitrate tolerance (426). Until a decade ago, two mechanisms of nitrate 
tolerance w ere recognized: i) neurohumoral counter-regulation, or
‘pseudotolerance’, associated with short-term treatment and involving increased  
intravascular volume and levels of catecholamines, vasopressin, renin, 
angiotensin 11, and aldosterone; and ii) vascular or intrinsic tolerance, associated 
with chronic treatment and involving increased sensitivity to receptor-dependent 
vasoconstrictors such as endothelin-1 and big endothelin-1, which activate protein 
kinase C (PK C ). Subsequently proposed mechanisms include increased activity 
of phosphodiesterase 1A1, desensitization of soluble guanylyl cyclase, increased  
production of reactive oxygen species, and impairment of nitrate 
biotransformation. Sydow in M unzel’s group proposed another mechanism
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involving NTG-induced mitochondrial production on reactive oxygen species and 
inhibition of A LD H -2  (which bioactivates NTG) (430). A  major contributor to 
vascular tolerance is superoxide (O 2 ), a physiologically reactive free radical. 
Increased vascular superoxide reacts with vascular N O  to form peroxynitrite 
(O NG O *), which in turn leads to uncoupling of NO S and inhibition of soluble 
guanylyl cyclase and PG I2  synthase. Although N O  interacts readily with 
superoxide, providing detoxification, the resulting peroxynitrite may dam age blood 
vessels and oxidize lipids. This oxidative stress hypothesis may explain why anti­
oxidants reduce nitrate tolerance.
6.5.2.3. Biology of nitric oxide in the cardiovascular system
This topic has been reviewed (416-418). Nitric oxide (N O  or NO) is a ubiquitous 
molecule that can have beneficial and deleterious effects depending on 
conditions. In nature, NO is a poisonous gas that is formed by oxidation of 
ammonia and is generated by incomplete combustion of gasoline in exhausts. In 
physiologic solutions, NO has a short half-life. In tissues, N O  is a physiological 
regulator that plays key roles in signal transduction and cytotoxicity and 
participates in physiological functions, such as vasodilation, neurotransmission, 
and elimination of pathogens. Being an uncharged molecule, NO diffuses freely 
across cell membranes. NO  also plays a major role in the pathophysiology of 
several diseases in the cardiovascular and other systems.
The biological actions of N O  in the cardiovascular system are quite 
complex. Since N O  is a free radical with an unpaired electron in the t t  molecular 
orbital, this electronic configuration imparts high reactivity to the molecule. 
Collective evidence indicates that N O  acts by several mechanisms, including 
activation of soluble guanylyl cyclase, S-nitrosylation of thiols, and formation of 
peroxynitrite.
W hether NO  is cytotoxic or cytoprotective depends on the form of delivery 
or transport and the quantity. Three NOSs have been cloned. Constitutive 
endothelial eN O S  and neuronal nN O S release small am ounts of NO transiently 
while inducible iN O S releases large amounts for prolonged periods. NO is 
protective in small amounts but toxic in excess. Low dose N O  increases cardiac 
contractility while high dose NO  reduces contractility. Increased angiotensin II 
inactivates NO, forms peroxynitrite and produces cardiotoxicity. N O  produces 
post-translational modification of several effector molecules. S-nitrosylation may
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be key in regulating myocardial performance and vascular tone.
The  interaction between NO and superoxide, referred to as the nitroso- 
redox balance, plays a critical role in cardiovascular disease. Physiologically, the  
levels and location of NO and the production of superoxide are balanced within 
the cell. This facilitates post-translational modification of the effector proteins. 
Pathophysiologically, as in heart failure, the level and location of N O  synthesis 
and excessive superoxide production result in interruption of effector signalling, 
leading to vasoconstriction, decreased contractility, cellular dysfunction and cell 
injury or cell death. Increased angiotensin II after ischaemia-reperfusion may 
contribute to injury by inactivating NO and forming peroxynitrite. Therapies that 
enhance NO bioavailability by increasing eN O S may be beneficial after 
ischaemia-reperfusion. This may explain the reports of beneficial effects of low- 
dose intravenous N TG  (50) and A C E inhibitors (352) or ARBs (373-375) in 
reperfused acute M l.
Genetic mouse models of NO S deletion and over-expression have been  
studied. In rats, eN O S  expression is decreased after Ml. In mice, eN O S  deletion 
is associated with increased mortality and over-expression with improved survival 
and limitation of LV  dysfunction and remodelling after Ml. In 2005, nNO S  
deficiency in mice w as also reported to increase mortality and remodelling (431) 
and functional deterioration (432) after Ml.
Several studies have underscored the cardioprotective role of NO in 
coronary artery disease, ischaemic preconditioning, ischaemia-reperfusion and 
heart failure (see 4 3 3  for review: A ppend ix  46). After ischaemia-reperfusion, low 
levels o f NO are beneficial but high levels are harmful and contribute to 
reperfusion injury. Thus, reperfusion of ischaemic myocardium triggers the  
release of oxygen free radicals and a cascade involving endothelial dysfunction, 
decreased eN O S  and eNO S-derived NO, neutrophil activation, increased 
cytokines, further increase in oxygen free radicals, increased iNO S and high 
levels of iNOS-derived NO, increased peroxynitrite, and cellular injury.
6 .5 .2 .4 . H yd ra laz in e  and prevention  o f n itrate  to lerance
Agents with anti-oxidant properties might prevent nitrate tolerance (426). 
Potential agents include A C E  inhibitors, ARBs, statins, L-arginine, tetra- 
hydrobiopterin (BH4, co-factor for eN O S), ascorbic acid, ebselen and uric acid
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(which decrease mitochondrial production of reactive oxygen species and 
preserve A LDH -2), and hydralazine.
Hydralazine interacts favourably with nitrates in several ways. It not only 
inhibits superoxide production but also iNO S and cyclo-oxygenase-2 (C O X-2). It 
is also pro-angiogenic. The  rationale proposed for combining ISDN and 
hydralazine is that ISDN stimulates the NO  pathway (eN O S) while hydralazine 
inhibits superoxide production and iNOS, so that together they m ay restore the 
balance between NO  and superoxide production.
Experimentally, hydralazine combined with ISDN was shown to prevent 
nitrate tolerance and improve mortality (434). The combination also improved 
mortality in patients with heart failure (144). In the recent African-Am erican heart 
failure trial’ (A -HeFT), the addition of ISDN and hydralazine on top of standard 
therapy increased survival in the African-Americans with advanced heart failure
(435). This beneficial effect of hydralazine appears to involve its anti-oxidant 
properties, with inhibition of the activation of membrane-bound NADH oxidase
(436) and inhibition of superoxide generation. The venodilatory effect of nitrate 
complements the arteriolar dilatory effect of hydralazine (86, 437 ). A  sub-study of 
A -H eFT  showed that the fixed-dose combination of ISDN and hydralazine reduced 
hospitalizations and was cost-effective in African-Americans (438). Another sub­
study underscored the importance of considering ethnicity in clinical trials (439).
In sum m ary, studies presented in this thesis illustrate the general principle 
that ventricular unloading therapy yields maximal benefit when it is begun very 
early and is prolonged, spans the infarct-healing process and extends beyond. 
The overall evidence to date does not favour long-term nitrates. However, the 
combination with hydralazine is beneficial in African-Americans. The caveat 
concerning avoidance of hypotension and the paradoxical J-curve effect with early 
unloading therapy after Ml still applies (100 ,122 ,123 , 440). Irrespective of the 
therapeutic approach that is selected, outcome depends critically on the timing 
and duration of therapy, and attention to the pathological processes.
6.5.3. Novel concepts , ap p ro ach es  and te c h n o lo g ie s
New knowledge of the biology of remodelling after Ml underscores its complexity 
and the participation of various molecules, including cytokines, growth factors and 
hormones as well as various cellular responses and signalling pathways (27,278). 
Numerous new therapies are being proposed to modify and modulate these
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processes in efforts to optim ize outcome. New approaches to limit remodelling 
after Ml include application of novel pharmacological interventions that target the  
dam aged myocardium, the  supporting ECM or both.
6 .5 .3 .1 . M yocard ia l sa lv ag e  and  card ioprotection
Advances w ere made in five major areas.
First, improved reperfusion strategies, with thrombolytic and anti-platelet 
agents and percutaneous coronary intervention (PCI), have impacted positively on 
outcome post Ml. However, despite extensively documented overall benefits of 
reperfusion, A C E  inhibitors, beta-blockers, statins, aspirin, ARBs and aldosterone  
antagonists after Ml, cardiac enlargem ent and heart failure remain problematic 
(441), especially in survivors of ST-segm ent elevation Ml (STEM I) (442). A  
challenge after reperfused STEM ! is reperfusion injury, with myocardial stunning 
and persistent LV dysfunction, inflammation and cellular responses linked with 
healing, increased M M Ps, EC M  dam age, decreased Infarct collagen, decreased  
density of collagen cross-links, increased ruptures, necrosis and apoptosis, and 
no-reflow (27 ,442,443). Adjunctive therapies to protect against early ECM  
dam age and decrease reperfusion injury in STEM I are therefore being studied. 
Combining regional therapy with a selective MM P inhibitor and an ARB during PCI 
plus stenting and abcixim ab very early after STEM I, might provide the opportunity 
to preserve more myocardium and ECM , and thereby improve outcome.
S econd , novel drugs aimed at protecting the ischaemic myocardium have  
been developed for potential clinical application. One approach involves the use 
of metabolic modulators. Perhexiline, an anti-anginal drug that augments glucose 
metabolism by blocking mitochondrial free fatty acid uptake, has been shown to 
improve peak exercise oxygen consumption, LV ejection fraction, other measures  
of function, and skeletal muscle energetics in patients with heart failure (444). 
W hether metabolic modulators might improve remodelling needs study.
T h ird , stem cell therapy aimed at myocardial regeneration is being 
developed to repair injured hearts. In one report in 2005 (445), the granulocyte- 
colony-stimulating factor (G -C S F ) was given after reperfusion (primary PC I/ 
stenting and abciximab) in patients with acute STEM I. G -CSF mediates 
mobilization of CD34+ m ononuclear blood stem cells (M N C ^‘^ '^^ )^. The  patients 
showed improvement in metabolism (^^F-deoxyglucose uptake) in the infarct
1 6 6
zone, and LV ejection fraction and decrease in LV diastolic dimension on Echo, 
suggesting prevention of remodelling.
Fourth, inhibitors of apoptosis or programmed cell death (1 9 0 ) may 
prevent more myocardium and prevent remodelling. Until recently, cardiologists 
endorsed the dogma that the heart is terminally differentiated with no regenerative  
capacity and opposed the concept of apoptosis (446). Evidence from 
experimental and clinical studies indicate that cardiomyocyte cell death early after 
the onset of acute Ml involves apoptosis followed by necrosis (188 ,190 ,447 ). In 
addition, low-grade apoptosis contributes to LV remodelling in chronic M l (448). 
The application of confocal microscopy (449), the use of biochemical markers 
(449), and the application of in-vivo imaging techniques for apoptosis using 
annexin-V (450,451) have advanced apoptosis research (190). Importantly, early 
interventions have been shown to prevent necrosis (452) as well as apoptosis 
(453,454) after acute ischaemia or ischaemia-reperfusion and long-term  
interventions have been shown to prevent apoptosis and adverse remodelling 
(455,456). Although these interventions involved RAAS inhibitors (4 5 4 ,4 56 ) and 
broad-spectrum caspase inhibitors (453,456), more selective anti-apoptotic agents 
are being developed. It might therefore be possible to target early apoptosis and 
necrosis in acute Ml as well as long-term apoptosis in chronic Ml, and quantify the 
effects using in-vivo imaging of apoptosis in studies aimed at preventing post-MI 
remodelling.
Fifth, therapies targeted at cytokines and the inflammatory process have 
been tested. Agents such as tumor necrosis factor-o (TN F-a) antagonists and 
endothelin antagonists were studied in clinical trials of heart failure and found not 
to be beneficial despite their benefit in experimental studies (457). Recently, large 
randomized clinical trials of C O X -2  inhibitors (rofecoxib, celecoxib, and 
valdecoxib) for various indications confirmed cardiovascular toxicity (458 ,459 ).
6 .5 .3 .2 . P ro tecting  the su p p o rtin g  ex trace llu la r m atrix
Several approaches have been proposed.
First, MMP-inhibition is aimed at preventing E C M  damage. The rationales
(27,278) include: I) the ECM  plays a critical role in both early and late LV 
remodelling after Ml; ii) activation of M M Ps that degrade the ECM  has been linked 
to adverse LV remodelling; iii) a fine balance between M M Ps and T IM P s  is 
essential for maintaining ECM integrity and optimal structural support; and iv)
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selective M M P inhibitors are becoming available. The inflammatory and healing 
responses elicited by acute Ml involve inflammatory, fibroblast and vascular cells 
as well as growth factors, bioactive proteins and cytokines. In addition, a sharp 
rise in M M P above that of T IM P  drives rapid ECM  degradation, myocyte slippage 
and acute infarct expansion (early remodelling). Subsequently, M M P and T IM P  
levels subside but chronically higher M M P  than T IM P in some hearts favour 
continued matrix degradation, thereby contributing to progressive, global LV  
dilatation. In contrast, higher T IM P  than M M P  levels and activities in remote Ml 
contribute to increased ECM  deposition and interstitial fibrosis. Release of growth 
factors (such as TG F-p ) (460) and cytokines (including angiotensin II, TN F-a  and 
interleukin-10) (443) into the interstitial space seem to modulate M M P/T IM P  
expression and EC M  degradation or interstitial fibrosis.
To date, over 20  M M Ps and 4  T IM P s have been described (27). MM Ps are  
synthesized by m any cells in a latent form (pro-M M P) and activated by proteolytic 
cleavage or conformational changes. Several MMPs, including M M P-2 and M M P- 
9, are associated with adverse LV  remodelling after Ml. Substrates for M M P-2  
and M M P-9 include the three major collagen types I, II, and III that are involved in 
scar formation and fibrosis during healing after Ml. However, the M M P-2 is 
constitutive while M M P -9  is inducible (461). In brief ischaemia-reperfusion, where  
inflammatory cells are absent, the major source of increased myocardial M M P-2  
appears to be the myocyte. In contrast, the major source of increased myocardial 
M M P-9 during reperfused Ml, w here  inflammation is enhanced, is the neutrophil 
and most likely involves M M P -9  induction. M M P-2 Is the main M M P reported 
increased in rodents (462), w hereas M M P -9 is the M M P reported increased in 
dogs with reperfused Ml (461), suggesting differences among species.
All T IM P s may bind and inactivate M M Ps, including M M P-2 and M M P-9. 
Decreased T lM P -3  is associated with adverse remodelling in human heart failure 
(463). Experimental studies using genetic mice or other models have implicated 
M M P  activation in adverse remodelling after Ml (303,304 ,464-468). For example, 
targeted deletion of M M P-9 attenuated LV dilation after Ml in mice (303,464). 
Broad-spectrum MMP-inhibition limited late infarct expansion after Ml in dogs 
(467). Data in M M P -2  and M M P -9  knock-out mice suggest that high M M P-2  
and/or M M P -9 contribute to LV rupture after Ml (464,469,470).
The recent P R E M IE R  trial, using the broad-spectrum MMP-inhibitor PG - 
116,800 that was designed to target M M P -13  and MM Ps 2, 3, 8, 9, and 14, did not
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show limitation of LV remodelling in patients after S TEM I (471). However, 
potential confounders in that study included late initiation of therapy with PCI 
within 29 hours and oral P G -1 16800 within 48 hours, background therapies with 
potential pleiotropic effects in both treatm ent arms, and the lack of selective M M P  
inhibition. This study did not measure RSD.
Second, other drugs used after Ml may exert pleiotropic effects on 
M M P /T IM P  balance. For example, RAAS-inhibition which induces cardio- 
protection in reperfused Ml m ay improve the M M P /T IM P  balance. In the dog 
model of reperfusion after prolonged ischaemia, valsartan given 30 minutes 
before ischaemia normalized the balance between M M P-9 and T IM P-3, improved  
LV contractile function, and limited acute infarct remodelling and infarct size (461). 
In the sam e model, valsartan reversed the changes in metabolic, functional and  
structural proteins induced by post-ischemic reperfusion (472,473). These studies 
suggest that the ARB valsartan not only limits reperfusion injury but also improves 
remodelling by matrix modulation.
Th ird , supporting structures have been targeted in an attempt to decrease  
the regional bulging and global dilatation after Ml by applying external restraint
(22 ,39 ,278). Some experimental studies have used a mesh over the infarct zone. 
The A corn ’ cardiac support device, designed to provide diastolic support to the  
heart and thereby decrease LV diastolic wall stress and limit LV dilatation, has  
been shown to be effective in animal models of heart failure as well as patients 
with heart failure (474).
Fourth, alternative approaches have been targeted at improving ventricular 
function and limiting dilatation. These include ventricular reduction surgery 
(Batista procedure) (475), dynamic cardiomyoplasty (476), and implantation of 
pacing devices to control electrical/mechanical asynchrony and produce 
resynchronization (477). O f these, cardiac resynchronization is the only approach  
that is widely used in heart failure.
Fifth, cardiac tissue engineering is an innovative approach for creating a  
muscle patch and is undergoing investigation (478). Several scaffolds, 
cardiomyocyte-populated gelatin and alginate gelatin grafts have been tested in 
animals. It is being combined with stem cell transplantation enhanced with growth 
factors and angiogenic factors to achieve myocardial regeneration.
Sixth, local drug or gene delivery that separately target the infarct and non­
infarct zones is undergoing evaluation. G ene therapy using various growth factors
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such as the vascular endothelial growth factor (VEG F) has been studied, with some 
favourable effects reported on angiogenesis and ventricular function although 
controversy exists.
6 .5 .3 .3 . Novel ap p ro ac h e s  and c o n ce p ts
Four major points need to be considered.
First, markers of immune reactions, collagen turnover, and MM Ps can be 
used to monitor adverse EC M  and cardiac remodelling. Since post-MI survivors 
who develop heart failure on therapy have a 10-fold greater risk of dying (441), a  
plasma marker that can identify those a t high risk of adverse LV remodelling 
would be useful. Currently available surrogate markers of adverse outcome after 
Ml include BNP (479), C-reactive protein (C R P ) (480) and TN F-a  (481). M M Ps  
and T IM P S  have been proposed. Thus, increased plasma M M P-9 after Ml is a  
fairly consistent finding (4 8 2 ) that may reflect a spillover. Several studies have  
documented increased plasm a M M P-9 (483,484), or both M M P-9 and M M P-2  
levels (485,486), after acute (483 ,485 ,486 ) and remote (484) Ml, increased 
plasma M M P-9  in acute coronary syndromes including Ml (482,485), and 
increased plasma M M P -9  in heart failure (487,488). In one study, both plasma 
M M P-9 and TIM P-1 w ere  increased in acute Ml (482). Importantly, Squire et al 
(486) found that after M l, plasma M M P -9  levels correlated with LV dysfunction 
whereas plasma M M P -2  correlated inversely with LV volumes. Squire (486) also 
found that M M P-9 levels did not differ for anterior and inferior Ml whereas M M P -2  
levels were higher in anterior Ml and T IM P -1  levels were higher in inferior Ml. In 
one study that measured plasma M M P  levels serially over 6 months after Ml, 
increases in M M P-9 and T IM P-1 were most marked in moderate to large Ml (483). 
In another study, M M P -9  correlated with cardiovascular risk (489). A  potential 
confounder in acute Ml studies is that increased plasma M M P-9 also correlated  
with plaque rupture (482 ,485 ). In remote M l, plasma M M P-9 was a predictor of Ml 
but also reflected inflammation and atherosclerosis progression (484).
In a broader perspective, plasma markers of collagen turnover (307,490- 
494) or the connective tissue growth factor (C TG F) gene can be used to monitor 
anti-fibrotic effects of drugs (495). Other proteins and cells can be used to monitor 
the effects of drugs on inflammation and healing (496). Markers of immune 
reactions (497), adverse remodelling (498), phenotypes of responders to AC E
17 0
inhibitors and beta-blockers (499,500), and pharmacogenomic (501) approaches 
can all be applied to further improve outcome of survivors after Ml.
S econd, several novel imaging techniques are applicable for clinical 
studies of post-MI remodelling. Improved Echo imaging techniques include tissue 
Doppler Imaging for diastolic function, tissue characterization imaging, myocardial 
strain and strain rate imaging based on Doppler, myocardial contrast imaging for 
perfusion/function mismatch, and 3D-Echo (502). Recently, speckle tracking for 
LV torsion (or twist) and LV systolic function w as reported (503). Magnetic  
resonance imaging (M R I) tagging is also available but its use has been limited by 
its cost and complexity. It uses more transverse tomographic sections than is 
possible with 2D-Echo and the images are superior. . The combination of data  
from first-pass and delayed contrast-enhanced imaging can predict functional 
recovery in reperfused Ml (504). However, MRI cannot be easily applied to study 
high-risk patients with acute Ml although it is well suited for studies of post-MI 
survivors. M M P-targeted radio-tracers have been developed for imaging the 
localization of M M P activation and tracking M M P-m ediated remodelling post Ml 
(505). Imaging of apoptosis is also being evaluated (450,451).
Th ird , polypharmacy is common in post-MI and heart failure patients. The  
use of RAAS inhibitors on top of background therapy increases the possibility of 
interactions. The pleiotropic effects of the drugs are becoming important. 
Experimental studies suggest that combination therapy is often more beneficial 
than monotherapy. In atrial pacing-induced heart failure in the pig, the 
combination of valsartan and the endothelin blocker bosentan resulted in additive 
beneficial effects on loading, neurohumoral activity and LV performance (506). In 
the rat model of post-MI heart failure, the combination of valsartan and the AC E  
inhibitor fosinopril resulted in suppression of histopathological changes associated 
with remodelling, such as normalization of collagen I, m acrophages and 
myofibroblasts (507).
Although the effects of A C E  inhibitors and ARBs on LV structural 
remodelling in post-MI survivors initially em phasized the haemodynamic  
m echanism (decreased blood pressure, preload and afterload and wall stress), 
the importance of the non-haemodynamic mechanism (‘beyond decreasing blood 
pressure ) involving inhibition of angiotensin ll-induced growth, hypertrophy and 
apoptosis was later appreciated (27 ,508,509). A T 2 receptor stimulation was  
suggested to explain vasculoprotective effects of RAAS-inhibition with AC E
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inhibitors and ARBs (372). In both dog and rat models of post-ischaemic 
reperfusion, ARB-induced cardioprotection was associated with enhanced A T2  
receptor expression (510,511). However, evidence suggests that AT2 receptor 
stimulation may enhance acute ischaemia-reperfusion injury under certain 
conditions (512,513), and promote cardiac hypertrophy and vascular fibrosis, and 
reduce neo-vascularization in ischemic tissues (514). These negative effects of 
A T 2 stimulation may explain why ARBs are not found to be superior to A C E  
inhibitors in clinical trials.
A  potential source of concern with the combination of AG E inhibitors, ARBs  
and aldosterone antagonists, is that they both very effectively decrease collagen 
and interstitial fibrosis. Although the anti-fibrotic effect of RAAS-inhibition results 
in improvement of LV diastolic function that m ay be beneficial in patients with 
post-Ml hypertrophy and interstitial fibrosis, the possibility remains that over- 
aggressive reduction in collagen matrix may increase LV distensibility on the long­
term and contribute to deterioration, especially in patients with large transmural Ml 
(27). In 2005), a new mechanism for the anti-fibrotic effect of A C E inhibitors was 
identified. This involves the inhibition of the hydrolysis of N-acetyl-seryl-aspartyl- 
lysyl- proline (Ac-SDKP), resulting in decreased cardiac cell proliferation (possibly 
fibroblasts), inflammatory cell infiltration, expression of transforming growth factor- 
P (TGF-(3), activation of Sm ad2 (the mediator of effects of TG F-p ) and collagen 
deposition (515). Further studies linking markers o f ECM  and LV remodelling are  
therefore needed.
Fourth, it has been suggested that attention to differences in genetics, 
RAAS/ACE polymorphisms, race and age m ay further improve outcome in Ml 
survivors. Pharmacogenetics and identification of the phenotypes of responders to 
A C E inhibitors (and beta-blockers) may be applied to select high-risk sub-groups. 
For example, AC E gene polymorphism is associated with higher levels of 
angiotensin II (516) and increased risk of cardiovascular disease (517) and Ml 
(518). Several trials suggested that A C E gene polymorphism might influence the 
response to A C E  inhibitors, with carriers of the D D  genotype being associated 
with a more favourable effect, but controversy persists since chronic ACE inhibitor 
therapy increases angiotensin II levels. However, the A C E ID polymorphism is 
associated with higher ACE activity that may result in more favourable response 
to ACE inhibitors. In one study, only quinapril (not the A RB losartan, the calcium  
channel blocker amlodipine, or enalapril) w as associated with a significant
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improvement in brachial artery flow-mediated vasodilatation and this effect w as  
related to the presence of A C E  ID and II genotypes (519). In another study, A C E  
inhibitors did not increase re-stenosis after coronary stenting in patients with the  
AC E DD phenotype, irrespective of their tissue ACE affinity (520).
Recently, RAAS gene polymorphisms were linked to non-familial structural 
atrial fibrillation, providing further rationale for RAAS-inhibition with A C E inhibitors 
and ARBs to suppress atrial fibrillation in survivors of Ml (521). RAAS-inhibition 
and genetics needs further study.
W hether pharmacotherapy should be based on racial background is 
controversial. The response to heart failure therapy is suboptimal in African- 
American patients (361,522-524), possibly due to a relative resistance to A C E  
inhibitors secondary to low renin (522). The A -H eFT (435) suggested that the  
ethnic background might influence the response to therapy with ISDN and 
hydralazine (439). Differences In response to RAAS-inhibition due to race needs  
further study.
6.6. Conclusions
The potential for preventing aneurysm formation and progressive LV dilatation and  
dysfunction after acute Ml, by pharmacological limitation of early RSD and infarct 
expansion, is an exciting and achievable goal. The improved understanding of the  
early and late phases of the healing process after Ml and the concurrent adverse  
ventricular remodelling process will permit the design of more rational therapy to 
prevent topographic deterioration and congestive heart failure. The early  
prediction of patients at high risk for infarct expansion, by measuring R SD  and 
other robust remodelling indices using non-invasive imaging with 2D -Echo or 
other imaging modalities, such as M RI, will permit earlier intervention.
Collective evidence suggests that successful myocardial reperfusion 
therapy prevents transmural or 0 -w a v e  infarction and acute expansion, and 
subsequent prolonged pharmacotherapy provides additional benefit. Since late 
reperfusion can experimentally reduce expansion and thinning, adjunctive 
therapies m ay widen the window for salvaging LV shape and function. Clearly 
current pharmacotherapy after Ml is not ideal, since ventricles continue to enlarge  
and the number of patients with LV dysfunction waiting for transplantation has not 
decreased.
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The overall results of the studies in this thesis indicate that, after an acute 
Ml, progressive regional and global changes in ventricular topography occur 
throughout the healing phase over a period of several w eeks. This remodelling, 
which is most marked with large transmural and anterior infarction, involves a 
sequence of early remodelling with expansion of the infarcted zone (stretching, 
thinning, regional dilatation), collagen deposition into the  already thinned and 
stretched infarct segments, followed by further late remodelling with more infarct 
wall thinning, aneurysm formation with a firm inelastic scar, and further 
progressive dilatation of the non-infarct segment. The early  regional remodelling 
initiates a vicious cycle of LV dysfunction, decreased cardiac output, more cardiac 
dilatation, cardiac failure, neurohumoral activation and decreased survival. Major 
factors influencing remodelling include infarct size and transmurality, afterload, 
preload, wall stress, contractile function of adjacent normal myocardium, collateral 
blood flow and the healing process itself.
Pharmacological therapy, with intravenous low-dose NTG in the early 
phase followed by prolonged therapy with nitrates (eccentric dosing) or ACE  
inhibitors were effective for limiting LV regional remodelling, limiting global 
dilatation, preserving function and potentially improving survival after Ml. 
Thrombolytic therapy also limited remodelling but only preserved muscle and 
function If performed very early. N TG  and A C E  inhibitors appeared to be effective 
as adjunctive therapy after reperfusion, although subsequent large clinical trials 
over the last decade only showed significant survival benefit with A C E  inhibitors. 
The measurement of RSD and other indices of LV remodelling by quantitative 2D - 
Echo might be potentially important for assessing the effects of anti-remodelling 
strategies on the infarct zone during healing after Ml and identifying patients at 
high risk for LV aneurysm and rupture. The relation of E C M  disruption to RSD, as 
unmasked in the studies using 2D-Echo, m ay be applied for assessing future anti­
remodelling therapies. Other imaging modalities such as M RI may be applied to 
detect RSD in future.
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